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Summary 
The androgen receptor (AR) is widely expressed in human and rodent uterus 
during development, adulthood as well as in different uterine diseases, 
indicating an important role of AR-mediated androgen actions in uterine 
development, function and pathology. However, the specific role(s) and 
mechanisms remain controversial. Hence, the aim of this thesis was to 
investigate the role of androgen actions mediated via AR in uterine 
development, function and PTEN inactivation induced uterine pathology. 
 
In the first experiment, the uterine glandular epithelial specific AR knockout 
mouse model (ugeARKO) was generated to investigate the role of AR in 
uterine development and function. Uterine development and function was 
compared between ugeARKO, global AR knockout (ARKO) and wild-type 
(WT) females. The uterine development and fertility appeared normal in 
ugeARKO females despite the uterine gland specific inactivation suggesting 
AR mediated endogenous androgen actions in uterine gland epithelium are 
not critical for normal uterine development and function. Following 
ovariectomy, the uterus regressed to about 15% of intact control uterine 
weights in all genotypes. However, after ovariectomy and androgen 
(testosterone or dihydrotestosterone, DHT) treatment, full regrowth from 
ovariectomy level was detected in WT uterus, only partial regrowth in 
ugeARKO and no regrowth in ARKO females. These findings suggest that 
androgens acting via AR specifically within uterus can promote full uterine 
regrowth in the absence of estrogens (Chapter 3). 
 
iv 
 
In the second experiment, the role of AR mediated androgen actions in 
PTEN inactivation induced uterine pathology was investigated. Uterine 
cancer incidence was compared between WT, ARKO, heterozygous PTEN 
knockout (PTENKO) and combined heterozygous PTEN and complete AR 
knockout (PTENARKO) female mice. PTENKO-induced uterine cancer 
incidence was significantly reduced by simultaneous AR inactivation, 
indicating androgen actions via AR either systemically or locally within uterus 
modifies PTEN knockout induced uterine cancer incidence. This could be 
due to reduced estrogen receptor alpha (ERα) expression in PTENARKO 
compared to PTENKO uterus. AR inactivation did not modify PTEN or P-AKT 
levels (Chapter 4). 
 
In the third experiment, the role of glandular epithelial AR in PTEN 
inactivation induced uterine pathology was determined. We compared 
development and progression of uterine pathology between WT, ugeARKO, 
uterine glandular epithelial specific PTEN knockout mouse model 
(ugePTENKO) and uterine glandular epithelial specific AR and PTEN 
knockout mouse model (ugePTENARKO). The AR inactivation enhanced 
PTEN knockout-induced uterine pathology with development of intraepithelial 
neoplasia in ugePTENARKO uterus but not in ugePTENKO. This could be 
due to reduced progesterone receptor (PR) expression in ugePTENARKO 
uterus compared to ugePTENKO suggesting PR expression could be 
regulated by glandular epithelial AR (Chapter 5). These findings together 
with Chapter 4 indicate that indicating that androgen actions via uterine AR 
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can modify PTENKO-induced uterine pathology, but the role may differ 
depending on site of androgen actions 
 
In summary, this thesis has resulted in a number of significant findings on the 
role of AR-mediated androgens actions in uterine development, function and 
uterine pathology. I have generated and validated novel uterine glandular 
epithelial cell specific knockout mouse models that could be utilized in future 
research exploring uterine development and pathology. The findings support 
a significant role for androgens via AR inducing uterine growth that could be 
mediated locally via AR present in glandular epithelial cells. Furthermore, I 
have shown that AR modifies PTEN inactivation induced uterine pathology 
and the androgen actions can be mediated locally via uterine cell specific, 
AR mediated androgen actions modifying other hormone receptors such as 
ERα and PR. 
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Chapter 1: Literature review 
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The uterus is a major reproductive sex organ in female mammals including 
humans and rodents. Both the development and carcinogenesis of the uterus 
are highly dependent on ovarian hormones including estradiol (E2) and 
progesterone (P4). However, recent studies have suggested that androgens 
acting via androgen receptor (AR) could also play a vital role in the human and 
rodent uterus (Somboonporn and Davis, 2004, Walters et al., 2010, Beral et al., 
2005) . 
 
1.1 Anatomy and histology of the mouse uterus 
Mice have a bicornuate uterus consisting of two lateral horns (cornua) that join 
distally into a single body (corpus) (Figure 1.1). The mouse uterus is suspended 
from the dorsal body wall by the mesometria, which are heavy broad ligaments 
carrying blood and lymphatic vessels as well as abundant nerves. The body of 
mouse uteri consists of cranial/fundal and caudal/cervical segments. The 
mouse cranial segment is divided into two cavities by a median septum. The 
caudal segment or cervix consists of a single cavity that protrudes into the 
vaginal opening. In mice, the walls of the cervix and the vagina are continuous 
both dorsally and ventrally but not laterally. The lateral vaginal walls extend 
superiorly and form deep fornices on either side (Treuting and Dintzis, 2012). 
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Figure 1.1. Mouse uterus at 5 weeks of age. Mouse uterus has two uterine 
horns which are connected by cervix. Ovaries are attached to each end of 
uterine horns via oviducts. 
 
Histologically, mouse uterus comprises two main tissue compartments: 
endometrium and myometrium (Figure 1.2). Endometrium is the inner layer 
which mainly consists of stromal (loosely arranged reticular connective tissue 
with many small polyhedral cells) and epithelial cells and also contains 
endometrial glands, vessels and nerves. In the non-pregnant mouse uterus, the 
invaginating endometrium is arranged in elevated transverse folds supplied by 
vessels and nerves. The mucosal epithelium consists of simple columnar cells 
that extend into branched tubular glands within the endometrial stroma. The 
endometrium typically contains only 10-20 glands in a cross-section of the 
uterine wall and does not contain the tightly coiled and slightly branched glands 
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characteristic of endometria in humans (Branham et al., 1985a, Branham et al., 
1985b). Myometrium is the outer layer of the uterus which mainly consists of 
smooth muscle fibers separated by loose, highly vascularized connective tissue, 
the stratum vasculosum (Treuting and Dintzis, 2012). The myometrium is 
composed of an inner circular layer and outer longitudinal layer of smooth 
muscle fibres separated by loose connective tissue, the stratum vasculosum. 
The outer serosa is continuous with the mesometrium.  
Endometrial glands in the uterus are lined by epithelial cells (Figure 1.2). They 
synthesize, secrete and transport proteins and related substances that nourish 
the developing embryo (Bazer, 1975, Roberts and Szego, 1953, Simmen and 
Simmen, 1990) and these secretions are vital for the survival and development 
of embryos (Gray et al., 2001b). Therefore, successful morphogenesis of the 
endometrial glands is critical to the gestational capacity of the uterus. 
Furthermore, disrupted endometrial gland formation in adult mice can result in 
permanent infertility (Jeong et al., 2010, Franco et al., 2010). There is also 
evidence that endometrial glands play a role in uterine cancer as a previous 
study has shown that uterine cancers arise from the endometrial glands 
(Newbold et al., 1990). 
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Figure 1.2. Morphology of mouse uterus. Left: mouse uterus consists of 
myometrium (outer layer) and endometrium (inner layer). Endometrium has 
endometrial glands and lumen. Right: endometrial glands and lumen is lined by 
epithelial cells.  
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1.2 Mouse as an experimental model 
The mouse has been widely used to study the hormonal influence on 
development and tumorigenesis of different organs including uterus. Recent 
development of transgenic and knockout mouse models has emerged as a 
powerful tool to experimentally study uterine development and cancer. The 
greatest benefits of the mouse as an experimental model include easy 
availability, low maintenance cost, practicality to perform large group studies 
and availability of technology to genetically modify mice. Despite the great 
advantages, disadvantages exist as well. For developmental studies, rodent 
uterus develops after birth initially involving differentiation of the mesenchyme 
into endometrial stroma and myometrium, whereas the uterine mesenchyme in 
humans is already at birth radially patterned into endometrial stroma and 
myometrium (Gray et al., 2001a). For uterine disorder studies, mice do not shed 
their endometrial tissue like humans and non-human primates and therefore do 
not spontaneously develop certain uterine disorders (i.e. uterine cancer and 
endometriosis) (Grummer, 2006). 
The female genital system in both the female mouse and women is very 
dynamic with morphologic appearance powerfully influenced by hormones 
during estrous/menstrual cycle, pregnancy and ovarian senescence. In 
particular, although the gross anatomy differs between the two species, the 
histologic appearance and basic functions are similar. Although both humans 
and mice are mammals with uteri, there are several structural and functional 
differences (Table 1.1).  
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Table 1.1. Uterine anatomy of mouse and human. Adapted from 
Comparative anatomy and histology by Treuting and Dintziz 2012. 
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1.3 Hormone dependency of the uterine development 
In prior to introducing hormone dependency of the uterus, terminology of 
estrogen and progestogen will be briefly explained. Firstly, estrogen refers to a 
group of female sex hormones which includes hormones such as estrone (E1) 
and E2. E2 is the most abundant estrogen in premenopausal women and it is 
also the most potent estrogen whereas E1 is the most abundant estrogen in 
postmenopausal women.  Secondly, progestogen refers to a group of steroid 
hormones that binds to progesterone receptor (PR) such as P4 and progestins. 
P4 is the major progestogen produced in women whereas progestin is a 
synthetic progestogen. 
Uterus is a highly hormone dependent organ where its growth is promoted by 
estrogens and inhibited by progestins. However, the role of ovarian hormones 
varies depending on the developmental stage of the uterus.  
In 1973, Jost et al established the concept that prenatal uterine development in 
mammals is an ovary-independent process (Jost et al., 1973) as ovariectomy at 
birth did not affect uterine development. Similarly, early postnatal events in 
rodent uterine development and endometrial gland development are both 
ovary-independent (Clark and Gorski, 1970) and adrenal-independent 
processes (Ogasawara et al., 1983, Branham and Sheehan, 1995). In contrast, 
in rodents, from postnatal day 10 to 14, uterine growth becomes ovary-
dependent as ovaries develop and start producing estrogens (Branham and 
Sheehan, 1995). The change is thought to be mediated by the secretion of 
systemic estrogens beginning at this age (Dohler and Wuttke, 1975). 
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Early studies have shown the estrogen-induced growth of the rodent uterus 
(Roberts and Szego, 1953, Mueller et al., 1958, Mueller, 1971). In 1937, it was 
demonstrated that the mitotic activity first became evident in the uterine 
epithelial cells of ovariectomised mouse about 13.5 hours after the 
subcutaneous administration of estrone (Allen, 1937). The mitotic activity 
resulted in hyperplasia and hypertrophy of uterine muscular components 
(Worthington and Allen, 1939). After treatment with E2, uterine weight gradually 
increased with time with substantial increase in the dry weight and cell 
proliferation (Astwood, 1938, Cole, 1950, Roberts and Szego, 1953). 
Furthermore, estrogens stimulate proliferation of both epithelial and stromal 
cells in neonatal mice and this proliferative activity appears to be confined to 
the epithelial compartment in the adult mouse (Martin et al., 1973b, Quarmby 
and Korach, 1984). Mice with low levels of estrogens due to the absence of 
aromatase enzyme (Cyp19a1), have underdeveloped external genitalia and 
uteri at nine weeks of age further supporting the growth promoting role of 
estrogens in uterus (Fisher et al., 1998).  
The uterus undergoes continuous cycle of proliferation and differentiation in 
response to the rise and fall of E2 and P4 during the estrous cycle (Hall, 1969, 
Marcus, 1974) resulting in the morphological changes of the mouse 
endometrium depending on the stage of the estrous cycle. Estrogens act via 
estrogen receptors (ER)s of which there are two types: ERα and ERβ. In the rat 
uterus, overall patterns of ERα and ERβ expression were very similar with both 
receptors present in the luminal epithelium, glandular epithelium and stroma 
(Saunders et al., 1997, Wang et al., 1999). However, ERβ mRNA and protein 
levels are much lower than those of ERα (Kuiper et al., 1997, Wang et al., 1999, 
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Saunders et al., 1997, Matsuzaki et al., 1999). Uterine ERα expression is 
regulated by other steroid hormones such as estrogens, P4 and androgens 
(Rochefort et al., 1972, Wang et al., 1999, Bergman et al., 1992, Wang et al., 
2000).  
The growth promoting role of estrogens through ER has been shown using ER 
knockout mouse models. Complete ERα knockout mice (ERαKO) have 
hypoplastic uteri that contain all characteristic cell types but in reduced 
proportions (Lubahn et al., 1993), which suggest that ERα-mediated actions are 
not essential for organogenic development and differentiation of the uterine 
histogenesis (Hewitt et al., 2010), but essential for normal peripubertal uterine 
growth and development in mice (Lubahn et al., 1993). Hence, this also 
suggests that estrogen action via ERα is required for normal peripubertal 
development and androgens alone cannot support normal peripubertal uterine 
development. On the other hand, complete ERβ knockout mice (ERβKO) mice 
have no defects in female reproductive tract differentiation or fertility (Krege et 
al., 1998), suggesting that estrogen action via ERβ is not essential for normal 
uterine growth and development in mice.  
In contrast, P4 is known to inhibit estrogen-induced hyperplasia of the luminal 
and glandular epithelial compartments (Martin et al., 1973a). As a result, P4 is 
often administered clinically to remove the hyperplastic endometrial effects of 
unopposed estrogen given for postmenopausal hormonal replacement therapy 
(Persson, 1996). Despite growth inhibiting role of P4, functional differentiation 
of the uterus after puberty requires P4 (Spencer et al., 2004). This is supported 
by findings that treatment of neonatal mice with P4 after birth for 5 days 
delayed formation of uterine glands before puberty (at 3 weeks) but increased 
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gland formation after puberty (at 8 weeks) (Stewart et al., 2011). P4 acts via 
progesterone receptor (PR) which is expressed throughout uterus including 
luminal and glandular epithelium, endometrial stroma and myometrium (Kurita 
et al., 2000). In mouse uterus, PR is regulated by E2 via ER (Kurita et al., 2000, 
Tibbetts et al., 1998, Murakami et al., 1990). 
The role of androgens in uterine development will be discussed in a separate 
section 1.5 as it is of the major interest of this thesis. 
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1.4 Androgens and AR 
1.4.1 Androgens 
Androgens are a group of 19-carbon steroid hormones produced mainly in the 
testes and to lesser extent ovaries, adrenal glands and placenta but also in 
peripheral tissues by conversion of precursors. In males, androgens are 
essential for the induction of male secondary sexual characteristics. While 
estrogens (18-carbon steroid hormones) are the main female hormones, there 
are higher concentrations of androgens in circulation than estrogens. 
Androgens circulate from nanomolar to micromolar range, in contrast to the 
picomolar range of circulating estrogens because of the two order of magnitude 
potency difference (Somboonporn and Davis, 2004). The major androgens are 
testosterone and its 5α-reduced more potent metabolite 5α-dihydrotestosterone 
(DHT). Androgens mediate their effects via the AR present in target tissues 
(Somboonporn and Davis, 2004). Using global AR knockout (ARKO) female 
mouse model generated by Cre/loxP system (natural breeding is not possible 
as explained in section 1.4.3) it was recently confirmed that androgens can also 
act directly via AR throughout the female body and exhibit important 
physiological effects (Walters and Simanainen, 2010). In addition, androgens 
are indirectly important in females as testosterone is the precursor hormone for 
E2 biosynthesis in the ovaries and other tissues (Simpson et al., 2000).  
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In addition to the roles of the androgens in sexual function and fertility, 
androgens also have important roles in prostate disorders, cardiovascular risk 
and body composition, bone metabolism, testicular cancer, psychiatric status, 
neurodegenerative disorders. How androgens action in these roles and its 
complexity in its mode of action have recently been reviewed in depth 
(Tirabassi et al., 2015) 
 
1.4.2 Androgen biosynthesis 
In women androgens are biosynthesized in the ovary and in the adrenal gland, 
but in mice the adrenal androgen production is minimal (van Weerden et al., 
1992) (Figure 1.3). The biosynthesis of androgens is modulated by two 
cytochrome P450 (CYP) enzymes. Cholesterol side-chain cleavage enzyme 
(P450Scc) catalyzes cholesterol side-chain cleavage and P450 C17 catalyzes 
17-hydroxylation and 17-20 bond cleavage (17/20 lyase), which is required for 
the production of dehydroepiandrosterone (DHEA) and androstenedione from 
pregnenolone and P4, respectively. DHEA and androstenedione are 
proandrogens because they need to be converted into testosterone to exhibit 
androgenic effects (Somboonporn and Davis, 2004). Circulating testosterone 
can be converted to DHT by 5α-reductase (type 1 and 2) and to E2 by the 
aromatase enzyme. Hence, the regulation of 5α-reductase and aromatase 
enzyme controls DHT or E2 levels. 
 
While 5α-reductase type 1 is expressed in mouse uterus (Mahendroo et al., 
1997), clinical studies have shown contradictory results on aromatase activity in 
human uterus. Endometrium is unable to convert androstenedione to estrone 
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by aromatase activity (Baxendale et al., 1981) whereas another study showed 
aromatization of testosterone in human endometrium (Tseng et al., 1982), 
demonstrating differences possibly due to species in uterine aromatase activity. 
More recent studies have suggested that normal uterine tissues do not have 
aromatase activity, whereas pathological uterine tissues display aberrant 
aromatase activity (Noble et al., 1997, Bulun et al., 1994).  
 
 
 
Figure 1.3. Biosynthesis and metabolism of androgens. Green boxes 
represent progestogens, blue boxes represent androgen and proandrogens and 
pink boxes represent estrogens.  
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1.4.3 Androgen receptor (AR) 
AR is a member of the steroid/thyroid/retinoic acid receptor superfamily. 
Members of this superfamily, including AR, contain several functional domains 
encoded by 8 exons: exon 1 encodes the large N-terminal, exons 2 and 3 
separately encodes the DNA-binding domain consisting of two zinc fingers, and 
exons 4-8 encodes the information for the ligand-binding domain (Figure 1.4) 
(Chang et al., 1988, Trapman et al., 1988). AR exists in a non-DNA-binding 
state as an inactive complex with heat shock proteins in the absence of 
androgens. The AR has higher affinity for DHT than for testosterone (Nicolas 
Diaz-Chico et al., 2007). 
The Ar gene is only located on the X chromosome with no relation to the Y 
allele. Hence, in males it functions solely as a single-copy gene, as shown by 
the complete loss of androgen effect in XY (male) hemizygous individuals with 
an inactivating mutations of the Ar (Avila et al., 2001, Chang et al., 1995). This 
is evident in ARKO male mice where they display female external genitalia, 
typical for complete androgen insensitivity syndrome (cAIS) phenotype in men 
and male mice (Notini et al., 2005b, Quigley et al., 1995). Men and male mice 
with cAIS phenotype are infertile due to loss of spermatogenesis; hence, ARKO 
females cannot be produced by natural breeding. 
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Figure 1.4. Schematic structure of human Ar gene and protein. Top, The Ar 
gene: contains eight coding exons. Bottom, AR protein: the N-terminal domain 
(NTD), the DNA-binding domain (DBD), which contains a pair of zinc finger 
motifs; the hinge region and the ligand-binding domain (LBD).  
 
1.4.4 AR signaling pathway 
In the absence of androgens, AR is located in cytoplasm and exists in a non-
DNA-binding state bound to heat shock protein as chaperones (Figure 1.5). 
When androgens bind to AR, heat shock protein disassociates and AR 
dimerises in an anti-parallel configuration to reveal its DNA-binding domain and 
translocates to nucleus. In the nucleus, AR binds to the androgen responsive 
element (ARE) of the regulated gene with two zinc fingers and thereby activates 
specific gene transcription (Figure 1.5) (Carson-Jurica et al., 1990). In addition, 
it is suggested that AR transactivation could also be induced by growth factors 
such as epidermal growth factor, insulin-like growth factor-1 (IGF-1), 
keratinocyte growth factor (Culig et al., 1994) and cytokines like interleukin-6 
(IL-6) in a ligand independent manner (Hobisch et al., 1998).  
Furthermore, non-genomic signalling of androgens has been suggested which 
occurs through cell-surface receptors. In vitro studies have shown that 
androgens can rapidly induce second messengers such as kinase signalling 
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cascades and these effects have been observed in the presence of 
transcription and translation inhibitors (Kousteni et al., 2001, Heinlein and 
Chang, 2002b). These rapid changes are regarded as non-genomic actions but 
still require binding of androgens to the cell surface receptor. However, full 
molecular characterization of this mechanism has yet to be reported.  
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Figure 1.5. AR signaling pathway. Top: inactivate AR signaling pathway. 
Bottom: active AR signaling pathway. AR=androgen receptor, HSP=heat shock 
protein, ARE=androgen responsive element, green ovals=DNA-binding domain. 
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1.4.5 AR Coregulators 
The functional properties of AR (via transcriptional activity of AR) can be 
regulated by AR coregulators (Heinlein and Chang, 2002a, Heemers and 
Tindall, 2007). By a definition, AR coregulators are proteins that are recruited 
by AR and either act as coactivators or corepressors of transcription activity. 
But AR coregulators do not alter the basal transcription rate and do not typically 
possess DNA binding ability. Instead, coregulators influence AR-mediated 
transcription by acting at the target gene promoter region to facilitate DNA 
occupancy, chromatin remodelling, and/ or recruitment of general transcription 
factors associated with RNA polymerase II, or by assuring the competency of 
the AR to enhance gene expression directly (Heemers and Tindall, 2007). 
There are more than 200 nuclear receptor coregulators identified. In-depth 
reviews on AR coregulators have been published by Heinlein and Chang 
(Heinlein and Chang, 2002a) and Heemers and Tindall (Heemers and Tindall, 
2007). Androgen-responsive tissues like prostate and breast rely on AR-
coregulators as suggested by studies in various mouse models and cell lines 
(reviewed in (Heemers and Tindall, 2007, Heinlein and Chang, 2002a)). 
There are coregulators reported to either positively or negatively modulate or 
modify ligand-dependent transcription by nuclear receptors (reviewed in 
(Heemers and Tindall, 2007)). Some AR coregulators are specific to AR alone 
but most other coregulators have broader range of interaction and coregulation 
with other nuclear receptors (reviewed in (Heemers and Tindall, 2007)). For 
example, ARA70 was initially regarded as AR specific coregulators but has 
since been shown to modulate transcription by several other nuclear receptors 
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such as ER, PR and glucocorticoid receptor (GR) (Alen et al., 1999, Yeh and 
Chang, 1996). 
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1.5 Androgens, AR and uterus  
There is increasing evidence that androgens and AR play a vital role in uterine 
physiology. This section discusses the expression, regulation and role of 
androgens in uterus. 
1.5.1 AR expression in the uterus 
AR is expressed in the uterus both in rodents (Pelletier et al., 2004, Hirai et al., 
1994) and humans (Kimura et al., 1993, Ito et al., 2002) in a similar manner. AR 
protein was detected in the epithelial and stromal cells in endometrium and 
myometrial cells of the human uterus (Ito et al., 2002, Kimura et al., 1993). 
Similarly in the mouse uterus, AR mRNA was expressed in the luminal and 
glandular epithelial cells, stromal cells and smooth muscle cells (Pelletier et al., 
2004) and the intensity of AR mRNA labelling is quite uniform throughout the 
different uterine compartments (Figure 1.6). 
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Figure 1.6. AR immunopositivity in adult mouse uterus. AR 
immunopositivity (brown staining) is abundant throughout different 
compartments of uterus including glandular and luminal epithelial cells, stroma 
and myometrium at diestrus stage (Choi, unpublished). 
 
1.5.2 Regulation of AR expression in the uterus 
Expression and localization of AR is highly regulated by E2 as ovariectomy 
significantly reduces uterine Ar mRNA expression (18% in the epithelial cells, 23% 
in the stromal cells and 50% in the myometrial cells compared to WT controls) 
and the expression was completely restored after E2 administration (Pelletier et 
al., 2004). In addition to E2, AR expression is also regulated by P4 with P4 
treatment in women and rhesus macaques reducing uterine AR expression that 
was reversed by P4 antagonists (RU 486) (Slayden et al., 2001). Furthermore, 
RU 486 treatment caused striking up-regulation of glandular epithelial AR 
staining and enhanced stromal AR signaling (Slayden et al., 2001). Due to the 
hormonal regulation, AR expression also varies depending on the estrous cycle. 
In human uterus, AR was immunolocalized predominately in stromal cells during 
the proliferative phase and in epithelial cells during the secretory phase (Ito et 
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al., 2002). AR expression is not detectable during the late secretory phase 
(Mertens et al., 2001). In addition, AR expression may be regulated by 
androgens in an auto-regulation manner as shown in the rat prostate where 
castration reduced AR expression (Prins and Birch, 1993).  
 
1.5.3 Androgen effects on uterine growth  
Androgens may have growth promoting role in the rodent uterus as shown in 
previous studies (Armstrong and Papkoff, 1976, Schmidt and Katzenellenbogen, 
1979, Nantermet et al., 2005, Walters et al., 2009). In 1976, Armstrong and 
Papkoff demonstrated that the administration of androgens (testosterone or 
DHT) for 3 days in immature hypophysectomised rats at three weeks old caused 
marked increase in uterine weights (Armstrong and Papkoff, 1976) suggesting 
the growth promoting role of androgens in uterus. This was further supported 
when DHT treated immature rats showed increased uterine growth which was 
reversed by antiandrogen treatment (flutamide) (Schmidt and Katzenellenbogen, 
1979).  
The growth promoting effect of androgens was suggested to involve interaction 
of androgens with both the AR and ER in the uterus. This was supported as 
high dose of DHT (5 or 10mg) causes nuclear translocation and cytoplasmic 
depletion of the ER (Schmidt and Katzenellenbogen, 1979). In addition, a more 
recent study suggested that in E2 induced epithelial cell proliferation, ERα 
induces stromal AR and AR in reverse amplifies the ERα signal by induction of 
IGF-1 (Weihua et al., 2002) an effect that is blocked by AR antagonist 
(bicalutamide) (Nantermet et al., 2005). This indicates an important proliferative 
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role of androgens acting via AR in uterus where estrogens and androgens may 
act via one pathway in sequential steps (Weihua et al., 2002). Furthermore, it 
has been suggested that the non-aromatizable androgen, DHT, requires ERα to 
promote uterine growth as DHT could not induce uterine growth in ERαKO mice 
(Nantermet et al., 2005). However, DHT does not appear to directly activate 
ERα as multiple ERα dependent genes were not induced by DHT. The growth 
promoting role of androgens in uterus was further supported by global AR 
knockout (ARKO) transgenic mouse model. The ARKO female mice have 
thinner uterine wall and reduced total uterine area compared to the controls 
(Walters et al., 2009), suggesting the growth promoting or morphogenesis role 
of androgens in uterus is via AR. Hence, these in vivo studies collectively build 
evidence to suggest a growth promoting AR dependent role of androgens in 
uterus.  
However, an in vitro study suggested a local, uterine specific AR mediated 
inhibitory role of aromatizable pro-androgen, androstenedione on the 
proliferation of human endometrial epithelial cells. The effect was mediated via 
AR as it was reversed by antiandrogen (cyproterone acetate) (Tuckerman et al., 
2000). Therefore, the role of androgens on uterine growth still remains 
contradictory from in vivo and in vitro studies; hence, part of this PhD project 
aimed to clarify the contradicting findings in the past by confirming the in vivo 
role of AR mediated androgen actions in uterine growth. In addition it was 
intended to determine the extrauterine and intrauterine androgen effects as well 
as cell specific role of AR in uterus as AR is expressed in all the uterine cells. 
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1.6 Uterine cancer 
1.6.1 Uterine cancer statistics 
Globally, uterine (endometrial) cancer is the seventh most common malignant 
disorder and most commonly diagnosed gynaecological cancer (Parkin et al., 
1999). Uterine cancer incidence varies among regions with less developed 
countries (i.e., African countries) having low endometrial cancer incidence but 
higher specific mortality when compared to developed countries (i.e., European 
countries) (Hill et al., 1996, Madison et al., 2004). In 2010, uterine cancer was 
the second most common cause of gynaecological cancer death in Australia, 
accounting for 2% of all cancer deaths in women (Welfare, 2012a) and around 
4% of all new cancers in Australian women (Welfare, 2012a). The time of 
uterine cancer diagnosis is at 64.1 years of age with the risk of developing 
uterine cancer before the age of 85 years in women was 1 in 48 (Welfare, 
2012a). The incidence of uterine cancer has increased between 1982 and 2009 
in Australia. The age-standardised incidence increased from 13.8 to 17.1 cases 
per 100,000 women (Welfare, 2012a). However, the age-standardised mortality 
rate of uterine cancer in women decreased from 3.3 to 2.7 deaths per 100,000 
women between 1982 and 2010 (Welfare, 2012a), likely due to the improved 
diagnosis and treatment. The relative survival rates for uterine cancer have 
increased in recent years in Australia. Five-year relative survival rate was 82% 
between 2006 and 2010 which has been steady in previous reports (Welfare, 
2012a).  Therefore, uterine cancer remains a fatal and frequent cancer among 
women in developed countries and warrants further investigation into uterine 
cancer prevention and treatment.  
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Despite the improving mortality rate and high five-year survival rate, uterine 
cancer is estimated to be the leading cause of the burden of disease in 
Australia (Welfare, 2012a) as removal of the uterus as a treatment results in 
females becoming infertile. In 2012, uterine cancer was estimated to account 
for 5,300 disability-adjusted life years (DALYs) in Australia; of these, 3,700 
were years lost due to premature death and 1,600 were years of health life lost 
due to disease, disability or injury (Welfare, 2012b).  
 
1.6.2 Hormonal risk factors for uterine cancer 
Although the mechanisms still remain unknown, endogenous hormones appear 
to play an important role in the development of uterine cancer. Increased 
uterine cancer risk has been associated with early menarche and late 
menopause suggesting a relationship with greater lifetime estrogen exposure at 
premenopausal levels (Kaaks et al., 2002). Other factors related to hormone 
exposure include nulliparity (exposure to P4 in pregnancy), long term use of 
tamoxifen as a breast cancer treatment (tamoxifen acts as estrogen agonist in 
uterus), hormone replacement therapy (progestagens) and years of 
menstruation (estrogen exposure) (Kaaks et al., 2002, Weiss and Hill, 1996, 
Emons et al., 2000, Rose, 1996). Furthermore, plasma concentrations of 
increased estrogens and androgens and decreased P4 are known to increase 
risk of uterine cancer (Potischman et al., 1996). 
The most popular theory describing the relationship between endogenous 
steroid hormones and endometrial cancer risk is known as the “unopposed 
estrogen hypothesis” (Siiteri, 1978, Key and Pike, 1988). This hypothesis 
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proposes that endometrial cancer risk increased in women with high plasma 
estrogens and/or low plasma P4, so that overall mitogenic effects are increased 
causing proliferation. This theory was proposed based on two important 
observations: 
i) Increased endometrial proliferation rates during the follicular phase of 
the menstrual cycle, during which progesterone levels are low, 
whereas E2 levels are at normal premenopausal concentration (Key 
and Pike, 1988, Ferenczy et al., 1979).  
ii) Increased endometrial cancer risk among women using exogenous 
estrogens without progestins (1999).  
In addition, to classical ovarian hormones, recent studies have suggested 
androgens and AR play a vital role in uterine cancer (Ito et al., 2002, Rodriguez 
et al., 2006). The role of androgens has been associated with 5-fold increased 
risk of uterine cancer in patients with polycystic ovarian syndrome (PCOS) 
(Kaaks et al., 2002). The PCOS is a metabolic and endocrine alteration that 
results in hyperandrogenism. However, the excessive androgens that are 
produced can be converted to estrogens to produce an estrogen enriched 
environment and therefore the specific role of androgens is not clear (further 
discussed in section 1.9).  
On the other hand, factors that are suggested to reduce uterine cancer risk 
include multiparity (increase P4 exposure due to pregnancy) (Hinkula et al., 
2002), oral-contraceptives (P4 based) (Deligeoroglou et al., 2003), smoking 
(decreases estrogen sensitivity) (Viswanathan et al., 2005), physical activity 
(Schouten et al., 2004) and phyto-estrogens reduced diet (Unfer et al., 2004). 
28 
 
The relevant factors that regulate the risk of uterine cancer have been 
summarised in table 1.2. 
Table 1.2. Factors regulating the risk of uterine cancer (adapted from Amant et 
al, 2005). 
 
These hormonal risk factors mentioned above were supported by experimental 
studies (Takasugi et al., 1962, Rustia and Schenken, 1976, Rustia, 1979, Troisi 
et al., 2007). The protective effect of P4 on uterine cancer has been shown 
using progestins (synthetic analogs of P4) (Mortel et al., 1990). The human 
endometrial carcinoma transplants treated with high doses (2 and 5mg) of 
progestin resulted in the better control of uterine cancer growth (Mortel et al., 
1990). The protective role of P4 in uterine cancer was further supported using 
PR knockout mouse (PRKO) model (Kurita et al., 1998, Mulac-Jericevic et al., 
2000). P4 treatment significantly decreased uterine size in mice with 
endometriosis, while PRKO females did not respond to P4 treatment, 
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demonstrating that the effect of P4 was PR mediated. In addition, the E2 
treatment induced growth of uterus was suppressed by P4 treatment in WT but 
not in PRKO females (Fang et al., 2004). This finding suggests P4 actions 
through PR are responsible for opposing E2 dependent uterine growth. 
However, as the model has PR inactivation not only in the uterus but also in 
other organs such as ovary and pituitary (Lydon et al., 1995), the study cannot 
conclude whether the protective role of P4 is via intra-uterine or extra-uterine 
PR, however, this was confirmed in another study (Kurita et al., 1998).  
 
1.6.3 Prevention and treatment of uterine cancer 
As described above, uterine cancer is highly hormone dependent cancer and 
accordingly hormonal prevention and treatment methods have been widely 
implemented.  As mentioned previously (Section 1.3), P4 is known to inhibit 
estrogen-induced hyperplasia of the luminal and glandular epithelial 
compartments (Martin et al., 1973a). Hence, progestins have been widely used 
to treat uterine cancer. However, not all uterine cancers respond well to 
progestin treatments, this is mainly due to the variable PR expressions in 
uterine cancers. Some studies have reported ineffectiveness of progestin 
treatments in uterine cancer (reviewed in (Banno et al., 2012)) and also PTEN 
(phosphatase and tensin homolog) inactivation induced uterine cancers in mice 
are nonresponsive to progestin treatments (Fyles et al., 2008). On a positive 
note, there are other treatments used for uterine cancers which include use of 
anti-estrogens (i.e. tamoxifen), aromatase inhibitors (i.e. letrozole) and 
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gonadotropin-releasing hormone agonists (i.e. leuprolide), and also surgery 
(total hysterectomy) and radiotherapy (Bender et al., 2011, Amant et al., 2005). 
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1.7 PTEN and uterine cancer  
In addition to hormonal factors, genetic factors such as first-degree relative with 
endometrial cancer and PTEN mutations may increase the risk of uterine 
cancer (Risinger et al., 1997). Deletions and mutations in Pten gene are found 
in a high frequency in many sporadic human cancers, including glioblastomas, 
as well as endometrial, prostate, and breast cancers (Dahia, 2000). 
1.7.1 PTEN pathway 
The PTEN protein consists of a 179-residue N-terminal domain (residues 7-185) 
and a 166-residue C-terminal domain (residues 186-351). The N-terminal 
domain contains the protein tyrosine phosphatase (PTP) signature motif and 
the large phosphatase active site in PTEN allows accommodation of a 
phosphotidylinositol-3,4,5-triphosphate (PIP3) substrate. (Lee et al., 1999).  
PTEN functions as a phosphatase with both lipid and protein phosphatase 
activities (Maehama and Dixon, 1998, Myers et al., 1998, Li and Sun, 1997). As 
a lipid phosphatase, PTEN dephosphorylates PIP3, a product of 
phosphotidylinosital-3-kinase (PI3K) (Maehama and Dixon, 1998, Stambolic et 
al., 1998, Sun et al., 1999). By dephosphorylating PIP3, PTEN inhibits the 
growth factor signals transduced through PI3K by inhibiting the AKT 
phosphorylation (Figure 1.7). PTEN deficiency leads to accumulation of PIP3 
that in turn activates several signaling molecules including the 
phosphotidylinositol-dependent kinases (PDKs), the serine/threonine kinases 
AKT/PKB, S6 kinase, and mTOR, as well as small GTPases Rac1 and Cdc42 
(Anderson et al., 1998, Liliental et al., 2000, Pene et al., 2002, Stiles et al., 
2002, Sun et al., 1999, Wu et al., 1998). 
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Figure 1.7. Influence of PTEN and PI3K in AKT pathway. PI3K 
phosphorylates PIP2 to PIP3 which promotes cell survival by phosphorylating 
AKT (P-AKT). Whereas, PTEN opposes PI3K pathway by dephosphorylating 
PIP3 to PIP2, hence AKT remains unphosphorylated. 
 
1.7.2 Function and biological role of PTEN 
PTEN has a broad impact on cell growth, cell migration, cell death, and cell 
differentiation, processes involved in normal development (reviewed in (Stiles et 
al., 2004)). An important role during development is demonstrated in PTEN 
knockout mouse models where the homozygous PTEN knockout is embryo 
lethal with fetal mice dying between gestation day 6.5-9.5 (Suzuki et al., 1998, 
Podsypanina et al., 1999). Mice with heterozygous PTEN inactivation do 
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survive but develop various cancers including uterine cancer during their 
lifetime (Stambolic et al., 2000). Therefore, PTEN is identified as a tumor 
suppressor gene which inhibits cell growth/survival (Liscovitch and Cantley, 
1994, Vanhaesebroeck et al., 1997) and cell migration/adhesion (Tamura et al., 
1998) through its lipid and protein phosphatase activities, respectively. PTEN 
induces growth suppression by at least two mechanisms. Firstly, it promotes 
cell-cycle arrest at the G1 phase and also increases apoptosis induced by 
multiple distinct stimuli. As an example, in the presence of ectopic expression of 
PTEN, glioblastoma and renal carcinoma cells arrest at G1 phase (Furnari et al., 
1998, Ramaswamy et al., 1999). This function of PTEN is dependent on P-AKT, 
where P-AKT rescued the cell line from PTEN-induced G1 arrest (Li and Sun, 
1998, Ramaswamy et al., 1999). PTEN also have ability to suppress growth 
and tumor progression by increasing cellular apoptotic rates (Li and Sun, 1998, 
Stambolic et al., 1998). PTEN inactivation in mice was shown to reduce the 
sensitivity to apoptosis induced by UV, heat shock and radiation, while the 
introduction of PTEN to these mice restored the apoptotic sensitivity (Stambolic 
et al., 1998).  
 
1.7.3 PTEN and estrogen sensitivity 
While the PTEN deletion and estrogen actions via ER are both associated with 
the development of uterine cancer, a relationship between PTEN and estrogen 
sensitivity has also been reported. A physiological and functional link between 
loss of PTEN and increase in ER activity was suggested by the development of 
estrogen-related neoplastic lesions in the non-hyperestrogenic mouse models 
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with PTEN inactivation (Vilgelm et al., 2006). Supporting this, several in vitro 
studies have further suggested the existence of co-operation between PTEN 
and ERα through P-AKT. It was suggested that activation of P-AKT pathway by 
loss of PTEN also activates ERα (Campbell et al., 2001, Sun et al., 2001). 
Similarly, in MCF-7 breast cancer cells the activation of PI3K/ AKT pathway 
increases ERα transcriptional activity (Stoica et al., 2003), these findings also 
supported by in vivo studies (Lian et al., 2006, Vilgelm et al., 2006). Increased 
activation of both P-AKT and ERα is required for uterine cancer development in 
heterozygous PTEN inactivated mouse models. Conversely, induction of PTEN 
resulted in reduction of P-AKT and parallel decrease in the ERα activation 
resulting in reduced uterine cancer in mice (Vilgelm et al., 2006). Furthermore, 
increased ERα activity following PTEN inactivation is supported by findings that 
heterozygous PTEN inactivation altered the known ERα regulated genes in the 
uterus, mimicking hyperestrogenic environment (Lian et al., 2006).  
 
1.7.4 PTEN and AR interaction 
The possible interaction of AR and PTEN has been established in hormone 
dependent cancers like breast and prostate cancers (Wang et al., 2011b). 
Recent in vivo and in vitro studies have shown that AR and PTEN can cross-
regulate each other by reciprocal feedback (Carver et al., 2011, Mulholland et 
al., 2011).  
In prostate cancer cells, depending on the growth stages of cell lines, AR 
transactivation was suppressed or not effected by PTEN via PI3K/AKT 
pathways (Lin et al., 2001, Mulholland et al., 2011, Li et al., 2001, Nan et al., 
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2003, Lin et al., 2004). Suppression of AR transactivation was supported by 
finding that PTEN loss in the prostate epithelium suppressed androgen-
responsive gene expression in vivo (Mulholland et al., 2011). Furthermore, 
PTEN was demonstrated to repress AR nuclear translocation and induce AR 
degradation in prostate cancer cells (Lin et al., 2004, Lin et al., 2002). PTEN 
can bind to the hinge region of AR resulting in the interruption of the nuclear 
localization signal (NLS) and thereby inhibiting nuclear translocation of AR (Lin 
et al., 2004). Alternatively, PTEN could also compete with other AR 
coregulators for the same binding region, inhibiting nuclear translocation (Lin et 
al., 2004). Moreover, it has been reported that the PI3K/AKT pathway promotes 
AR ubiquitination, leading to AR degradation (Lin et al., 2002). This suggests 
that both PTEN and the PI3K/AKT pathway can promote AR degradation. While 
the interaction has been demonstrated mainly in prostate cancers and to some 
extent in breast cancers, similar PTEN mediated inhibition of AR could occur in 
other PTEN-AR target tissues such as the uterus. As PTEN can regulate AR in 
prostate cancers, it strongly suggests the PTEN and AR interaction; however, in 
reverse whether AR can regulate PTEN has not been studied in depth. 
Although a recent study suggests the reverse interaction where AR regulates 
PTEN transcription and translation in breast cancer cells (Wang et al., 2011a). 
The study suggested that AR upregulates PTEN transcription in breast cancer 
cells (Wang et al., 2011a) and AR and PTEN may interact in certain apocrine 
type breast cancers (Banneau et al., 2010). However, there have been no 
previous reports suggesting the interaction in uterine cancer and our current 
study aims to investigate the role of AR in PTEN regulation in uterine cancers.  
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1.7.5 PTEN mutations  
PTEN is frequently inactivated by somatic mutations in a wide array of human 
tumors including uterine cancer (Chow and Baker, 2006). In addition, germline 
mutation of one allele of PTEN results in hereditary cancer predisposition 
causing Cowden syndrome (CS) (Liaw et al., 1997). PTEN mutations in CS 
tend to cluster at, but are not limited to, exon 5, which encodes the 
phosphatase signature motif. CS is an autosomal dominant disorder which 
comprises multiple hematomas in tissues derived from the three major 
embryological layers, and is associated with a higher risk of endometrial cancer, 
breast cancer and thyroid cancer (25-50% of affected females), and in a subset 
of cases, a dysplatic gnaglyocytoma of the cerebellum, Lhermitte-Duclos 
disease, might also develop (Dahia, 2000). 
Previous studies have shown that germline PTEN mutations are observed in 
30-80% of type I endometrial carcinomas (EMCs) and in ~20% of complex 
atypical hyperplasia where complex atypical hyperplasia is a precursor stage to 
type I EMC (Risinger et al., 1998, Tashiro et al., 1997).  
 
1.7.6 PTEN knockout mouse as uterine cancer model 
Mice do not naturally develop uterine cancer; however, such cancers are only 
observed by using genetically modified mouse models (i.e. Pten inactivation) 
and/or hormone treatments (i.e. estrogens). In the context of genetically 
modified mouse models, PTEN knockout mouse models have been widely used 
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as these models develop atypical endometrial hyperplasia with ~20% of them 
progressing to develop well-differentiated uterine cancer by age of 40 weeks, 
although the timing and incidence varies between mice and studies (Daikoku et 
al., 2008, Vilgelm et al., 2006, Podsypanina et al., 1999, Stambolic et al., 2000). 
Therefore, the PTEN knockout females provide a good environment to 
investigate uterine cancer in short experimental time with low cost. PTEN 
knockout mouse models are generated using specific Cre/loxP transgenic 
system. Cre/loxP system allows generation of either global heterozygous PTEN 
knockout (global Cre deletor mouse line) or tissue specific, homozygous PTEN 
knockouts (tissue specific Cre deletor line).  
Heterozygous global Pten knockout: Heterozygous global PTEN 
knockout mouse models have been created by homologous recombination 
strategy (Di Cristofano et al., 1998) and cre/loxP system using global-cre 
promoter (Stambolic et al., 2000). Both of these models generated by 
homologous recombination strategy and cre/loxP system induced wide range of 
tumors resembling CS patients with uterine cancers. A majority of the tumors 
exhibited loss of heterozygosity at the Pten locus and activated P-AKT and ERα 
pathway (Stambolic et al., 2000, Di Cristofano et al., 1998). All heterozygous 
PTEN knockout females generated using cre/loxP system (65 out of 65) 
developed endometrial hyperplasia and 14 of 65 mice developed uterine cancer 
(Stambolic et al., 2000).  
The advantage of this global, heterozygous PTEN knockout mouse model is 
that uterine cancers in these mice resemble uterine cancers in CS patients; 
hence it is an excellent model to investigate PTEN-related hematoma 
syndromes as well as the role of PTEN in uterine cancer. However, the 
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disadvantage of this model in experimental studies is that there is still an intact 
copy of Pten as it is a heterozygous inactivation. This brings complexity of 
investigating the sole role of PTEN in experimental studies.  
Endometrial specific Pten knockout: To generate homozygous 
endometrial specific Pten knockout mouse model (Soyal et al., 2005), the PR 
promoter was used to drive the Cre (PR-Cre) in the uterine endometrial cells. 
All these mice developed endometrial cancer as early as age of one month with 
myometrial invasion occurring by 3 months  and had a lifespan of around five 
months compared to eight months in WT females (study only followed up to 
eight months of age so far) (Daikoku et al., 2008). All early stage lesions found 
in this mouse model exhibited elevated P-AKT levels. The disadvantage of this 
model is the non-uterine expression of Cre in the PR-Cre females. Cre 
expression and Cre mediated excision of DNA between the loxP sites was also 
detected in ovary, oviduct, mammary gland and pituitary (Soyal et al., 2005). 
Therefore, the knockout model generated using this model could also exhibit 
systemic effects making this mouse model not a truly endometrial specific 
knockout. 
Uterine endometrial epithelium and stroma specific PTEN 
inactivation: Conditional gene recombination by adenovirus-driven cre has 
been used to generate homozygous epithelial and stromal specific PTEN 
knockout (advPTENKO) in the endometrium of mouse uterus (Joshi and 
Ellenson, 2011, Wang et al., 2006). advPTENKO had increased incidence of 
uterine carcinoma when compared to the global heterozygous Pten inactivated 
mouse model (Joshi and Ellenson, 2011). Furthermore, the uterine carcinomas 
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found in advPTENKO were more aggressive with invasion into myometrium and 
also surrounding adipose tissues.  
The advantage of this model is that PTEN inactivation is specific to the 
endometrial layer of the uterus (epithelial and stromal cells). However, the 
disadvantage is the recombination strategy as it is difficult to control the amount 
and the localization of cre administered by adenovirus within the endometrial 
layer of the uterus. This may result in high variability of amount and localization 
of the PTEN knockout between individual experimental mice. 
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1.8 Androgens, AR and uterine cancer 
As previously described in section 1.5, androgens and AR play an important 
role in regulating uterine growth and development, but androgens and AR are 
also suggested to play a significant role in uterine cancer. The possible role of 
androgens acting via AR is supported by previous studies showing AR 
expression in 65-80% of endometrial cancers (Ito et al., 2002, Prodi et al., 1980, 
Takeda et al., 1990, Mertens et al., 1996, Horie et al., 1992). In endometrial 
hyperplasia, AR was detected in the nuclei of both epithelial, stromal cells and 
in hyperplastic glands (Ito et al., 2002). In uterine cancer, weak AR 
immunoreactivity was detected in the stromal cells and strong AR was detected 
in the nuclei of carcinoma cells (Ito et al., 2002). 
The indirect role of androgens in uterine cancer has been extensively 
suggested in patients with PCOS. PCOS is a complex metabolic syndrome, 
which is characterized by elevated plasma androgens and ovarian 
hyperandrogenism (Potischman et al., 1996, Austin et al., 1991, Gimes et al., 
1986, Mollerstrom et al., 1993, Nagamani et al., 1986) and patients with PCOS 
have increased risk of developing uterine cancer (Coulam et al., 1983, 
Smyczek-Gargya and Geppert, 1992).  Most widely accepted mechanism may 
explain the risk of uterine cancer in PCOS patients is known as “unopposed 
estrogen” as these patients have persistently elevated levels of circulating E2 
from aromatization of excess androgens(further described in section 1.6.2). 
The role of AR in uterine cancer is also supported by the findings that the 
increased AR activity in women may increase uterine cancer risk (McGrath et 
al., 2006) suggesting androgens via AR may increase uterine cancer. The 
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increased AR activity in these women is due to shorter CAG repeat in AR and it 
has been demonstrated that CAG repeat in exon 1 of the Ar gene is inversely 
correlated with androgen sensitivity (Simanainen et al., 2011a). In contrast, also 
a positive correlation between increased CAG repeat length in Ar gene 
(reduced androgen sensitivity) and uterine cancer risk has been reported 
(Sasaki et al., 2003, Yaron et al., 2001). The discrepancy among these studies 
could be due to the different ethnic differences in genotype distribution, sample 
size and control selection. 
Despite the clinical findings suggesting androgen actions in uterine cancer, the 
experimental studies supporting these findings are sparse. In 1961, 
testosterone was shown to induce uterine cancer in mice, however, the 
histological characteristics of these specific uterine cancers differ from the 
uterine carcinomas and uterine sarcomas described previously (van et al., 
1961). In addition, more recently, the 5α-dihydrotestosterone-benzonate (DHT-
B) alone (implant) induced proliferation of uterine endometrial epithelium and 
myometrial smooth muscle cells (Zhang et al., 2004) and when co-administered 
with E2, the females developed severe endometrial and myometrial hyperplasia 
that was greater than induced by E2 alone. This study suggests carcinogenic 
effects of androgens in the uterus and also suggests the synergistic effects of 
androgen with already well known carcinogen, E2. 
Contradicting the postulate that androgens increase uterine cancer risk, one 
study has shown that danazol (synthetic androgen with no estrogenic activity) 
has preventive effects on E2 induced-uterine cancer in mice (Niwa et al., 2000). 
The possible mechanisms suggested for the preventive effects of danazol 
include the suppression of endometrial cell growth by inhibiting estrogen-
42 
 
induced c-fos/jun-expression, decreasing ovarian E2 synthesis (Niwa et al., 
2000) and/or directly acting via AR in the uterus (Rigano et al., 1999). However, 
it should be noted that danazol has ability to shut down the hypothalamus-
pituitary-gonad axis and activate PR; hence, these characteristics of danazol 
could have an indirect effect on uterine cancers. Furthermore, an in vitro study 
has shown proliferation of MFE-296 cells [AR-positive endometrial cancer cell 
line (unresponsive to estrogen)) was inhibited by DHT (Hackenberg et al., 
1994). The effect of DHT was antagonized by anti-androgens, suggesting the 
involvement of the AR.  
In summary, despite the contradictory studies on the role of androgens and AR 
in uterine cancer, it is certain that androgens and AR do play important roles in 
uterine cancer progression. Different results from previous studies could be due 
to the distinct types of androgens used in the experiments (i.e. aromatizable vs 
non-aromatizable). Also, the role of androgens acting via AR in uterine cancer 
could be dependent on presence of other steroid hormones such as E2. Hence 
further investigation on the role of androgens via AR in uterus and uterine 
cancer is warranted. 
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1.9 Objectives and aims 
Previously, androgens have been known as “male hormones” where most 
extensive studies have been conducted investigating the role of androgens in 
male reproductive physiology and pathology such as prostate. However, 
although recent studies have shown important direct role of androgens via AR 
in female reproductive physiology and pathology, the role of androgens via AR 
in females remains not well characterized. Hence, the current project aims to 
provide novel evidence and specific mechanistic information on androgen 
actions in the highly hormone dependent organ, the uterus, both in 
developmental physiology and uterine carcinogenesis. This has been achieved 
by utilizing our laboratory’s novel female mouse model, where AR is inactivated. 
Furthermore, to induce uterine cancers, AR inactivated mouse model is 
combined with a unique mouse model with inactivation of PTEN and therefore 
susceptible for development of uterine cancers. Therefore our specific 
hypothesis and aims are: 
 
Hypothesis one: Androgens acting via AR can support uterine growth and the 
growth promoting effect of androgens is mediated via AR in uterus.  
Aim one: Generate and validate uterine glandular epithelial specific AR 
knockout (ugeARKO) mouse model using Cre/LoxP strategy. Thereby 
investigate the role of AR in uterine growth and functions (Chapter 3). 
 
Hypothesis two: Androgen actions via AR may increase PTEN inactivation 
induced uterine pathology 
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Aim two: Investigate the role of global AR inactivation in PTEN deletion 
induced uterine cancer (Chapter 4). 
 
Hypothesis three: Androgen actions via glandular epithelial AR may increase 
PTEN inactivation induced uterine pathology 
Aim three:  
Investigate the effect of glandular epithelial AR inactivation in PTEN inactivation 
induced uterine pathology (Chapter 5). 
 
Thus, the combination of these unique mouse models provide exciting platform 
to determine the mechanisms of male hormone, androgen actions in initiation, 
progression and therapy of breast and uterine cancer.  
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Chapter 2: General methods and 
materials 
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2.1 Mouse models 
All experiments conducted in this PhD project were approved by the Animal 
Welfare Committee of the Sydney Local Health District within NHMRC 
guidelines for animal experiments. All experimental mice were bred and kept in 
the animal facility at the ANZAC Research Institute, Molecular Physiology Unit 
(MPU). This facility is maintained under the PC2 requirements and equipped 
with 12 hour light/dark cycle with lights on from 6am to 6pm daily. Mice were 
kept in a plastic cage with filter top lids under specific pathogen free (SPF) 
conditions and had unlimited access to food and water. 
 
2.1.1 Mouse lines 
Tg(Sox2-cre)1Amc (denoted SOX2-Cre)  
SOX2-Cre mice with FVB/N background were kindly donated by Dr. L Rob 
(Walter and Eliza hall Institute, Australia) and Professor A McMahon (Harvard 
University, USA). The Cre expression is regulated by the SRY-box containing 
gene2 (Sox2) promoter to drive Cre expression in all cells already during early 
embryonic development (embryonic day 6.5) (Hayashi et al., 2002). 
 
Tg(Pbsn-cre)20Fwan (denoted PBSN-Cre) 
PBSN-Cre mice with FVB/N background were kindly donated By Dr. F Wang 
(Centre for Cancer Biology and Nutrition in Houston, USA). The Cre expression 
is regulated by probasin (PBSN) promoter to drive Cre expression in prostate 
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epithelial cells (Jin et al., 2003) and in uterine glandular epithelial cells (Chapter 
3). 
 
Artm1Jdz (denoted ARflox)  
ARflox mice were originally C57BL/6 background and were generated in 
collaboration with Professor J Zajac (University of Melbourne, Australia). For this 
PhD project, ARflox mice were backcrossed to the FVB/N background for at 
least 6 generations. In these mice, the exon 3 of the Ar gene is surrounded by 
the LoxP sites, where exon 3 encodes the 2nd zinc finger of the AR DNA binding 
domain which is required for stabilizing DNA binding of the AR. Excision of exon 
3 causes in-frame mutation leading to continuous transcription and protein 
translation (Figure 2.1) (Notini et al., 2005a). It is important to note that there are 
number of different Ar knockout models available which have been thoroughly 
compared in two recent review papers (Rana et al., 2014, Walters and 
Simanainen, 2010). The exon 3 deleted Ar knockout model was chosen due to 
its unique characteristic of in-frame mutation of Ar gene rather than frameshift 
mutation in other models. This creates a minimally truncated AR which is fully 
inactivated but is much closer to physiological than the major deletions of the 
AR protein created by introducing stop codons early into the translated protein 
which abrogates all co-regulator interactions. 
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Figure 2.1. Schematic presentation of Cre/LoxP mediated excision of exon 3 of 
Ar. 
 
Ptentm1Hwu (denoted PTENflox)  
In PTENflox mice with FVB/N background, the exon 5 of the Pten gene is 
surrounded by the LoxP sites. Excision of exon 5 produces premature stop 
codon, leading to early termination of transcription and protein translation 
(Figure 2.2) (Lesche et al., 2002). 
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Figure 2.2. Schematic presentation of Cre/LoxP mediated excision of exon 
5 of Pten. 
 
Gt(ROSA)26Sor (denoted R26R) 
R26R mice were kindly donated by Dr. W Alexander (Walter and Eliza hall 
Institute, Australia). R26R mice have a bacterial lacZ gene encoding the 
enzyme β-galactosidase (Soriano, 1999). In R26R mouse, a transcriptional stop 
codon (bacterial lacZ gene) is flanked by loxP sites. When intact, this stop 
codon prevents the expression of β-galactosidase (β-gal) from the downstream 
lacZ coding sequence. When Cre is present, stop codon is excised and permits 
expression of β-galactosidase (β-gal), which stains x-gal to blue cells (Figure 
2.3). 
 
All founder lines are viable, fertile, and normal in size and display no gross 
physical abnormalities. 
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2.1.2 Breeding protocol for experimental mice 
The following breeding protocol outlines the generation of experimental female 
mice used in this PhD project: R26R (PBSN-Cre characterization), global 
knockout models and uterine glandular epithelial specific knockout models. 
 
R26R mouse model to localize PBSN-Cre activity in female mouse 
Characterization of PBSN-Cre model was achieved by crossing the PBSN-Cre 
mouse with R26R mouse to localize PBSN-Cre activity in female mouse. In 
R26R mouse, a transcriptional stop codon is surrounded by LoxP sites. When 
intact, this stop codon prevents the expression of β-galactosidase from the 
downstream LacZ coding sequence. When Cre is expressed (i.e. PBSN-Cre), 
excision of the stop codon permits expression of β-galactosidase which 
converts 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) to blue color 
in the cells, hence, Cre activity can be visually localized (Figure 2.3). 
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Figure 2.3. R26R mouse model to characterize PBSN-Cre in female 
mouse. PBSN-Cre will excise stop codon surrounded by LoxP sites permitting 
the expression of β-galactosidase to localize PBSN-Cre (blue staining). 
 
Generation of global knockout mouse model 
For the generation of the global knockout mouse model, three founding lines 
have been used: a SOX2-Cre, PTENflox and ARflox mice. The following 
breeding steps were used (Figure 2.4) to generate the experimental mice. 
Firstly, PTENflox mouse (Ptenflox/flox male) is crossed with ARflox mouse 
(ARflox/wt female) to generate Ptenflox/wtARflox/wt females (used in step 2 of 
breeding protocol ) as well as Ptenflox/wtARflox and Ptenflox/wtARwt males (step 3).  
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In step 2, Ptenflox/wtARflox/wt female is crossed with Sox2-Cre mouse (Soxcre/cre 
male) to produce Ptenwt/wtARflox/wtCre+/- female in which the exon 3 of floxed AR 
allele is deleted by Cre creating AR cut allele. This female is used to generate 
all the global knockout experimental mice used in this PhD project (step 3).  
As a result, we generated: WT (wild-type AR and PTEN), ARKO (global 
homozygous AR inactivation), PTENKO (global heterozygous PTEN deletion) 
and PTENARKO (global homozygous AR inactivation with global heterozygous 
PTEN deletion) female mice (Figure 2.4). 
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Figure 2.4. Breeding protocol to generate global knockout mouse model. 
White boxes represent male mice and black boxes represent female mice and 
grey boxes represent experimental groups. PTENflox mice have ARwt/wt and cre-
/- alleles whereas ARflox mice have PTENwt/wt and cre-/- alleles. Sox2-cre mice 
have ARwt/wt and PTENwt/wt alleles. 
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Generation of uterine glandular epithelial specific mouse model 
For the generation of the uterine glandular epithelial knockout mouse model, 
three founding lines have been used: a PBSN-Cre, PTENflox and ARflox mice. 
Similar breeding steps as global knockout mouse model was used (Figure 2.5). 
Firstly, PTENflox mouse (Ptenflox/flox male) is crossed with ARflox mouse 
(ARflox/wt female) to generate Ptenflox/wtARflox/wt females (used in step 2 of 
breeding protocol) as well as Ptenflox/wtARflox and Ptenflox/wtARwt males (step 3).  
In step 2, Ptenflox/wtARflox/wt female is crossed with PBSN-Cre mouse 
(PBNScre/cre male) to produce Ptenflox/wtARflox/wtCre+/- female in which the exon 3 
of floxed AR allele is deleted by Cre creating AR cut allele. This female is used 
to generate all the uterine glandular epithelial specific knockout experimental 
mice used in this PhD project (step 3).  
As a result, we generated: WT (wild-type AR and PTEN), ugeARKO 
(homozygous AR inactivation in uterine glandular epithelial cells), ugePTENKO 
(homozygous PTEN deletion in uterine glandular epithelial cells) and 
ugePTENARKO (homozygous AR inactivation and PTEN deletion in uterine 
glandular epithelial cells) female mice (Figure 2.5). 
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Figure 2.5. Breeding protocol to generate uterine glandular epithelial 
specific knockout mouse model. White box represent male mice and black 
box represent female mice and grey box represent experimental groups. 
PTENflox mice have ARwt/wt and cre-/- alleles whereas ARflox mice have 
PTENwt/wt and cre-/- alleles. PBSN-cre mice have ARwt/wt and PTENwt/wt alleles. 
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2.2 DNA extraction and PCR genotyping 
2.2.1 DNA extraction 
Experimental mice as well as their breeders were genotyped using genomic 
DNA (gDNA) extracted from tissue biopsies (Walters et al., 2007). Tissue 
biopsies were either from a toe from pups collected prior to weaning for 
identification or a small piece of tail following sample collection. Genotyping by 
PCR was performed using a Proteinase K lysed sample. Tissue samples were 
incubated with 250µl lysis mixture, containing 25µl PCR buffer (Fisher Biotech, 
Australia, TQRB-5), 25µl 20mM MgCl2, and 1.7µl proteinase K (Roche 
Diagnostic, Mannheim, Germany, recombinant PCR grade 18±4mg/ml), for 2 
hours at 55°C to break the tissue and release the DNA. This was followed by 15 
minutes at 98°C to inactivate the proteinase K. Lysed samples were stored at 
4°C. 
In addition, for specific confirmation of Cre activity in tissues of interest, DNA 
was extracted using QIAGEN DNeasy Blood & Tissue kit (QIAGEN, Doncaster, 
Australia) from uterus to confirm excision of exon 5 of Pten and exon 3 of Ar at 
the DNA level. DNA extraction kit was used to obtain purified DNA. DNA 
extraction was performed according to the manufacturers’ instructions 
(Appendix I). Briefly, small piece of tissue (<25mg) was placed in a 1.5ml 
microcentrifuge tube with 180µl of Buffer ATL with 20µl of proteinase K to lyse 
the tissue. Then, samples were vortexed and incubated at 56°C until tissue was 
completely lysed. Lysed sample was vortexed for 15 seconds and 200µl of 
buffer AL and 200µl of 100% ethanol was added to purify the DNA. Then, the 
solution was pipetted into a DNeasy Mini spin column in a 2 ml collection tube 
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and centrifuged. In the spin column, DNA binds to the column for extraction. 
DNA was extracted from spin column using 200µl of Buffer AE and stored at -
20°C. 
 
2.2.2 PCR 
All primers (Table 2.1) for PCR genotyping were purchased from Sigma Aldrich 
Pty (Sydney, Australia). Water was used as a negative control instead of DNA 
and positive controls (gene of interest) was used in all PCRs for specific PCR 
reaction and determination. Details of all PCR reagents used are listed in 
Appendix 1. 
 
Table 2.1. Primers used for genotyping 
Cre-F (forward primer) 5’-CTGACCGTACACCAAAATTTGCCTG-3’ 
Cre-Rv (reverse primer) 5’-GATAATCGCGAACATCTTCAGGTTC-3’ 
ARCut-F (forward primer) 5’-CAGAAATCCACGTGCCTCTACC-3’ 
ARIN3-Rv (reverse primer) 5’-GGGAGACACAGGATAGGAAATT-3’ 
AREx3-F (forward primer) 5’-CTTCTCTCAGGGAAACAGAAGT-3’ 
AR-Neo-F (forward primer) 5’-TAGATCTCTCGTGGGATCATTG-3’ 
PTEN-F (forward primer) 5’-TCCCAGAGTTCATACCAGGA-3’ 
PTEN-Rv1 (reverse primer) 5’-GCAATGGCCAGTACTAGTGAAC-3’ 
PTEN Rv2 (reverse primer) 5’-AATCTGTGCATGAAGGGAAC-3’ 
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Cre PCR: The primer pair used for detecting the presence or absence of the 
Cre gene in gDNA was Cre-F and Cre-Rv (Table 2.1). The presence of Cre was 
confirmed by the PCR product at 213bps. PCR reaction steps were 94ºC for 3 
minutes, then 30 cycles of 94ºC for 1 minutes, 68 ºC for 1 minutes, 72 ºC for 1 
minutes, then 72 ºC for 5 minutes and hold at 10 ºC. 
 
ARCUT PCR: The primer pair used for detecting the intact and exon3-deleted 
AR in gDNA was ARCut-F and ARIN3-Rv (Table 2.1). The deletion of AR exon 
3 was confirmed by the PCR product at 510bps whereas the intact AR exon 3 
was detected at 1650bps (sometimes this band is not produced which depends 
on the activity and efficacy of the enzyme). PCR reaction steps were 94ºC for 3 
minutes, then 35 cycles of 94ºC for 1 minutes, 62 ºC for 1 minutes, 72 ºC for 1 
minutes, then 72 ºC for 5 minutes and hold at 10 ºC. 
 
ARFLOX PCR: The primer pair used for detecting the intact and floxed AR in 
gDNA was AREx3-F, AR-Neo-F and ARIN3-Rv (Table 2.1). The intact AR was 
confirmed by the PCR product at 613bps whereas the floxed AR was detected 
at 289bps. PCR reaction steps were 94ºC for 3 minutes, then 30 cycles of 94ºC 
for 1 minutes, 58 ºC for 1 minutes, 72 ºC for 1 minutes, then 72 ºC for 5 minutes 
and hold at 10 ºC. 
 
PTEN PCR: The primer pair used for detecting the intact PTEN, floxed PTEN 
and exon5-deleted PTEN in gDNA was PTEN-F, PTEN-Rv1 and PTEN Rv2 
(Table 2.1). The location of these primers is shown in Figure 2.6. The deletion of 
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PTEN exon 5 was confirmed by the PCR product at 300bps, floxed PTEN at 
650bps and intact PTEN at 500bps. PCR reaction steps were 94ºC for 3 
minutes, then 40 cycles of 94ºC for 45 seconds, 60 ºC for 30 seconds, 72 ºC for 
1 minutes, then 72 ºC for 5 minutes and hold at 10 ºC. 
 
 
Figure 2.6. Locations of PTEN primers in the Pten allele.  
 
2.2.6 Agarose gel 
All the PCR samples in this PhD project were analysed on a 1.5% agarose 
(Amresco, Solon, OH, USA, Biotechnology grade) gel in 1X TBE buffer 
(Appendix II) containing 7.5 µl SYBR safe (Invitrogen, Oregon, USA) per 150 ml 
gel. SYBR safe binds the DNA and allows visualization of DNA band under the 
UV transilluminator (Bio-Rad Laboratories Pty Ltd, Gladesville, Australia). Each 
gel had a control lane containing 4 µl of control ladder (Bioline, Alexandrian, 
NSW, Australia, Hyperladder 1) for band size comparison. 
 
  
60 
 
2.3 Surgery 
2.3.1 Anaesthetic for surgery 
The anaesthetic mixture was prepared to keep the mice asleep for the duration 
of the surgery (approximately 10minutes). Anaesthetic for surgery contained 
90mg/mL of Ketamine (Parnell Laboratories, Alexandria, NSW, Australia, 
100mg/ml) and 10 mg/mL Xylazine (Troy laboratories, Smithfield, NSW, 
Australia, LLium Xylazil 100mg/ml) diluted with 0.9% saline solution (Appendix 
II). 100µl of anaesthetic mixture was injected subcutaneously per 10g of body 
weight using a 1ml insulin syringe (Thermo Medical Corporation, Elkton, USA). 
To make sure if the mice were anesthetized, paws were pinched and if there 
was no reflex, surgery was performed. After surgery, mice were wrapped in a 
towel and placed under a heat lamp until conscious and movement was 
observed. Health of these mice was monitored daily.  
 
2.3.2 Ovariectomy and hormone implants 
Ovariectomy and hormone implant surgeries were performed in MPU. Following 
the full anaesthesia, small incisions were made at both lateral abdominal skins. 
Then, another incision was made on the peritoneal wall to access ovaries. 
When ovaries were located they were removed under the microscope to make 
sure that the whole ovary was removed leaving the uterus intact. Peritoneal wall 
was sutured with 6-0 silk suture treads (Johnson and Johnson, North Ryde, 
NSW, Australia) and skin was sutured with 4-0 silk suture treads (Johnson and 
Johnson, North Ryde, NSW, Australia).  
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Following ovariectomy, silastic implants (inner diameter=1.47mm and outer 
diameter=1.95mm, Dow-Corning, Sydney, Australia) of 1cm length testosterone 
containing ~10mg crystalline testosterone (Merck, Darmstardt, Australia) or 
2x0.5cm length DHT containing ~10mg crystalline DHT (Merck, Darmstardt, 
Australia)  or empty (negative control) implants were inserted subdermally 
through a small incision at the back of the neck. Wounds were sutured with 4-0 
silk suture tread (Johnson and Johnson, North Ryde, NSW, Australia). 
Mr Mark Jimenez of the ANZAC Research Institute (ARI) kindly prepared the 
implants. 
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2.4 Fertility assessment 
To evaluate effect of endometrial gland specific AR inactivation on fertility, the 
8- to 10-wk-old WT and ugeARKO females were continuously mated with an 
individual WT male (at least 8 weeks old) for a 5-month period. Cages were 
monitored daily and the number of pups and litters were recorded. 
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2.5 Sample collection 
2.5.1 Estrous cycle stage 
In female mice, the cyclical physiologic changes induced by endogenous 
reproductive hormones are known as estrous cycle, with each cycle lasting 4-5 
days. Mouse estrous cycle has four stages, proestrus, estrus, metestrus and 
diestrus (Figure 2.7). As uterus is a highly hormone dependent organ, all the 
mice used in this PhD project were collected at diestrus stage. 
 
Figure 2.7. Estrous cycle stage of mice: Proestrus, estrus, metestrus and 
diestrus. Estrous stage was determined by vaginal smears stained by toluidine 
blue staining. 
 
At proestrus, the smear consists of predominantly nucleated epithelial cells, with 
few keratinized epithelial cells or smaller leukocytes also present. Estrus is 
characterized by keratinization of all epithelial cells, which increase in size and 
the nuclei is degenerated. Metestrus is characterized by the presence of a 
mixture of both the small leukocytes as well as larger keratinized epithelial cells. 
Lastly, diestrus is predominantly leukocytes though some epithelial cells, 
nucleated or keratinized may be present. During diestrus the cells are often 
entangled within stringy mucus. 
64 
 
Estrous cycle of female mice was detected by vaginal smear. Using a pipette, 
20µl of 0.9% saline was flushed in and out of vagina. Then, the solution in the 
pipette was smeared on a glass slide (Livingstone Premium Microscope Glass 
Slides). Vaginal smears were allowed to air dry and stained with 0.5% toludine 
blue (Appendix II) and examined under the light microscope. 
 
2.5.2 Anaesthetic for sample collection 
Anaesthetic for tissue collection contained 50 mg/mL Ketamine (Parnell 
Laboratories, Alexandria, NSW, Australia, 100 mg/mL) and 50 mg/mL Xylazine 
(Troy Laboratories, Smithfield, NSW, Australia, Ilium Xylazil 100 mg/mL) diluted 
with 0.9% saline solution. 100µl of anaesthetic was injected per 10g body weight 
using 1 mL insulin syringes (Terumo Medical Corporation, Elkton, USA). Mouse 
foot was lightly pinched to make sure that the mouse was under the influence of 
anaesthetics. If the mouse had reflex to pinched feet, more time was given or 
more anesthetic was injected before any procedures. 
 
2.5.3 Blood and serum collection 
Blood was collected from anaesthetized mice by cardiac puncture using 1cc/mL 
tuberculin syringe (Laguna, Philippines) and 25 G x 5/8 inch needle (Terumo, 
Tokyo, Japan). Blood was left at room temperature for at least 20 minutes to 
allow coagulation of the blood and centrifuged at 2300g for 5 minutes to 
separate the serum. Pipette was used to extract the serum (top clear layer) and 
it was transferred to a new Eppendorf tube and stored in -20°C.  
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2.5.4 Tissue collection 
After blood collection, the mice were euthanized by neck dislocation. A small 
piece of tail was collected and stored at -20°C for genotype confirmation. 
Peritoneal wall was incised to collect uterus and ovaries. These organs were 
dissected clean of surrounding fat under a dissecting stereo-microscope 
(Olympus SZ40) using extra fine forceps (Dumoxel non-magnetic, World 
Precision Instruments Inc, Florida, USA) and fine spring scissors (Scissors, 
Vannas, 8cm, STR, World Precision Instruments Inc, Florida, USA) and 
weighed using a fine scale (Mettler AE 163). Uterus (without oviduct) and 
ovaries were either snap frozen or fixed in 4% paraformaldehyde (PFA) 
(Appendix II).  
For the global knockout study, other organs such as mammary gland, spleen, 
liver and adrenal gland were also weighed and fixed in 4% PFA for histological 
analysis. All the abnormalities found were recorded and photographs were 
taken for future references. 
 
2.4.5 Laser capture micro-dissection 
Laser capture micro-dissection was used to capture glandular epithelial cells 
from formalin fixed paraffin embedded (FFPE) uterine section (chapter 3). 
FFPE uterine sections were sectioned at 15µm thickness on to a membrane 
slides (MembraneSlide NF 1.0 PEN (D), Carl Zeiss, Sydney, Australia). 
Standard hematoxylin and eosin (H&E) staining was performed to visualise 
glandular epithelial cells. PALM Duoflex Combi System (Bosch Institute, The 
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University of Sydney) was used for laser capture micro-dissection. PALM 
system allows non-contact laser capitulation meaning the cutting and 
capitulation of the sample is performed out by the power of the laser beam 
alone. This system is advantageous in minimising sample degradation and 
contamination. Upon laser micro-dissection (Figure 2.8), glandular epithelial 
cells were captured in adhesive cap (AdhesiveCap 500 opaque (D), Carl Zeiss, 
Sydney, Australia).  
 
Figure 2.8. Laser micro-dissected glandular epithelial cells. Left: 
Histological section of uterus before the micro-dissection showing presence of 
glandular epithelial cells. Right: after the micro-dissection showing absence of 
glandular epithelial cells. 
 
DNA was extracted from laser micro-dissected glandular epithelial cells and 
rest of the uterus using QIAGEN micro DNA kit (QIAGEN, Doncaster, Australia) 
as manufacturer’s protocol. 
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2.6 Histology 
2.6.1 Tissue fixation 
Tissues were fixed in 4% PFA overnight at 4°C and transferred to 70% ethanol 
on the following day and kept in room temperature until further processing. 
 
2.6.2 Tissue processing & embedding (paraffin) 
Tissues in 70% ethanol were embedded at ANZAC research institute for paraffin 
embedding (Appendix III). For uterus, mid-section from a fixed uterine horn was 
used for all histology. 
 
2.6.3 Tissue cutting (paraffin) 
Rotary microtome (MicroTEC Cut 4060) was used to cut paraffin blocks. 
Paraffin blocked tissues were cut at 5µm thickness and floated on a water bath 
of 40°C to flatten the tissue. Then, the sections were put on a glass slide (Lomb 
Superfrost Plus, Menzel-Glaser) and left in the 37°C oven for overnight to bond 
the tissue to the slide. 
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2.7 Staining 
2.7.1 Haematoxylin and Eosin (H&E) 
H&E staining was used for basic histological analysis (Appendix III). 
Haematoxylin stains the nuclei of the cells of virtually all tissues in a bluish color 
and the cytoplasmic portions of the cells of most tissues stain pink by eosin. 
Nuclei of cells are stained by haematoxylin due to their high nucleic acid (DNA 
and RNA) content that makes them basophilic. On the other hand, cytoplasmic 
portions are generally not basophilic but acidophilic or eosinophilic and eosin 
readily combines with acidophilic or eosinophilic molecules. 
Briefly, the tissue sections on slide were rehydrated and stained in Harris 
haematoxylin (Fronine, Thermo-Fisher Scientific, Waltham, USA) following 
bluing of the color in acid alcohol (1% HCl in 70% ethanol) and Scott’s tap water 
(Fronine, Thermo-Fisher Scientific, Waltham, USA) and staining with Eosin (1% 
Alcoholic Eosin, Fronine, Thermo-Fisher Scientific, Waltham, USA). Following 
the staining the sections were dehydrated, left air dry and coverslipped next day 
using DPX mountant for histology (Sigma, St. Louis, USA) and 24mm by 50mm 
coverslip (Coverglass No.1, ProSciTech, Thuringowa, Australia). 
 
2.7.2 Histomorphological analyses 
Using light microscopy, different areas of uterine section were marked (total 
area, myometrium, endometrium and lumen) (Figure 2.9) and each area was 
calculated using CASTGRID software (Olympus, Aarhus, Denmark). 
Measurements were repeated on three different uterine sections for each 
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sample and measurements were averaged. All sections were counted two 
times in order to assess inter-observer variability.  
 
 
Figure 2.9. Different areas of uterine sections. E=endometrium, L=lumen, 
M=myometrium. 
 
2.7.3 Immunohistochemistry 
A detailed procedure for immunohistochemistry is provided in Appendix III. In 
brief, paraffin sectioned uterus was deparaffinised and rehydrated and 
underwent microwave-induced antigen retrieval with 10mM citric acid (pH 6) for 
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10 minutes to improve the demonstration of antigens by breaking the protein 
cross-links formed by PFA fixation. Sections were blocked using Pierce 
Superblock (containing 0.5% Bovine serum albumin) (Life Technologies 
Australia Pty Ltd. Mulgrave, Australia) and non-biotinylated rabbit primary 
antibodies against the proteins of interest (Table 2.2). Primary antibodies were 
visualized using anti-rabbit secondary Vectastain Elite ABC kit (Vector 
Laboratories, California, USA). Uterus sections from same pool of samples were 
used as negative controls by treating with PBS buffer instead of primary 
antibody (Appendix III). 
 
Table 2.2. Details of primary antibodies and dilutions used for 
immunohistochemistry. 
Protein 
target  
Name of 
Antibody 
Manufacturer, catalogue #, 
and/or name of individual 
providing the antibody 
Species raised in; 
monoclonal or 
polyclonal 
Dilutio
n used  
ERα MC-20 Santa Cruz Biotech (sc-542) Rabbit; polyclonal 1:200 
PR PR (C-19) Santa Cruz Biotech (sc-538) Rabbit; polyclonal 1:100 
PTEN PTEN (138G6) Cell Signalling (9559) Rabbit; monoclonal 1:50 
AKT 11E7 Cell Signalling (4685) Rabbit; polyclonal IgG 1:50 
P-AKT D9E Cell Signalling (4060) Rabbit; polyclonal IgG 1:50 
p27 P27 (C-19) Santa Cruz Biotech (sc-528) Rabbit; polyclonal 1:50 
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2.7.4 Immunohistochemistry quantification 
ERα immunohistochemistry results in Chapter 4 were quantified to determine 
the % of ERα positivity and intensity of ERα staining. Immunopositivity and 
immunointensity of ERα was assessed by H Score as previously described 
(McNamara et al., 2013). Different compartments of uterus were assessed 
separately: glandular epithelial cells, luminal epithelial cells, stroma and 
myometrium. In brief, the H score was obtained by accessing immunointensity 
(scale of 0-3) and prevalence in 100 cells over five different areas in stroma and 
myometrium and prevalence in 20 cells over five different areas in glandular 
and luminal epithelial cells. All slides were counted two times in order to assess 
intra-observer variability.  
 
2.7.5 Whole mount LacZ staining 
To detect functional recombinase activity of a PBSN-Cre in females, PBSN-Cre 
mice were crossed with R26R (Section 2.1.2). In the R26R mice the Cre 
mediates activation of a floxed-lacZ gene and the following LacZ activity can be 
detected by whole mount β-galactosidase staining to localize the Cre activity. 
Whole mount β-galactosidase staining method has been used in previous 
studies on mouse uterus (Ismail et al., 2002, Mohamed et al., 2005). 
Mice are sacrificed by cervical dislocation and uterus, ovary, mammary gland 
and pituitary were collected and immersed in fixing solution (Appendix II) for 1 
hour at room temperature. Tissues were removed from fixing solution and 
washed 3 times in washing buffer (Appendix II) for 15 minutes each time. Then 
tissues were immersed in staining solution containing 1mg/ml of X-gal 
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(Appendix II) for overnight in the dark at 37ºC. Then tissues were postfixed in 4% 
PFA for overnight and paraffin embedded and sectioned in 10µm sections on 
glass slides as described in section 2.5. Slides were then deparaffinised and 
counterstained using Nuclear Fast Red (Sigma, St. Louis, USA). To confirm 
that the positive staining was not due to the endogenous cre activity, the PBSN-
cre negative tissues were used as negative controls.  
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2.8 Reverse transcription (RT)-PCR  
2.8.1 RNA extraction 
RNA was extracted from snap frozen uteri and ovaries. Tissues were 
homogenized in 1ml (0.5ml for ovaries) of TRIzol reagent (Sigma-Aldrich, St 
Louis, USA) in 1.5ml RNase-free Eppendorf tubes, vortexed for 15 seconds and 
incubated in room temperature for 5 minutes. Chloroform (Sigma-Aldrich, St 
Louis, USA) was added (0.2ml per 1ml of TRIzol used) to the homogenate to 
denature the protein and RNAse. Tubes were vortexed for 15 seconds and 
centrifuged at 12000g for 15 minutes at 4ºC. Top aqueous phase (contains RNA) 
was carefully transferred into fresh RNA free 1.5ml Eppendorf tubes. 
Isopropanol (Ajax, Tarem Point, NSW, Australia) was added (0.5ml per 1ml of 
TRIzol used) to precipitate the RNA. Samples were vortex for 15 seconds and 
incubated in room temperature for 10minutes with gentle shake. Samples were 
centrifuged at 12000g for 10 minutes at 4ºC.  The supernatant was removed 
and RNA pellets were washed with 80% ethanol (1ml per 1ml of TRIzol used) 
and centrifuged at 76g for 5 minutes at 4ºC. Supernatant was discarded and 
RNA pellets were air dried for 2 to 3 minutes (do not over dry) and pellets were 
redissolved in 20-60µl of RNAse free water. Samples were kept on ice and RNA 
concentrations and purity were measured on an Eppendorf Biophotometer. 
Purity of RNA was assessed with absorbance at 260nm and 280nm (ratio of 
1.7-2.1). Extracted RNA was stored at -80ºC until DNase treatment and 
complementary DNA (cDNA) conversion. 
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2.8.2 DNase treatment and cDNA conversion 
RNA samples were treated with DNase I, amplification grade (Invitrogen, CA, 
USA) to remove any DNA contamination. Then, DNase treated RNA samples 
were reverse-transcribed to produced cDNA using SuperScript® III First-Strand 
Synthesis SuperMix (Invitrogen, CA, USA). Detailed protocol is listed in 
Appendix I. 
After the cDNA conversion, PCR was performed to detect β-actin to confirm 
successful cDNA conversion. The primers used for this PCR was forward (5’-
CCTAAGGCCAACCGTGAA-3’) and reverse (5’-AACCGCTCGTTGCCAATA-3’). 
PCR reaction steps were 94ºC for 2 minutes, then 35 cycles of 94ºC for 5 
seconds, 58 ºC for 15 seconds, 72 ºC for 30 seconds, then 72 ºC for 2 minutes 
and hold at 10 ºC. 
 
2.8.3 RT-PCR 
This PCR was designed and performed to detect the intact Ar and exon 3-
deleted Ar at mRNA level. The primers used for this PCR were mARX2-F (5’-
GGACAGTACCAGGGACCAT-3’) located on exon 2 of Ar gene and mARX4-R 
(5’-CCAAGTTTCTTCAGCTTACGA-3’) located on exon 4 of Ar gene (Figure 
2.10). PCR reaction steps were 94ºC for 2 minutes, then 35 cycles of 94ºC for 5 
seconds, 58 ºC for 15 seconds, 72 ºC for 30 seconds, then 72 ºC for 2 minutes 
and hold at 10 ºC. As a result, intact Ar was detected at 288bps whereas exon 
3-deleted Ar was detected at 171 bps. 
 
75 
 
 
Figure 2.10. Locations of ARCUT RT-PCR primers in the Ar allele to detect 
exon 3-deleted Ar gene. 
 
2.8.4 Real-time PCR 
Quantitative real-time PCR was performed on cDNA samples using Corbett 
Rotor Gene 600 real time thermal cycler (Qiagen, Doncaster, Australia) in 0.1µl 
tubes. SensiMix SYBR Hi-ROX Kit (Bioline, Alexandria, NSW, Australia) was 
used as a master mix. The PCR reaction steps were 95ºC for 10 minutes, then 
30-50 cycles of 95ºC for 20 seconds, 57-67 ºC for 20 seconds, 72 ºC for 20 
seconds. Negative controls (RNase free water instead of cDNA) were included 
and a standard curve was used for each gene by serial dilutions (from PCR 
product generated by conventional RT-PCR made from the same primers used 
for the real-time PCR, Appendix I) between 10-2 and 10-14 (relative units). All 
quantifications were carried out in duplicates and the final volume of 10µl. 
Sample concentrations, relative to standards were established using mouse 
ribosomal protein L19 (Rpl19) or Cyclophilin as a cDNA loading control. Details 
of PCR reaction mixes used are listed in Appendix I. All primers used for real-
time PCR were purchased from Sigma Aldrich Pty, Sydney, Australia and are 
listed in the Appendix IV. 
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2.9 Protein extraction and western blot 
2.9.1 Protein extraction 
Protein was extracted from snap frozen uterus for western blot analyses. Uterus 
(~30mg) was added to 500µl of RIPA buffer (Sigma, St. Louis, USA) containing 
PhosStop (1 tablet/ml of RIPA buffer) (Roche Diagnostics Australia, Castle Hill, 
Australia) and cOmplete, Mini, EDTA-free (1 tablet/ml of RIPA buffer) (Roche 
Diagnostics Australia, Castle Hill, Australia) in Lysing Matrix S tubes (MP 
Biomedicals Australia, Seven Hills, Australia). The tube containing tissue was 
homogenized at 375g for 15 sections up to 4 times and left on ice for 30 minutes. 
Tubes were vortexed and centrifuged at 13500g for 15 minutes in 4ºC. Top 
aqueous phase (contains protein) was carefully transferred into fresh 1.5ml 
Eppendorf tubes. Samples were kept on ice and protein concentration was 
measured on Enspire multimode plate readers (PerkinElmer, Waltham, USA) 
using Thermo Pierce 660nm protein assay (Life Technologies Australia Pty Ltd. 
Mulgrave, Australia) added with ionic detergent compatibility reagent (Life 
Technologies Australia Pty Ltd. Mulgrave, Australia). Extracted protein was 
stored at -80ºC for western blot. 
 
2.9.2 Western blot 
Western blots performed in chapter 4 were performed as previously described 
(Vignarajan et al., 2014). In brief, Bolt Western Blot and reagents from Life 
Technologies Australia Pty Ltd. Mulgrave, Australia was used. 10µg of protein 
was used for each sample. Proteins were denatured and loaded on to a gel 
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(Bolt 4-12% BT plus 10 well) and gel was ran on MES buffer at 165 volts for 1 
hour. Protein was transferred to a membrane on NuPAGE transfer buffer at 30 
volts for 2.5 hours at room temperature. Membrane was blocked with 5% Skim 
milk/TBST for 1 hour at room temperature followed by overnight primary 
antibody incubation at 4ºC. Primary antibody was washed three times in TBST 
for 10 minutes each and incubated with secondary antibody for 1 hour at room 
temperature and followed by TBST wash. Proteins on a membrane were 
visualized using Pierce ECL Western Blotting Substrate and detected under UV 
transilluminator (Bio-Rad Laboratories Pty Ltd, Gladesville, Australia). Image 
lab software (Bio-Rad Laboratories Pty Ltd, Gladesville, Australia) was used to 
quantify the intensity of proteins. 
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Table 2.3. Details of primary antibodies and dilutions used for western 
blot.  
Protein 
target  
Name of 
Antibody 
Manufacturer, catalogue #, 
and/or name of individual 
providing the antibody 
Species raised in; 
monoclonal or 
polyclonal 
Dilution 
used  
PTEN PTEN (138G6) Cell Signalling (9559) Rabbit; monoclonal 1:500 
AKT AKT 1/2/3 (H-
136) 
Santa Cruz Biotech (sc-8312) Rabbit; polyclonal 
IgG 
1:500 
P-AKT P-AKT 1/2/3 
(Ser 473)-R 
Santa Cruz Biotech (sc-7985) Rabbit; polyclonal 
IgG 
1:300 
p27 P27 (C-19) Santa Cruz Biotech (sc-528) Rabbit; polyclonal 1:500 
Β-actin Anti-beta Actin  Abcam (ab8229) Goat; polyclonal 1:3000 
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2.10 Liquid chromatography tandem mass 
spectrometry (LC-MS/MS) 
LC-MS/MS was used to analyse steroid hormone levels in serum and ovaries by 
API-5000 triple-quadrupole mass spectrometer (Applied Biosystems, Ontario, 
Canada). 
 
2.10.1 Tissue preparation 
Frozen ovary samples were transferred into 5 mL glass tubes. Ovary samples 
were then treated with 300 µL of homogenization buffer (0.5% BSA (w/v), 5mM 
EDTA in PBS, pH 7.4) and homogenized on ice for 20 seconds using an IKA 
T10 basic disperser on the highest setting. The dispersion tool (probe) was 
cleaned between samples by rinsing in PBS. If any tissue sample remained, the 
probe was removed and the inside gently wiped. To pellet insoluble debris from 
the homogenate, samples were centrifuged at 840g for 20 minutes at 4°C 
before the supernatants were transferred to fresh 5 mL glass tubes. These were 
stored at -80°C until analysis. Blood serum was separated as described in 
above (section 2.4.3). 
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2.10.2 LC-MS/MS analysis 
LC-MS/MS was operated by Ms Reena Desai at the Andrology laboratory, 
ANZAC research institute. The sample processing and analysis of serum and 
tissue steroids was performed as previously described in a study by Harwood 
and Handelsman (Harwood and Handelsman, 2009) and modified for mouse 
serum and tissue by McNamara and coworkers (McNamara et al., 2010a). 
The lowest limits of quantification (defined as detectable with coefficient of 
variation <20%) were 10pg/mL for T, 20pg/mL for DHEA, 50pg/mL for DHT, 
2.5pg/mL for E2, 1pg/mL for E1. 
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2.11 Corpus lutea (CLs) count 
2.11.1 Ovary processing & embedding (resin) 
PFA fixed ovaries were transferred into 70% ethanol and incubated for 1 hour. 
Then ovaries were transferred to 100% ethanol for 1 hour and this was repeated 
3 times using fresh 100% ethanol each time. Then, in fume hood, ovaries were 
incubated in butanol for 1 hour twice.  
Ovary was embedded in glycol methracrylate resin using TECKNOVIT KIT 
7100 (Heraeus Kulzer, Chatswood, Australia). Infiltration solution was prepared 
by dissolving 1g of hardener I (1 sachet) in 100ml of methacrylate solution. 
Then embedding solution was prepared with 15ml of infiltration solution mixed 
with 1ml of hardner II. In fume hood, 1-2ml of embedding solution was placed in 
a mould to orientate ovary at the bottom centre of the mould. Then, pre-labelled 
block holder was place on top. The mould was left unmoved for 2 hours to 
maintain its orientation. After the embedding solution was hardened, mould with 
block holder was left in room temperature for 1-2 weeks until the block was 
completely solid.  
Once, the blocks were completely solid, ovaries were serially sectioned at 
20µm using Polycut S sliding microtome (Reichert Technologies, New York, 
USA). Sectioned were left to dry in 37ºC oven for overnight and Periodic acid 
Schiff staining was performed 
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2.11.2 Periodic acid Schiff staining and CLs count 
Sectioned resin blocks were incubated in periodic acid (POCD Scientific, 
Artamon, Australia) for 30 minutes at room temperature followed by 10 minutes 
wash in running tap water. Then, in the fume hood, sections were incubated in 
Schiffs solution (Fronine, Thermo-Fischer Scientific, Waltham, USA) for 45 
minutes at room temperature followed by 10 minutes wash in running tap water. 
Section were incubated in Mayers haematoxylin (Signma, St. Louis, USA) for 2 
hours at 37ºC followed by 10 minutes wash in running tap water. Then, sections 
were incubated in Scott’s bluing solution (Fronine, Thermo-Fischer Scientific, 
Waltham, USA) for 3 minutes and rinsed in tap water to remove Scott’s bluing 
solution. Following the staining the sections were left air dry and coverslipped 
next day using DPX mountant for histology (Sigma, St. Louis, USA) and 24mm 
by 50mm coverslip (Coverglass No.1, ProSciTech, Thuringowa, Australia). 
When the slides were completely dry, corpus lutea (CLs) was identified by 
morphological properties consistent with luteinized follicles and by being 
present in several serial sections. CLs were counted on each ovary using an 
Olympus microscope with Stereo investigator software (MicroBright Field, 
Williston, VT, USA) (Walters et al., 2009).  
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2.12 Data analysis 
All the data were analysed using SPSS (SPSS, Chicago, IL, USA) software. 
Statistical significance was set at 95% confidence interval (P<0.5). Data were 
tested for normal distribution by homogeneity of variance test and evaluated 
using a one-way ANOVA (>2 groups), two-way ANOVA (2 variables) and 
independent samples t-test (2 groups) unless stated otherwise. Post-hoc tests 
were performed after a significant ANOVA (P<0.05) to determine the 
significance among groups. Non-parametric results were analysed using 
Kruskal-Wallis non-parametric test and combined with Mann–Whitney U post-
hoc test.  
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Chapter 3: 
The role of androgens acting via AR 
in uterine growth: Development and 
characterization of uterine glandular 
epithelium specific AR knockout 
mouse models 
 
 
The content in this chapter has been published as: 
Jaesung (Peter) Choi, Yu Zheng, Kate Skulte, David Handelsman, and Ulla 
Simanainen. Development and characterization of uterine glandular epithelium 
specific AR knockout mouse model. Biology of Reproduction. 93(5):120 (2015). 
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3.1 Abstract 
While estrogens are the major driver of uterine development, androgens acting 
via the androgen receptor (AR) may also promote uterine growth as suggested 
by uterine phenotype in global AR knockout (ARKO) female mice. As AR is 
expressed in all the uterine cell types including glandular epithelial cells our 
aims of this experiment were to: 
i) Generate and validate uterine glandular epithelial specific AR 
knockout (ugeARKO) mouse model using Cre/LoxP strategy. 
ii) Investigate the role of glandular epithelial AR in uterine growth and 
function (fertility). 
iii) Determine if AR mediated androgen actions are required for 
testosterone and DHT induced uterine regrowth upon ovariectomy. 
iv) Determine the role of glandular epithelial AR in androgen induced 
uterine regrowth upon ovariectomy. 
v) Determine if uterine glandular epithelial specific knockout mouse 
model could be used as a possible new uterine cancer model. 
Our results show that endogenous androgen actions via AR in uterine gland 
epithelium may not be critical for normal uterine development and function as 
ugeARKO females had normal uterine development and fertility. To determine if 
exogenous androgens acting via AR can fully support uterine growth in 
absence of estrogens the ARKO and ugeARKO females were ovariectomised 
(OVX) and treated with supraphysiological doses of  testosterone or DHT (non-
aromatizable androgen). Both DHT and testosterone supported full uterine 
regrowth in wild-type (WT) females while ARKO females had no regrowth 
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(comparable to OVX only). These findings suggest that androgens acting via 
AR can promote full uterine regrowth in the absence of estrogens. The 
ugeARKO had 50% regrowth of the uterus when compared to intact indicating 
that androgens can act locally via AR within the uterus to support uterine 
growth. Histomorphologically, both the endometrial and myometrial areas were 
significantly (p<0.05) reduced, suggesting glandular epithelial AR located in 
endometrium may indirectly modify myometrial development. Additionally, to 
confirm the Cre function in endometrial glands, we generated uterine glandular 
epithelium specific PTEN knockout (ugePTENKO) mouse model. The 
ugePTENKO females developed severe endometrial hyperplasia and therefore 
present a novel model of uterine pathology for future research. 
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3.2 Introduction 
Androgens are 19-carbon steroid hormones which mediate their effects via 
androgen receptor (AR). AR is encoded by an X chromosomal gene and 
belongs to the nuclear receptor superfamily (Lubahn et al., 1988). It is 
expressed in target organs including the uterus of both rodents (Pelletier et al., 
2004, Hirai et al., 1994) and humans (Kimura et al., 1993, Ito et al., 2002) being 
detected in the luminal and glandular epithelial and stromal cells in 
endometrium as well as myometrial cells of the human uterus (Ito et al., 2002, 
Kimura et al., 1993). Similarly in the mouse uterus, Ar mRNA is expressed in 
the luminal and glandular epithelial cells, stromal cells and smooth muscle cells 
(Pelletier et al., 2004) and the intensity of Ar mRNA labelling is quite uniform 
throughout the different uterine compartments. The biological effects of 
androgens in male physiology are well known, but their physiological roles in 
the female beyond being the obligate precursors for conversion to estrogens by 
aromatase (Hillier et al., 1994) have only recently been recognized (Walters et 
al., 2007).  
Androgens have growth and differentiation promoting actions in rodent uterus 
(Armstrong and Papkoff, 1976, Schmidt and Katzenellenbogen, 1979, 
Nantermet et al., 2005, Walters et al., 2009). Already in the 1970s, it was 
demonstrated that administration of androgens (testosterone or non-
aromatizable dihydrotestosterone, DHT) to immature hypophysectomised rats 
significantly increased uterine weights (Armstrong and Papkoff, 1976, Schmidt 
and Katzenellenbogen, 1979). In addition, the global AR knockout (ARKO) 
female mice have thinner uterine wall and reduced total uterine area compared 
to the WT controls (Walters et al., 2009), suggesting the growth promoting role 
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of androgens in uterus is mediated via the AR. Hence, these in vivo studies 
collectively suggest a uterine growth promoting function of androgens, acting via 
AR. However, in contradiction, the aromatizable pro-androgen, androstenedione 
was shown to inhibit the proliferation of human endometrial epithelial cells, an 
effect which was reversed by an antiandrogen (cyproterone acetate) indicating 
local, uterine cell specific AR mediated actions may also inhibit uterine growth 
(Tuckerman et al., 2000). Furthermore, the role of androgens in clinical uterine 
cancers has been proposed (Gibson et al., 2014). 
Androgens also have a role in optimal female fertility, as androgen insensitive 
ARKO female mice produce significantly fewer pups compared to the WT 
females in mating experiments (Walters et al., 2007). Glandular epithelial cells 
in the uterine endometrium synthesize, secrete and transport proteins and 
related substances that nourish the developing embryo (Bazer, 1975, Roberts 
and Szego, 1953, Simmen and Simmen, 1990) and these secretions are vital 
for the survival and development of embryos (Gray et al., 2001b). Therefore, 
successful morphogenesis of the endometrial glands is critical to the gestational 
capacity of the uterus. Furthermore, disrupted endometrial gland formation in 
adult mice can result in permanent infertility (Jeong et al., 2010, Franco et al., 
2010). As the AR is also specifically expressed in the endometrial gland 
epithelia, we therefore aimed to develop (Cre/loxP) and characterize uterine 
endometrial gland specific AR knockout (ugeARKO) mouse model. Using the 
ugeARKO in comparison to ARKO females, we further characterized the role of 
androgens acting via AR in uterine development and function. In addition, as 
most endometrial carcinomas originate from glandular epithelia, we further 
characterized the endometrial glands specific Cre activity by generating uterine 
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glandular epithelium specific PTEN tumor suppressor (Dahia, 2000) knockout 
(ugePTENKO) as  PTEN inactivation in uterus induces endometrial cancer in 
mice (Stambolic et al., 2000, Daikoku et al., 2008).  
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3.3 Experimental design  
Experimental designs for this part of the PhD project were carried out as the 
following: 
i) To validate the ugeARKO mouse model, WT, ugeARKO, R26R and 
ugePTENKO mice were generated as described in methods (see 2.1). 
WT and ugeARKO mice were collected at 20 weeks of age, R26R 
mice were collected at 10 and 20 weeks of age and ugePTENKO 
mice were collected at 30 weeks of age. 
ii) The role of glandular epithelial AR in uterine growth and function 
(fertility) was investigated by comparing WT, ARKO and ugeARKO 
females at 20 weeks of age.  
iii) To determine if AR mediated androgen actions are required for 
uterine regrowth and if glandular epithelial AR plays a role, WT, 
ARKO and ugeARKO females were ovariectomised and treated with 
androgens. Experimental details described below (Figure 3.1). These 
mice were collected at either 11 weeks or 20 weeks. Initially 20 
weeks was chosen to be consistent with intact mice. However, 11 
weeks were chosen for DHT treatment as we did not observe 
significant changes between 11 and 20 weeks. 
iv) To determine if ugePTENKO mouse model could be used as a 
possible new uterine cancer model, uterine weight and 
histopathology as well as PCNA (proliferating cell nuclear antigen) 
was compared between WT and ugePTENKO at 30 weeks of age. 
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Genotype confirmation 
Excision of exon 3 of Ar in ARKO and ugeARKO uterus was confirmed on 
genomic DNA and mRNA level. Genomic DNA was released using proteinase 
K digestion of uterus or by DNA extraction kit (Qiagen DNeasy Blood and 
Tissue Kit, Hilden, Germany). PCR on gDNA was performed as previously 
described (Notini et al., 2005b). In addition, excision of exon 3 of Ar in the 
uterus was confirmed by RT-PCR on the RNA extracted from uteri as 
previously described (Simanainen et al., 2007). Two product sizes were 
obtained, 288 bps for intact Ar and 171 bp for Cre-mediated exon 3 excised Ar.   
To confirm specific excision of exon 3 of Ar occurs solely in glandular epithelial 
cells of ugeARKO, genomic DNA was extracted from laser micro-dissected 
formalin fixed paraffin embedded (FFPE) uterus samples. In brief, FFPE uterine 
sections were sectioned at 15µm thickness on to a membrane slides 
(MembraneSlide NF 1.0 PEN (D), Carl Zeiss, Sydney, Australia). Standard H&E 
staining was performed to visualize glandular epithelial cells. PALM Duoflex 
Combi System was used for laser capture micro-dissection. Upon laser micro-
dissection, glandular epithelial cells were captured in adhesive cap 
(AdhesiveCap 500 opaque (D), Carl Zeiss, Sydney, Australia). In addition, laser 
micro-dissection was performed to capture non-glandular uterus (i.e. uterus 
excluding glandular epithelium). Excision of DNA between floxP sites of Ar 
(exon 3) was confirmed by PCR using same primers as previously described 
(Gao et al., 2014) creating an exon 3 excised Ar at 510bps. Furthermore, to 
confirm that functional Ar was still present in non-glandular uterus tissue, PCR 
using same primers as for genotyping (Simanainen et al., 2012) detected 
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undeleted (floxed) Ar at 280 bps confirming tissue-specificity of Cre activity for 
glandular and not non-glandular uterus.  
Excision of exon 5 in PTEN knockout was confirmed on genomic DNA. Exon 5 
excision of Pten was confirmed using same primers as for genotyping (Byun et 
al., 2011). Two product sizes were obtained, 650 bps for intact Pten and 300 bp 
for Cre-mediated exon 5 excised Pten. -Actin was used as a loading control. 
Exon 5 deletion in Pten was not confirmed by RT-PCR using RNA the Cre-
mediated excision of DNA between loxP sites of Pten produces stop codon and 
no exons are produced after exon 4 (Vlietstra et al., 1998).  
Real-time PCR was performed to determine Pbsn mRNA expression in the 
uterus. Prostate samples were used as a positive control. PBSN PCR was 
performed as previously described in (Simanainen et al., 2009, Doles et al., 
2005). 
 
Model characterization 
To characterize the uterine specificity of PBSN-Cre in females, the uterus, 
ovaries, mammary gland and pituitary were collected from R26RCre+ and 
R26RCre- females at 10 and 20 weeks of age.  In addition, to confirm that the 
PBSN-Cre mediated excision of tumor suppressor PTEN generates glandular 
hyperplasia, the ugePTENKO females were collected at 30 weeks of age to be 
subjected to PCR and immunocytochemistry for detection of Cre-mediated 
recombination. To determine the time of PBSN-Cre activation, ugePTENKO 
females were also collected at 3, 6 and 8 weeks. 
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Ovariectomy and implants 
To further characterize the androgen action in the uterus, a group of female 
mice were ovariectomised (OVX) under anaesthesia at 5 weeks and had 1 cm 
silastic implants (inner diameter=1.47mm and outer diameter=1.95mm, Dow-
Corning, Sydney, Australia) either containing ~10 mg crystalline testosterone or 
no steroid placed subdermally for 15 weeks and subsequently collected at 20 
weeks of age (Figure 3.1A). Initially, long term testosterone treatment was 
given to allow enough time for the testosterone to show effects on uterine 
regrowth. To investigate whether the non-aromatizable DHT behaved similarly 
to testosterone, a second group of female mice were ovariectomised at 8 
weeks and received silastic implants subdermally containing either testosterone 
or DHT (2x0.5cm silastic implant filled with ~5mg crystalline DHT (Simanainen 
et al., 2009)) or empty implant for 3 weeks with mice sacrificed for tissue 
collection at 11 weeks old (Figure 3.1B). Short-term treatment was used based 
on the findings from our long-term treatment together with our laboratory’s 
previous experiences with DHT treatment of male mice where significant 
changes occurred within three weeks of DHT treatment (Simanainen et al., 
2011a). Intact females were also collected at the age of 11 weeks and 20 
weeks. 
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Figure 3.1. Experimental design. A) Experimental procedure for the group of 
females ovariectomised (OVX) at 5 weeks of age and treated with testosterone 
(T) or empty implant for 15 weeks. B) Experimental procedure for the group of 
females with OVX at 8 weeks of age and treated with T or  dihydrotestosterone 
(DHT) or empty implant for 3 weeks. 
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3.4 Results 
3.4.1 Successful generation and validation of endometrial gland 
specific AR knockout mouse model 
PBSN-Cre mice are generally used to direct the Cre expression selectively into 
prostate epithelial cells (Simanainen et al., 2007). However, unexpectedly we 
observed possible uterine specific expression in female mice and therefore 
further validated the PBSN-Cre mouse model for uterine specific Cre 
expression. This was achieved by localizing the Cre activity in female mice. 
PBSN-Cre mice were crossed with R26R mouse. Tissues were collected at two 
different time points, at 10 and at 20 weeks of age.  The Cre activity was 
analyzed in uterus, ovary, mammary gland and pituitary of both the 10 and 20 
weeks of age. Blue lacZ staining was only detected in the glandular epithelial 
cells of the uterus (Figure 3.2A-B). No staining was detected in the Cre 
negative uterus (Figure 3.2C). Ovary, mammary gland, and pituitary (Figure 
3.2D-F) were all negative for lacZ staining. Morphology of Cre positive and 
negative uterus is shown in Figure 3.2G-H. 
PCR was used to confirm SOX2-Cre and PBSN-Cre mediated excision of exon 
3 of Ar in ARKO and ugeARKO uterus. Exclusively native or exon 3 deleted Ar 
RT-PCR product was detected in WT or ARKO uterus, respectively. Due to 
uterine glandular epithelial cell specific Cre activity, ugeARKO uterus showed 
weak exon 3 deleted Ar product (glandular epithelial cells) and strong native Ar 
PCR product (non-glandular uterine cells) (Figure 3.2I). Similar to the WT 
ovaries, the ovaries of ugeARKO females only expressed native Ar (Figure 3.2I). 
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Furthermore, laser micro-dissection was performed to confirm excision of exon 
3 of Ar in ugeARKO uterus is specific to glandular epithelial cells (Figure 3.2J-
K). Exon 3 deleted Ar PCR product was only detected in glandular cells of 
ugeARKO uterus (Figure 3.2L) whereas undeleted (floxed) Ar PCR product was 
detected solely in the non-glandular tissue of the uterus in ugeARKO mice 
(Figure 3.2M). 
Similarly, PCR was used to confirm PBSN-Cre mediated excision of exon 5 of 
Pten in ugePTENKO uterus. Due to uterine glandular epithelial cell specific Cre 
activity, ugePTENKO uterus shows weak exon 5 deleted Pten product 
(glandular epithelial cells) and strong naïve Pten PCR product (non-glandular 
epithelial cells) (Figure 3.2N). Similar to the WT ovaries, the ovaries of 
ugePTENKO females only expressed naive Pten (Figure 3.2N). To further 
confirm the gland specificity of PBSN-Cre activity, PTEN immunohistochemistry 
was performed in WT and ugePTENKO uterus.  Uterine glands were strongly 
PTEN immunopositive in WT uterus (Figure 3.2O), but were negative for PTEN 
immunostaining in ugePTENKO uterus (Figure 3.2P). Negative control did not 
show any PTEN immunostaining in uterus (Figure 3.2Q).  
Furthermore, to determine the age dependency of PBSN-Cre activation, the 
Pten PCR was performed on uteri at age of three, six and eight weeks. Exon 5 
deleted Pten product was only detected at eight weeks of age but not earlier 
(Figure 3.3) showing that PBSN-Cre is activated after six weeks but before the 
age of eight weeks.  
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Figure 3.2. Phenotypic (R26R mice) and genotypic characterization of 
endometrial glandular epithelial specific Cre expression. A-B) β-
Galactosidase staining of uterine section of PBSN-Cre positive 10 weeks old 
R26R mouse (n≥4; litter independent). C) β-Galactosidase staining of uterine 
section of PBSN-Cre negative 10 weeks old R26R mouse demonstrating lack of 
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endogenous β-galactosidase activity in uterus (n≥4). D-F) β-Galactosidase 
staining of ovary, mammary gland and pituitary sections of PBSN-Cre positive 
10 weeks old R26R mouse demonstrating lack of β-galactosidase activity (n≥4). 
E-F) Morphology of 10 weeks old PBSN-Cre positive (G) and negative (H) 
uterus.  I) RT-PCR showing WT Ar and exon 3 excised Ar products in the 
ugeARKO uterus and exon 3 excised Ar product only in ARKO as positive 
control. ugeARKO ovaries had only WT Ar product (20 weeks old mice). J-K) 
Representative photo of laser micro-dissection of uterine glands showing 
undissected FFPE section with glands (J) and the same section following 
dissection of glands (K). L) PCR products showing exon 3 excised Ar product in 
ugeARKO uterine glands only at 20 weeks old. Undissected FFPE ugeARKO 
was used as a positive control. M) PCR showing floxed Ar (functional Ar) 
product in ugeARKO non-glandular uterus at 20 weeks old. Undissected FFPE 
ugeARKO was used as a positive control. N) PTEN PCR showing WT Pten and 
exon 5 excised Pten present in ugePTENKO uterus while the WT uterus and 
ovaries of both WT and ugePTENKO females expressed only WT Pten at 20 
weeks old. O-Q) Representative photo of PTEN immunohistochemistry 
demonstrating gland specific PTEN deletion (PBSN-Cre activity) in 
ugePTENKO uterus (P) (arrows pointing PTEN immunonegative glands) 
compared to WT (O) (arrows pointing to PTEN immunopositive glands) and 
negative control (Q) at 20 weeks old. Scale bars= 1000µm (A and C), 400µm (B, 
D, E, F, O and Q), 200µm (P). 
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Figure 3.2. Determining time of PBSN-Cre activity using PTEN PCR. PTEN 
PCR has been conducted at 3, 6 and 8 weeks old uteri and ovaries to show 
time of PBSN-Cre activation in the uterus. Exon 5 deleted PTEN band (300bps) 
was only present at 8 weeks old uterus but not in other time points. Hence, the 
data indirectly shows that Pbsn-Cre is active at 8 weeks old uteri but not in 
ovaries. 
 
To further validate the functional PBSN-Cre activity in ugePTENKO mice, the 
uterine weights and morphology were compared between WT and ugePTENKO 
females. ugePTENKO uterine weight was significantly increased compared to 
WT females (Figure 3.4A). Macroscopic analysis of ugePTENKO uterus 
demonstrated clearly abnormal uterus compared to WT (Figure 3.4B-C). 
Histological analysis of ugePTENKO uterus suggested that the increased 
weight and abnormal appearance was due to the presence of hyperplastic and 
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neoplastic uterine glands in ugePTENKO uterus not present in WT uteri (Figure 
3.4D-F).  
 
Figure 3.4. Uterine weight and histology of endometrial gland PTEN 
knockout (ugePTENKO) uterus at 20 weeks of age. A) Uterine weights were 
compared between WT and ugePTENKO at 20 weeks of age [n≥9; 
a=significantly different to WT (p<0.05); T-test]. B-C) Morphology of WT (normal) 
(B) and ugePTENKO (abnormal) uterus (C). D-F) Representative histology 
(H&E) of normal WT uterus (D) (endometrium layer mainly consists of stroma 
and epithelial cells whereas myometrium area mainly consists of smooth 
muscle cells) and hyperplastic glands (E) and intraepithelial neoplastic glands 
(F) in ugePTENKO uterus. (Arrows indicating endometrial glands which are 
lined by epithelial cells; scale bars=200µm (D) and 400µm (E and F)).  
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Pbsn mRNA was not detectable in our uterine samples at the age of 20 weeks 
by real-time PCR (Figure 3.5). 
 
Figure 3.3. Real-time PCR comparing Probasin gene expression in the 
uterus at 20 weeks. Probasin gene expression was compared between 
prostate and uterus. Prostate samples (n=3) show fluorescence before water 
(negative control; ~40 cycles) at around 20 cycles. Whereas uterus samples 
(n=2) show fluorescence well after water at around 50 cycles. 
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3.4.2 Endometrial gland specific AR inactivation does not 
modify uterine growth or function (fertility)  
No significant differences in uterine weight were detected between WT females 
from ARKO or ugeARKO colonies (Figure 3.6) and therefore the data from both 
WT female lines were combined. The uterine weights were similar between WT, 
ARKO and ugeARKO females at 20 weeks of age (Figure 3.7 Table). Also, 
there were no changes in histomorphometric measurements such as total 
uterine area or endometrial and myometrial area (Figure 3.7 Table). 
 
Figure 3.4. Uterine weight of WTs from ugeARKO colony and ARKO 
colony. There was no difference between WTs from ugeARKO colony and 
ARKO colony. Hence, in our experimental data both WTs were combined. Data 
shown as mean±SE; n≥8. 
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Fertility of WT and ugeARKO females was compared by determining the pups 
per litter and total number of pups produced by the female over 5 months 
period. No difference in pups per litter was observed between WT and 
ugeARKO females where both produced approximately 11 pups per litter 
(Figure 3.7A). Also, total number of pups produced over 5 months period for 
each female did not differ between WT and ugeARKO, both groups producing 
approximately 50 pups over 5 months period (Figure 3.7B). This suggests that 
inactivation of endometrial glandular epithelial AR did not affect fertility of 
female mice aged between 8 weeks to 5 months. 
 
Figure 3.5. Uterine weight, morphological measurements and fertility. 
Uterine weights and morphology (Table) was compared between WT, ARKO 
and ugeARKO females at 20 weeks of age. In addition, the fertility (pups per 
litter, cumulative pups) was compared between ugeARKO and WT females (A-
B). Data shown as mean±SE; n≥4. 
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3.4.3 AR mediated androgen actions are required for 
testosterone induced uterine growth 
As expected, OVX at five weeks of age prevented normal uterine growth in all 
females with the uterine weights in OVX groups being about 15% of the intact 
female uterine weights at 20 weeks of age (Figure 3.8A). In WT females, T 
treatment following OVX (OVX+T) fully restored the uterine weight to the intact 
level at 20 weeks of age (Figure 3.8A). However, no uterine growth was 
detected following OVX and T treatment in ARKO females and the uterus 
weight remained similar to OVX only females (Figure 3.8A), suggesting that AR 
mediated T effects are required for uterine growth. Interestingly, in ugeARKO 
females, testosterone treatment in OVX+T group partial restoration 
(approximately 50%) of uterine weights were observed upon T treatment in 
OVX+T group when compared to intact ugeARKO uterus weights (Figure 3.8A).  
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3.4.4 Endometrial glandular AR modifies testosterone induced 
uterine growth (both the endometrium and myometrium) 
Morphological measurements notably total area, endometrial and myometrial 
area were measured in the uterus. However, these measurements could not be 
made in OVX group and OVX+T treated ARKO as these uteri were too 
underdeveloped to make these measurements accurately (Figure 3.8B-D). OVX 
group (Figure 3.8K-L) had similar histological appearances to OVX+T treated 
ARKO uteri (Figure 3.8G-H). 
OVX+T treated WT uterus had full regrowth of all the areas (endometrial and 
myometrial area) and they were similar to WT intact (Figure 3.8B-D). Uterine 
areas (total, endometrial and myometrial) of OVX+T treated ugeARKO were 
approximately 50% of OVX+T treated WT uterus (Figure 3.8B-D). This 
suggests that endometrial glandular epithelial AR plays a role in the uterine 
development modifying not only the endometrium but myometrium as well. This 
results in the maintenance of a stable endometrium to myometrium ratio such 
that both the WT and ugeARKO in OVX+T group had similar endometrium to 
myometrium ratio (Figure 3.8E). Representative figures of each OVX+T treated 
uterus are shown below (Figure 3.8F-M). 
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Figure 3.6. Uterine weights and morphological measurements of 
ovariectomised and T treated mice at 20 weeks of age relative to 
respective intacts. Uterine weights (A) and uterine morphology (B-D) following 
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ovariectomy with or with testosterone (T) treatment [a=significantly different to 
WT (p<0.05; one-way ANOVA), b= significantly different to ARKO (p<0.05; one-
way ANOVA); mean±SE; n≥5]. E) Endometrium to myometrium ratio between 
OVX+T treated WT and ugeARKO. Endometrium to myometrium ratio was 
similar between WT and ugeARKO uterus. E/M=endometrium/myometrium. 
Data shown as mean±SE; n≥5. F-M) Representative photos of uterine histology 
(H&E staining) of OVX+T treated WT (F and G), ARKO (H and I), ugeARKO (J 
and K) and OVX alone (L and M). (Scale bars=400µm in F and J; scale 
bars=200µm in G, H, K and L; scale bars=100µm in I and M). 
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3.4.5 Androgens alone can promote full uterine regrowth and 
do not require E2 in mice 
As T can be aromatized into E2 via aromatase activity, we used non-
aromatizable androgen, DHT to determine if AR mediated androgen effect on 
uterine growth requires E2. Intact WT and ARKO uterine weights were similar, 
while the OVX group at 11 weeks of age (ovariectomised at eight weeks old) 
significantly reduced (p<0.05; non-parametric test) uterine weights in both WT 
and ARKO (Figure 3.9A). Both T and DHT treatment at the time of OVX for 
three weeks, restored the uterine weights to intact level in WT but had no effect 
on uterine weights in ARKO females. This finding suggests that androgens 
(testosterone and DHT) alone acting via AR can promote full uterine regrowth in 
the absence of E2 (Figure 3.9A). 
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3.4.6 Treatment protocols produced supraphysiological serum 
levels of testosterone and DHT  
To determine if the comparability of the intact female mouse serum T and DHT 
levels to those produced by the steroid hormone implants used in the present 
study, serum T, DHT, DHEA, E1 and E2 levels were measured using LC-MS/MS. 
Serum testosterone was 20-fold higher (p≤0.05; non-parametric test) in OVX+T 
treated compared to intact WT and ARKO females, suggesting that T implant 
produced supraphysiological testosterone levels (Figure 3.9B). In addition, OVX 
reduced serum T levels when compared to intact females.  
Serum DHT levels were increased 8 and 36-fold in OVX+DHT treated 
compared to intact WT and ARKO females, respectively, demonstrating that 
also DHT implants produced supraphysiological DHT levels (Figure 3.9C). 
Unexpectedly, serum DHT was significantly higher in OVX+DHT treated ARKO 
females compared to OVX+DHT treated WT females despite the similar 
implants used. Serum DHT was also increased in OVX+T treated WT females 
(compared to intact and OVX) but not in ARKO suggesting significant 
conversion of T to DHT in WT but not in ARKO females. Serum DHEA, E1 and 
E2 were below the assay detection limits. 
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3.4.7 Testosterone and DHT via AR induced uterine regrowth in 
WT uterus and AR and ER may share the same signaling 
pathway  
To determine if androgen induced uterine regrowth was via AR and if AR and 
ER share a signaling pathway, we investigated ERα dependent gene, 
Lactoferrin mRNA expression (Figure 3.9D). As expected, ovariectomy in WT 
and ARKO significantly reduced (p<0.05) lactoferrin expression compared to 
intacts. Lactoferrin expression was significantly increased in OVX+T and 
OVX+DHT groups compared to OVX alone in WT (which was comparable to 
WT intact) but there were no changes in ARKO suggesting androgen induced 
lactoferrin expression was via AR. Similar results were shown in other ERα 
dependent genes, Complement component 3 (C3) and Glucose-6-phosphate 
dehydrogenase (G6PDH) (Figure 3.9 E-F). Furthermore, AR and ER may share 
same signaling pathway. Surprisingly, in intact females, lactoferrin, C3 and 
G6PDH expression was significantly increased (p<0.05; non-parametric test) in 
ARKO uterus compared to WT uterus.  
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Figure 3.7. Uterine weights, steroid hormone levels and ERα dependent 
gene mRNA expressions following ovariectomy at eight weeks of age and 
androgen (testosterone (T) or DHT) treatment for three weeks.  Uterine 
weight (A), serum T (B) and DHT (C) levels, lactoferrin (D), C3 (E) and G6PDH 
(F) mRNA expression was compared between WT and ARKO female upon 
ovariectomy and treatment with T or DHT [a= significantly different to other 
treated groups in respective genotype, b= significantly different to WT in the 
respective treatment group, c=significant to intact and OVX WT (p≤0.05; non-
parametric test); mean±SE; n≥3].   
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3.5 Discussion 
AR is expressed in the mouse (Pelletier et al., 2004, Hirai et al., 1994) and 
human (Kimura et al., 1993) uterus and direct androgen actions via AR has 
been suggested to regulate uterine physiology and growth (Walters et al., 2010). 
In mouse, AR is abundantly expressed throughout the uterus including 
endometrial glands (Pelletier et al., 2004). We therefore explored the role of 
androgens via the AR in experimental uterine development and, for the first 
time, generated and characterized endometrial gland specific knockout mouse 
model to investigate the role of endometrial gland specific AR in uterine 
development and fertility. Our discovery that the PBSN-Cre directs selective 
endometrial gland expression of Cre may be of value to further experimental 
research into uterine physiology and pathology.  
To determine the role of AR mediated, endogenous androgen actions in murine 
uterus development, we compared uterus weights and uterine structure 
between sexually mature WT, ugeARKO and ARKO females. AR inactivation in 
either endometrial glands or globally, did not significantly modify uterine weights 
or uterine structure in our study. Similarly, in our previous study uterine weights 
were similar between WT and ARKO females whereas the total, endometrial 
and myometrial uterine areas were significantly reduced in ARKO when 
compared to WT at 8 weeks old females (Walters et al., 2009). While the model 
of AR inactivation between the studies is similar, the discrepancy in the affected 
uterine areas between the previous and present study could be due to the 
different age and genetic background of the mice. Uterine function (as indicated 
by fertility) appeared to be unaffected by endometrial gland specific AR 
inactivation, as pups per litter and total number of pups over five-month mating 
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study were similar between ugeARKO and WT females. Although there are no 
studies suggesting the role of endometrial gland AR inactivation in fertility, our 
previous study has shown that global AR inactivation significantly reduced 
fertility by 60% compared to the control group (Walters et al., 2009). Despite 
endometrial glands synthesizing essential substances for survival and 
development of the embryo (Gray et al., 2001a), our study suggested that lack 
of endogenous androgen actions via endometrial gland AR does not have 
significant effect on uterine development and fertility in mice, presumably due to 
redundancies in molecular pathways to provide this essential support for 
embryo development. 
However, as androgens are suggested to support uterine growth (Armstrong 
and Papkoff, 1976, Schmidt and Katzenellenbogen, 1979), we further 
investigated the role of global AR and endometrial gland specific AR 
inactivation by removing ovarian steroids (estrogens, progesterone) by 
ovariectomy and administering a testosterone implant. As expected, 
ovariectomy reduced uterine weights to about 15% of intact weights without any 
significant difference among genotypes. On the other hand, while WT uterus 
displayed full regrowth to intact weights upon testosterone treatment after 
ovariectomy, the ARKO uterus displayed no regrowth and uterine weights 
remained at ovariectomy level; demonstrating that AR mediated androgen 
action alone can fully support uterine regrowth following ovariectomy.  
In addition, we show that the growth promoting effects of androgens are via AR 
present in uterus as the ugeARKO females showed only 50% regrowth of 
uterus following ovariectomy and testosterone treatment. This suggests a 
significant role of endometrial gland specific AR in androgen effects on uterine 
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regrowth following ovariectomy. The 50% regrowth is striking as uterine glands 
constitute only <5% of the uterine structure. Hence, AR activity in the 
endometrial uterine glands affects the myometrium suggesting AR mediated 
paracrine signaling between the endometrial and myometrial cells. However, 
the Cre expression in Tg(Pbsn-cre)20Fwan mice is driven by ARR2PB 
composite promoter, which contains two AR response elements in order to 
increase the efficacy for AR-driven transcription of Cre (Jin et al., 2003). Hence, 
it is possible the Cre-expression pattern in PBSN-Cre mice can change upon 
testosterone treatment, in other words, Cre could be expressed outside 
glandular epithelial cells as we have shown in this study. In future, this issue 
can be addressed by investigating Cre expression in PBSN-Cre females upon 
ovariectomy and testosterone treatment. 
As estrogens may modify androgen actions (Pelletier et al., 2004) and uterine 
function is estrogen dependent, we further explored if the testosterone 
conversion to E2 is required in AR mediated androgen effects on uterine 
regrowth. Using the non-aromatizable androgen DHT we observed full 
restoration of uterine growth in WT females whereas ARKO uterus had no 
regrowth remaining similar to the estrogen deficient uterus. This further 
supports our finding that androgens acting via AR alone can promote full 
uterine regrowth without requiring E2. This could be due to AR and ERα sharing 
similar molecular pathways as we demonstrated that androgens (T and DHT) 
acting via AR (lack of induction in ARKO) induced expression of ERα 
dependent genes, lactoferrin, C3 and G6PDH. However, further studies are 
required to understand the possible sharing of pathways by ER and AR as 
there could also be other pathways involved. Furthermore, the ERα knockout 
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(ERαKO) and aromatase knockout (ArKO) female mice with supraphysiological 
levels of circulating T lacked uterine growth suggesting the essential role of E2 
in normal peripubertal uterine growth and development in mice (Hewitt et al., 
2010, Lubahn et al., 1993, Fisher et al., 1998). In addition, although we expect 
E2 to be absent in the ovariectomised mice and E2 was under the detection limit 
(2.5pg/mL) of LC/MS-MS, we must consider the phytoestrogens that may be 
present through diet and may play a role uterine regrowth as high 
phytoestrogen diet elevated estrogen dependent genes in mice (Wang et al., 
2005, Kaitu'u-Lino et al., 2007).  
In our ugeARKO model, the floxed Ar gene creates a highly selective deletion 
of only the exon 3 (the second zinc finger of the DNA binding domain) of the AR. 
This creates a minimally truncated AR which is fully inactivated but is much 
closer to physiological than the major deletions of the AR protein created by 
introducing stop codons early into the translated protein. Unfortunately, the flip 
side of such highly selective, minimal deletion from a large protein is that it has 
proved impossible to obtain commercially or to custom generate specific 
antibodies specific to the truncated exon 3 deleted AR. Hence, AR protein is 
detectable to all commercial N and C terminal antibodies as well as any custom 
antibodies we tried to generate. However although the AR protein remains 
present immunohistochemically in its mutated form, it is functionally inactive 
(Notini et al., 2005b). Hence, as an alternative to prove the cellular-specificity of 
the Cre-mediated excision of exon 3, we micro-dissected uterine glandular 
epithelium from ugeARKO uterus and confirmed that the exon 3 deleted, 
inactive AR is only present in glands of ugeARKO uterus with no functional 
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(undeleted) Ar was detected in glands of ugeARKO uterus. Conversely, non-
glandular uterine tissue expressed only the undeleted Ar. 
We further validated and characterized the functional Cre activity in endometrial 
glands using ugePTENKO mouse model. Pten is a tumor suppressor gene 
(Dahia, 2000) and PTEN knockout causes endometrial cancer in mice 
(Stambolic et al., 2000, Daikoku et al., 2008). Firstly, we demonstrated PBSN-
Cre activity is only present in endometrial glands by PTEN immunolocalization, 
where only the endometrial glands of ugePTENKO uterus were PTEN 
immunonegative compared to PTEN immunopositive glands in WT. 
Furthermore, we demonstrated significantly increased uterine weight in 
ugePTENKO females with increased cell proliferation (PCNA staining) when 
compared to WT. As PTEN deletion mouse model has been widely used in 
uterine cancer research (Stambolic et al., 2000, Daikoku et al., 2008), our 
model would be a novel model to investigate uterine cancer as it has been 
suggested that adenocarcinoma in uterus arise from endometrial glands 
(Newbold et al., 1990). Hence, the model would provide new platform to future 
uterine cancer research.  
To create the endometrial gland specific knockout, we used PBSN-Cre mouse 
line for Cre/loxP system. PBSN has been known as a prostate specific protein 
which has been used to generate prostate specific genetically modified mouse 
models (Simanainen et al., 2007). Surprisingly, we have shown that the PBSN-
Cre mouse line (Jin et al., 2003) can also be used to generate uterine gland 
specific knockouts in females. Although, Pbsn mRNA was not detectable in our 
uterine samples at 20 weeks diestrus, there are possibilities that Pbsn may be 
expressed at earlier during uterine development or it may be dependent on the 
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estrous cycle or the specific expression generated using PBSN promoter is 
specific for this PBSN-Cre model with the mechanism remaining unknown (Jin 
et al., 2003). Also, we have shown that Pbsn is selectively active in glandular 
epithelial cells in the uterus. Hence, the PBSN-Cre mouse line (Jin et al., 2003) 
used can effectively generate uterine gland specific knockout mice.  
While other mouse models are also available to generate knockouts in the 
uterus, including endometrial knockouts using progesterone receptor (PR)-cre 
mouse line (Soyal et al., 2005) or conditional gene recombination by 
adenovirus-driven cre (Wang et al., 2006), these mice have some 
disadvantages. The disadvantage of PR-cre mouse line is that PR is also 
expressed in other tissues such as pituitary, ovary and mammary gland (Soyal 
et al., 2005) which depending on the knockout target could have systemic 
effects including changes in hormone profile hence effecting uterine physiology. 
The disadvantage of adenovirus-driven cre model is the recombination strategy 
is difficult to control the amount and the localization of cre delivered by the 
adenovirus vector. This may result in high variability of amount and localization 
of the knockout between individual experimental mice. 
In conclusion, our study has suggested that androgens acting solely via AR can 
support full uterine growth, however, it is not known if potential estrogenic 
activity from the standard chow may play a role. Furthermore, we have 
generated and characterized the first endometrial gland specific genetically 
modified mouse model and using the model we have shown endometrial gland 
AR mediates uterine (including myometrial) growth via AR mediated androgen 
actions. These findings warrant further investigations of the role of AR and 
cross-talk involving AR expression in different type of uterine cells such as 
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luminal, stromal and myometrial cells. Also, the role of endometrial gland AR 
should be investigated in uterine disorders such as endometrial cancer which 
could lead to better biomarkers and more effective novel treatment of uterine 
disorders.  
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Chapter 4: 
Androgen actions via androgen 
receptor promote PTEN inactivation 
induced uterine cancer 
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androgen receptor promote PTEN inactivation induced uterine cancer. 
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4.1 Abstract 
Haploinsufficient inactivating Pten mutations cause Cowden syndrome, an 
autosomal dominant risk genotype for hormone dependent reproductive 
cancers including uterine cancer. As androgen actions mediated via androgen 
receptor (AR) supports uterine growth and may modify uterine cancer risk, we 
hypothesized that a functional AR may increase PTEN inactivation induced 
uterine cancer. Our aims of this experiment were to determine: 
i) The role of global AR inactivation in PTEN deletion induced uterine 
cancer. 
ii) If global AR inactivation modifies PTEN expression and its AKT 
pathway in uterus and also if uterine ERα expression is affected. 
iii) If global AR inactivation modifies serum and ovarian steroid hormone 
levels which may modify uterine cancer incidence. 
To test the hypothesis, we compared the PTEN knockout induced uterine 
pathology in heterozygous PTEN knockout (PTENKO) and combined 
heterozygous PTEN and complete AR knockout (PTENARKO) female mice. 
PTEN knockout induced uterine pathology was significantly reduced by AR 
inactivation with severe macroscopic uterine pathology present in 21% of 
PTENARKO vs 46% of PTENKO at a median age of 45 weeks. This could be 
due to reduced stroma ERα expression in PTENARKO compared to PTENKO 
uterus, while AR inactivation did not modify PTEN or P-AKT levels. 
Unexpectedly, while progesterone is assumed protective in uterine cancers, 
serum progesterone was significantly higher in PTENKO females compared to 
wild type (WT), AR knockout (ARKO) and PTENARKO females consistent with 
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more corpora lutea in PTENKO ovaries. Serum testosterone and ovarian 
estradiol were similar between all females. Hence, our results demonstrated AR 
inactivation mediated protection against PTEN knockout induced uterine 
pathology and suggests a potential role for anti-androgens in uterine cancer 
prevention and treatment. 
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4.2 Introduction 
Endometrial cancer (EC) is a frequent gynaecological cancer. It is highly 
hormone dependent being promoted by estradiol (E2) and inhibited by 
progesterone (P4) (Bender et al., 2011), while the role of androgens remains 
controversial. Androgens are 19-carbon steroid hormones produced in females 
mainly by ovarian and adrenal gland secretion together with extraglandular 
conversion. Androgens mediate their effects via androgen receptor (AR) 
expressed in target tissues such as the uterus of women (Somboonporn and 
Davis, 2004) and rodents (Walters et al., 2010). AR is a member of the nuclear 
receptor superfamily and encoded by an X chromosomal gene (Quigley et al., 
1995). The biological effects of androgens in male physiology are well 
characterized, but the physiological roles in the female other than as precursors 
for conversion to estrogens by aromatase (Hillier et al., 1994) have only 
recently been recognized as critical for optimal female reproduction (Walters et 
al., 2007).  
The possible role for androgens in uterine growth is supported by in vivo 
experimental findings. The non-aromatizable androgen, dihydrotestosterone 
(DHT) promotes growth and differentiation of the rodent uterus (Schmidt and 
Katzenellenbogen, 1979) whereas AR inactivation in mice resulted in thinner 
uterus with reduced total uterine area compared to wild type (WT) females 
(Walters et al., 2009). However, in contrast, androstenedione (an aromatizable 
proandrogen) inhibited proliferation of human endometrial cells in vitro, an 
effect that was reversed by an antiandrogen (cyproterone acetate) suggesting 
these effects were mediated via AR actions in endometrial cells (Tuckerman et 
al., 2000). Androgens may also have a role in development and/or progression 
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of uterine carcinogenesis as increased androgen activity due to shorter CAG 
repeat in AR was related to increased endometrial cancer risk in women 
(McGrath et al., 2006). In addition, AR is strongly expressed in human 
endometrial disorders including different types of endometrial cancers (Ito et al., 
2002), further supporting a role of androgens acting via AR in uterine cancer. 
Pten, a phosphatase and tensin homolog, is a tumor suppressor gene located 
on chromosome 10 (Dahia, 2000). Pten is mutated or deleted in a wide range of 
human cancers including endometrial cancers (Dahia, 2000). PTEN functions 
as a phosphatase and inhibits the growth factor signals transduced through 
PI3K by inhibiting AKT phosphorylation (Li et al., 1998). Pten mutations are 
observed in 30-80% of type 1 endometrial carcinomas (EMC) and in 20 to 70% 
of complex atypical hyperplasia, a premalignant stage of EMC (Tashiro et al., 
1997, Levine et al., 1998, Lee et al., 2012). Global homozygous PTEN 
inactivation is “embryo” lethal and the mice die between gestation day 6.5 to 9.5 
(Suzuki et al., 1998). Global heterozygous Pten knockout (PTENKO) in mice 
resembles Cowden syndrome in patients and it causes endometrial cancer and 
therefore PTENKO females are used as endometrial cancer models (Stambolic 
et al., 2000). AR and PTEN interact in breast and prostate cancers (Wang et al., 
2011b) and they cross regulate by reciprocal feedback (Carver et al., 2011, 
Mulholland et al., 2011). Furthermore, PTEN knockout increases ERα 
expression in endometrial cancer cells (Lian et al., 2006) and activates ERα 
dependent pathways in mouse endometrial cancer (Vilgelm et al., 2006).  
The goal of this study was to investigate the role of AR mediated androgen 
actions in PTEN inactivation induced experimental uterine cancer. To achieve 
our goal, we have generated and characterized global homozygous AR 
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knockout (ARKO) females with or without global heterozygous PTEN 
inactivation using Cre/LoxP system to determine the effects of AR inactivation 
on PTEN inactivation induced uterine cancer susceptibility and possible 
mechanisms involved.  
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4.3 Experimental design 
Experimental design was carried out as it follows: 
i) The role of global AR inactivation in PTEN deletion induced uterine 
cancer was determine by comparing uterine weight and uterine 
cancer incidences in PTENKO (heterozygous PTEN deletion) and 
PTENARKO (combined heterozygous PTEN deletion and 
homozygous AR inactivation) females at 45 weeks old. Furthermore, 
to determine if global AR inactivation modifies serum and ovarian 
steroid hormone levels which may modify uterine cancer incidences, 
these steroid hormone levels were compared between WT, ARKO, 
PTENKO and PTENARKO females at 45 weeks of age using LC-
MS/MS. WT, ARKO, PTENKO and PTENARKO females were 
generated as described in methods (see 2.1). 
ii) To determine if AR mediated androgen actions are responsible for 
androgen induced uterine growth, PTENKO and PTENARKO females 
were ovariectomised at 5 weeks old and treated with testosterone or 
empty implants for 15 weeks and collected at 20 weeks of age. Upon 
collection, uterine weights were compared. 
iii) To determine if global AR inactivation modifies expression of PTEN, 
AKT, P-AKT or ERα expression in uterus, the immunopositivity of 
these proteins in uterus was compared between WT, ARKO, 
PTENKO and PTENARKO females at 20 weeks of age. The 
immunopositivity was compared at an earlier age to reduce variability 
due to different types of histopathologies developed in older (45 
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weeks) group. This also allowed comparison of the early molecular 
changes in neoplastic pathways. 
 
Genotype confirmation 
Excision of exon 5 in PTEN knockout and exon 3 in AR knockout were 
confirmed at genomic DNA and mRNA levels. The genomic DNA was released 
using proteinase K digestion of uterine tissues. Excision of exon 5 of Pten was 
confirmed using same primers as for genotyping (Byun et al., 2011). Excision of 
AR exon 3 was confirmed as described (Notini et al., 2005b). In addition, 
excision of exon 3 of Ar in the uterus was confirmed by RT-PCR as previously 
described (Simanainen et al., 2007). Two product sizes were obtained, 288 bps 
for intact Ar and 171 bp for Cre mediated exon 3 excised Ar.  Exon 5 deletions 
in Pten was not confirmed by RT-PCR using RNA because exon 5 deletion in 
Pten produces stop codon; hence no exons are produced after exon 4 meaning 
no bands will be produced at cDNA level. Two product sizes were obtained, 
650 bps for intact Pten and 300 bp for Cre mediated exon 5 excised Pten. -
Actin was used as a loading control.  
 
Ovariectomy and implants 
To determine the role of androgens in the uterine pathology in the controlled 
hormonal environment, PTENKO and PTENARKO mice were ovariectomised 
(OVX) under anaesthesia at 5 weeks of age and implanted with 1 cm silastic 
implants (inner diameter=1.47mm and outer diameter=1.95mm, Dow-Corning, 
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Sydney, Australia) either containing ~10 mg crystalline testosterone or no 
steroid placed subdermally for 15 weeks and subsequently collected at 20 
weeks of age.  
 
Uterine cancer classification  
All uteri from experimental mice were classified into two categories based on 
macroscopic characteristics: normal or abnormal. Normal uteri (Figure 4.1a) 
had uterine weight less than 300mg and did not exhibit any macroscopic 
abnormalities such as extensive vascularization (Figure 4.1b) or presence of 
unusual growths (Figure 4.1c). Abnormal uteri had uterine weight greater than 
or equal to 300mg (upper range of WT uterine weight mean±SD) resulting in 
enlarged uterine horns with any of the macroscopic abnormal features. 
 
 
Figure 4.1. Uterus morphological classification at the median age of 45 
weeks. A-C) Representative images of macroscopic uterine category: normal 
uterus (A) and abnormal uterus (B and C).   
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4.4 Results 
4.4.1 Confirmation of SOX2-Cre mediated excision of DNA 
between loxP sites of Ar and Pten  
PCR was used to confirm SOX2-Cre mediated excision of exon 3 of Ar and 
exon 5 of Pten in the uterus. The exon 5 deleted Pten PCR products (primers 
designed to amplify only the smaller, exon 5 deleted product) were detected 
only in the uterus of PTENKO and PTENARKO mice (Figure 4.2A), while only 
native Pten product was detected in WT and ARKO uterus (Figure 4.2B). 
However, native Pten product was also detected in PTENKO and PTENARKO 
uterus as these mice were heterozygous for Pten deletion. In addition, 
presence of native Ar (larger product containing exon 3) was confirmed in WT 
and PTENKO female uterus at a cDNA level (RT-PCR), while the ARKO and 
PTENARKO uterus showed exclusively the smaller exon 3 deleted Ar products 
(Figure 4.2C). Exon 5 excision in Pten gene was not confirmed at the mRNA 
level because exon 5 excision produces stop codon and early termination of 
transcription of mRNA.  
Western blot was used to compare PTEN protein levels between WT, ARKO, 
PTENKO and PTENARKO uterus (Figure 4.2D). While the PTEN levels were 
variable between individual uteri, the levels appeared to be decreased in 
PTENKO and PTENARKO uterus (note PTEN knockout is heterozygous 
thereby retaining a normal Pten allele) compared to WT and ARKO uterus.  
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Figure 4.2. Genotyping PCR on uterus cDNA. A) PTEN PCR showing PTEN 
deletion. B) PTEN PCR showing WT PTEN. C) ARCUT RT-PCR showing WT 
AR and exon 3 excised AR. D) PTEN western blot showing PTEN reduction in 
PTENKO and PTENARKO. 
 
  
130 
 
4.4.2 AR inactivation modifies PTEN deletion induced uterine 
pathology 
All uteri of WT and ARKO females at the mean age of 43 and 46 weeks 
respectively were macroscopically normal. In PTENKO females, mean age of 
46 weeks, 46% (24/52) had macroscopic abnormal uterus while only 21% (5/24) 
in PTENARKO females, mean age of 43 weeks (Table 4.1). PTEN deletion 
significantly increased (p<0.001; log-linear model) abnormal uterus incidence 
whereas AR inactivation significantly decreased (p=0.0012) the PTEN induced 
uterine cancer incidence; interaction between PTEN deletion and AR 
inactivation was not statistically significant. 
 
Table 4.1. Macroscopic categorization of uterine abnormalities. 
a=significantly different to PTENARKO, #=% over total number of mice, N/A= 
no incidences of abnormal uterus found. 
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Comparable to pathology, uterine weights at 45 weeks was increased in 
PTENKO and PTENARKO compared to WT and ARKO (Figure 4.3A). The 
uterine weights were significantly (p=0.004; two way ANOVA) increased by 
PTEN deletion but was not affected by AR inactivation (p=0.077); interaction of 
PTEN deletion and AR inactivation was not significant (p=0.091). Similar results 
were observed when uterine weights were standardized against the body 
weight (Figure 4.10). In addition, PTENKO uterus was significantly heavier than 
PTENARKO uterus. Uterine weights were similar between ARKO and WT 
females (Figure 4.3A). Uteri that were categorized as normal in each genotype 
did not exhibit any abnormal histology and appeared similar (Figure 4.3B-E). 
Histopathological analysis of the macroscopic abnormal uteri showed different 
types of histopathologies. In PTENKO, 58% (14/24) were high-grade (poorly-
differentiated) carcinoma, (Figure 4.3F), 29% (7/24) were low-grade 
adenocarcinoma (Figure 4.3J), and remaining 13% (3/24) were endometritis, 
hematoma and an indeterminate tumor. In PTENARKO, only high-grade 
carcinoma (3/5, 60%) and low-grade adenocarcinoma (2/5, 40%) were 
observed. There was no statistically significant difference between PTENKO 
and PTENARKO in the distribution of histological grade among high-grade 
carcinoma and low-grade adenocarcinoma. 
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Figure 4.3. Uterus weights and histopathology at the median age of 45 
weeks. A) Absolute uterine weight. [a= significantly different to WT, b= 
significantly different to ARKO, c= significantly different to PTENARKO (p<0.05; 
one way ANOVA) (mean±SE)]. B-E) Representative images of normal uterus of 
WT (B), ARKO (C), PTENKO (D) and PTENARKO (E) at 45 weeks (Scale 
bar=400µm). F-J) Representative images of major uterine histopathologies in 
PTENKO and PTENARKO: high-grade carcinoma with dedifferentiated 
morphology (F) and low-grade (focal) adenocarcinoma (J) (400x magnification). 
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Similarly to uterine weights at 45 weeks, uterine weight at 20 weeks were 
significantly (p=0.008; two way ANOVA) increased by PTEN deletion but was 
not affected by AR inactivation (p=0.065); interaction of PTEN deletion and AR 
inactivation was significant (p=0.009), with smaller uteri in PTENARKO than in 
PTENKO females (Figure 4.4A). Histologically, no uterine cancers were 
detected at 20weeks (Figure 4.4B-E) although PTENKO uteri were 
histologically abnormal with enlarged and disorganized endometrial glands not 
present in uteri from other genotypes (Figure 4.4D). 
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Figure 4.4. Uterine weight and histology (H&E) at 20 weeks of age. A) 
Uterine weight (mg). [a= significantly different to WT, ARKO and PTENARKO 
(p<0.05; one way ANOVA); mean±SE; n≥8]. B-E) Representative photos of 
H&E stained of WT (B), ARKO (C), PTENKO (D) and PTENARKO (E) at 20 
weeks. (Scale bar=400um). 
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4.4.3 AR mediated androgen actions are required for 
testosterone induced uterine regrowth 
OVX and testosterone treatment was performed on PTENKO and PTENARKO 
females to investigate the direct role of testosterone in uterus (Figure 4.5A). 
OVX prevented uterine growth in PTENKO and PTENARKO females with the 
uterine weights in OVX groups being about 15% of the intact female uterine 
weights at 20 weeks of age without any difference between the groups. In 
PTENKO females, testosterone treatments following OVX (OVX+T) fully 
restored the uterine weight to the intact level at 20 weeks of age. However, no 
uterine growth was detected following OVX and T treatment in PTENARKO 
females and the uterus weight remained similar to OVX only females. 
Histologically, uteri of PTENKO (OVX), PTENARKO (OVX) and PTENARKO 
(OVX+T) appeared similar (Figure 4.5B, D, and E). 
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Figure 4.5. Uterine weight and histology (H&E) at 20 weeks of age upon 
ovariectomy and testosterone treatment. A) Uterine weight (relative to 
intacts). [a=significantly different to OVX group and PTENARKO (OVX+T) 
(p<0.05; one way ANOVA) (mean±SE)]. B-E) Representative photos of H&E 
stained of PTENKO (OVX) (B), PTENKO (OVX+T) (C), PTENARKO (OVX) (D) 
and PTENARKO (OVX+T) (E)  (Note different size of scale bars. Scale 
bar=200um for image B, D, E and 400µm for image C). 
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4.4.4 AR inactivation did not significantly affect PTEN, P-AKT 
and p27 levels in heterozygous PTEN deleted uterus 
As it has been suggested that AR can regulate PTEN expression and hence 
modify AKT pathway (Wang et al., 2011b), we compared the PTEN, AKT and 
P-AKT levels in the PTENKO and PTENARKO uterus. While no significant 
differences were found in the PTEN protein expression (Figure 4.6A) between 
the PTENKO (native Ar) and PTENARKO (inactive Ar) uterus, the AKT levels 
(Figure 4.6B) were significantly (p=0.02; one way ANOVA) increased in 
PTENARKO uterus compared to PTENKO. However, the P-AKT (active form of 
AKT) levels (Figure 4.6C) were not affected by the AR inactivation in PTENKO 
uterus. As p27 is a key target of the growth regulatory activity exerted by AKT 
pathway (Liang et al., 2002) and is deregulated in multiple cancers including 
endometrioid uterus, however, p27 protein while reduced in PTENARKO 
(Figure 4.6D) was not significantly different (p=0.082) between PTENKO and 
PTENARKO uterus. Immunohistochemically, no differences were observed in 
PTEN (Figure 4.6E-F) and P-AKT (Figure 4.6H-I) expression in PTENKO and 
PTENARKO uterus in supporting the western blot results. Whereas, all cells of 
PTENKO were immunopositive for p27 while in PTENARKO uterus glandular 
epithelial cells were immunonegative supporting the lower protein levels 
observed by western blots (Figure 4.6K-L). 
To further examine the effect of androgens on PTEN, P-AKT and p27 
expression, we compared the levels between PTENKO and PTENKO (OVX+T) 
uterus. OVX + T treated PTENARKO uterus was not included as the uteri were 
underdeveloped (Figure 4.5). PTEN expression was decreased in all cells upon 
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OVX and testosterone treatment compared to intact PTENKO (Figure 4.6G) 
whereas P-AKT expression was increased in glandular and luminal epithelial 
cells (Figure 4.6J). p27 expression was increased in all cells upon OVX and 
testosterone treatment in PTENKO uterus compared to intact PTENKO (Figure 
4.6M). 
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Figure 4.6. p27, AKT, P-AKT and PTEN western blot and 
immunohistochemistry on PTEN deleted uterus at 20 weeks. 
Representative western blots for each proteins are shown in the figure with 
name of the protein labelled on the left and protein band (kDa) shown on the 
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right. A-D) Quantification of western blot bands by measuring the intensity of 
each band standardized using B-actin as a housekeeper (a= significantly 
different to PTENKO (p=0.043; one way ANOVA); mean±SE; n≥5). E-M) 
Representative images of immunohistochemistry of PTEN, P-AKT and p27 in 
PTENKO, PTENARKO and PTENKO (OVX+T) uterus at 20 weeks (Scale 
bar=100µm). Additional blots for PTEN have been included in Appendix V. 
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4.4.5 Increased uterine ERα expression in PTENKO females 
was inhibited by simultaneous AR inactivation in PTENARKO 
females at 20 weeks  
As ERα expression is significantly increased in PTENKO uterus (Vilgelm et al., 
2006, Lian et al., 2006), we examined if AR inactivation could influence this 
PTEN knockout induced increase in ERα. ERα positivity (Figure 4.7A) and 
intensity (Figure 4.7B) were quantified according to different cell types: 
glandular epithelial cells, luminal epithelial cells, endometrial stroma and 
myometrium. ERα positivity in each cell types was not significantly affected by 
genotype. However, ERa intensity in glandular epithelial cells was significantly 
decreased in ARKO (p=0.015; one-way ANOVA) and PTENARKO (p=0.026) 
uterus compared to WT. ERα intensity in endometrial stromal cells was 
significantly increased in PTENKO uterus compared to WT (p=0.036), ARKO 
(p=0.004) and PTENKARKO (p=0.002). A representative image of each 
genotype is shown in Figure 4.7C-F.  
Real time RT-PCR was performed to determine ERα gene expression. ERα 
mRNA expression was increased (p=0.064; one way ANOVA) in the PTENKO 
uterus compared to WT but this effect was prevented by simultaneous AR 
inactivation in PTENARKO uterus (Figure 4.7G). Congruent findings were 
observed in the expression of ERa target genes, G6PDH expression was 
significantly increased (p=0.019; t-test) in PTENKO uterus compared to WT and 
again this effect was prevented by simultaneous AR inactivation in PTENARKO 
uterus (Figure 4.7H). Although not statistically significant, other ERa dependent 
genes, lactoferrin (p=0.064; t-test) (Figure 4.7I) and complement C3 (p=0.097; 
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t-test) (Figure 4.7J) were also increased in PTENKO uterus compared to WT 
and similarly this effect was prevented by simultaneous AR inactivation in 
PTENARKO uterus. 
Furthermore, when compared to intact PTENKO uterus, OVX+T treated 
PTENKO uterus had marked increase in ERα expression immunopositivity 
(Figure 4.7K), which was observed in all cell types.  
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Figure 4.7. Expression of ERα and ERα dependent genes in the uterus of 
20 weeks old females. A-B) Percentage of ERa positive cells (A) and intensity 
(B) in glandular epithelial cells, luminal epithelial cells, stroma and myometrium 
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in experimental groups [a= significantly different to WT, b=significantly different 
to WT, ARKO and PTENARKO (one-way ANOVA; mean±SE; n=4)]. C-F) 
Representative images of ERa immunohistochemistry on WT (C), ARKO (D), 
PTENKO (E) and PTENARKO (F) (Scale bar=100µm) G-J) Relative expression 
(relative to 18s rRNA housekeeping gene analyzed by real-time RT-PCR) of 
ERa mRNA (G) and ERa dependent genes (H-J) in the uterus at 20 weeks of 
age [a= significantly different to WT; (p=0.019; t-test) (mean±SE; n≥6)]. K) 
Representative image of ERa immunohistochemistry on ovariectomised and 
testosterone treated PTENKO uterus (Scale bar=100µm). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
145 
 
4.4.6 PTEN knockout in females increased serum P4 
As uterine cancer is highly hormone dependent (Martin et al., 1973b, Martin et 
al., 1973a, Persson, 1996), circulating sex steroid levels were investigated to 
determine if PTEN deletion and/or AR inactivation modified exposure to key 
reproductive hormones. Serum testosterone was not affected by genotype 
(Figure 4.8A) whereas serum P4 (Figure 4.8B) was significantly increased 
(p=0.003; two way ANOVA) by PTEN deletion and significantly decreased 
(p=0.008) by AR inactivation; interaction of PTEN deletion and AR inactivation 
was significant (p=0.026). Resulting in serum P4 being significantly increased in 
PTENKO compared to other groups. 
In addition, the ovarian E2 content was analyzed as serum E2 in intact female 
mice is usually below the detection limit of LC-MS/MS (2.5pg E2/ml; (McNamara 
et al., 2010b)). Ovarian E2 content was similar between the genotypes (Figure 
4.8C). Ovarian P4 (Figure 4.8D) was also increased in PTENKO when 
compared to other genotypes; however, it was statistically non-significant due 
to the high variability in PTENKO. 
Furthermore, as high levels of P4 are produced by the CL in the ovaries 
(Stocco et al., 2007) and PTEN is known to affect ovarian CL numbers (Fan et 
al., 2008), we quantified ovarian CL content in WT, ARKO, PTENKO and 
PTENARKO females. CL number was significantly (p=0.006; two way ANOVA) 
reduced by AR inactivation and increased by PTEN deletion (p=0.08); 
significance of AR inactivation and PTEN deletion interaction was 0.053 (Figure 
4.8E-F), suggesting that increased P4 levels could be due to increased CL 
number and that the increase in CL due to PTEN  deletion was reversed by AR 
inactivation. 
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PR immunohistochemistry was performed on PTENKO (Figure 4.8G) and 
PTENARKO (Figure 4.8H) uterus at 20 weeks and both the PTENKO and 
PTENARKO uterus expressed PR without obvious differences. However, 
compared to intact PTENKO uterus, OVX+T treated PTENKO uterus had 
marked increase in PR immunopositivity (Figure 4.8I). This increase was 
observed in all cell types.   
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Figure 4.8. Steroid hormone levels and CL count at 45 weeks and PR 
expression in PTENKO and PTENARKO uterus at 20 weeks. Serum T (A) 
and P4 (B) levels [a= significantly different to WT, b= significantly different to 
ARKO, c= significantly different to PTENARKO (p<0.05; one way ANOVA); 
mean±SE; n: WT=32, ARKO=7, PTENKO=43, PTENARKO=23]. Ovarian P4 
(C) and E2 (D) levels (mean±SE; n=4). E-F) Total number of Corpus Luteum 
(CL) in ovaries of WT, ARKO, PTENKO and PTENARKO females with 
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representative image (F) [a= significantly different to WT, b= significantly 
different to ARKO, c= significantly different to PTENARKO (p<0.05; 
nonparametric test); mean±SE; n=4]. PR immunohistochemistry on PTENKO 
(G), PTENARKO (H) and PTENKO (OVX+T) (I) at 20 weeks old (Scale 
bar=100µm). 
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4.4.7 Multiple organs were affected by PTEN deletion and AR 
inactivation in females 
Body weight was significantly (p<0.001; two way ANOVA) increased by PTEN 
deletion but AR inactivation did not affect body weight; interaction between 
PTEN deletion and AR inactivation was significant (p=0.001) (Figure 4.9). As a 
result, other organ weights were evaluated with and without adjustment for 
body weight.  
Ovary and adrenal gland weights were significantly (p<0.02) increased by 
PTEN deletion but was not affected by AR inactivation; there was no significant 
interaction between PTEN deletion and AR inactivation (Figure 4.9). However, 
when adjusted for body weight, ovary weights were not affected by PTEN 
deletion whereas adrenal gland remained similar (Figure 4.10). Absolute liver 
and spleen weights were not affected by AR inactivation and PTEN deletion, 
however the interaction between AR inactivation and PTEN deletion was 
significant (p<0.05) for both organs (Figure 4.9). When adjusted for body weight 
only the interaction between AR inactivation and PTEN deletion was significant 
(0.043) in spleen but not in liver. (Figure 4.10). 
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Figure 4.9. Body weight and absolute organ weight of female mice at the 
median age of 45 weeks. a= significantly different to WT, b= significantly 
different to ARKO, c= significantly different to PTENARKO [(p<0.05; oneway 
ANOVA) (mean±SE); n: WT=32, ARKO>7, PTENKO>43, PTENARKO>23]. 
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Figure 4.10. Standardized organ weight of female mice at the median age 
of 45 weeks. a= significantly different to WT, b= significantly different to ARKO, 
c= significantly different to PTENARKO, (p<0.05; mean±SE; n: WT=32, 
ARKO>7, PTENKO>43, PTENARKO>23).  
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4.4.8 Other incidental abnormalities  
Global heterozygous PTEN knockout also induced abnormalities other than 
uterine pathology in female mice (Table 4.2). Mammary gland abnormalities 
were the most frequent with 54% of PTENKO and PTENARKO females bearing 
abnormal mammary glands (palpable tumors or alveolarized mammary gland 
with milk production (Li et al., 2002)) compared with none detected in WT and 
ARKO. Histologically, the palpable tumors within mammary glands were 
lymphomas (17% vs 21% in PTENKO vs PTENARKO) and fibroadenomas (23 
vs 30%). In addition, some females had benign mammary abnormalities 
comprising alveolarized mammary glands with milk production (13 vs 4%) 
(Table 4.2).   
Very low frequencies of macroscopic abnormalities were also observed in 
adrenal glands, liver, lung, ovaries, pancreas and spleen (Table 4.2). Among 
these, the most frequent abnormality was the appearance of unusual black 
spots on the organ surface.  
 
Table 4.2. Abnormalities found in 45 week old experimental female mice. 
% shown are calculated over total number of mice. 
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4.5 Discussion 
Direct AR mediated androgen actions on female reproductive physiology have 
been established (Walters et al., 2010) leading to suggestions that they may 
have impact on the physiology and pathology of the uterus and breast (Walters 
et al., 2010, Somboonporn and Davis, 2004). As AR is expressed in uterus of 
mice (Walters et al., 2010) and humans (Somboonporn and Davis, 2004), we 
therefore explored the role of androgens acting via the AR in experimental, 
PTEN knockout induced murine uterine cancer. Our findings demonstrate that 
androgens acting via AR have a significant role in the uterine carcinogenesis 
although it remains to be determined whether this is manifesting directly in the 
uterus or indirectly via systemic hormonal effects. We demonstrate that global 
AR inactivation significantly reduces the frequency of uterine cancers induced 
by PTEN deletion. Our findings also suggest that this preventive effect may be 
mediated by elimination of heterozygous PTEN knockout induced increase in 
uterine ERa expression. Furthermore, it is important to note that our uterine 
cancer model resembles Cowden syndrome, the germline mutation of one 
allele of PTEN resulting in hereditary cancer predisposition (Liaw et al., 1997). 
Hence, the prevention of uterine cancers by interrupting androgen action in our 
model may represent not only an effective simulation of the endometrial 
cancers in Cowden syndrome but also point to the potential role of anti-
androgens in its treatment. 
This study demonstrates that androgens acting via AR decrease uterine cancer 
incidence in PTENKO experimental uterine cancer model. Heterozygous PTEN 
knockout induced uterine cancers as previously reported (Stambolic et al., 2000, 
Risinger et al., 1997). However, these changes in PTENKO uterus were 
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significantly reduced by AR inactivation in PTENARKO females. Our findings 
also suggest that the AR inactivation slows the carcinogenic process as at 20 
weeks of age PTENKO females showed only premalignant uterine hyperplasia, 
a premalignant precursor to endometrial cancer. While not experimentally 
tested before, an influence of androgens on uterine cancer development is 
consistent with a previous clinical study showing an excess of shorter CAG 
repeat in AR gene, which increases tissue androgen sensitivity (Simanainen et 
al., 2011a), being associated with increased endometrial cancer risk (McGrath 
et al., 2006). Furthermore, there is also evidence that PCOS patients with 
elevated plasma androgens (Nagamani et al., 1986) have increased risk of 
uterine cancer (Smyczek-Gargya and Geppert, 1992). Also, our study has 
shown AR mediated uterine regrowth upon ovariectomy and testosterone 
treatment.  
In breast and prostate cancers the AR is suggested to regulate the PTEN levels 
(Wang et al., 2011b) and therefore we determined if the PTEN expression was 
modified by AR inactivation in PTENARKO uterus and could therefore modify 
the risk of uterine cancer. However, we were unable to detect a significant 
effect of AR inactivation on PTEN gene expression in the uterus. However, the 
total AKT levels were significantly increased in PTENARKO uterus when 
compared to PTENKO, whereas the active phosphorylated AKT levels were 
unaffected. These findings suggest that the reduced uterine cancer incidence in 
PTENARKO females may not be due to modification of AKT signaling pathway. 
Yet, in prostate cancer cells, AR mediated protection from PTEN induced 
apoptosis is independent of AKT pathway activation (Li et al., 2001). In addition, 
our study showed diminished PTEN expression in PTEN (OVX+T) uterus 
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compared to the intact suggesting that testosterone alone, in the absence of 
other steroid hormones, negatively regulate PTEN expression in the uterus. 
This was supported in a prostate cancer cell study, where DHT via AR inhibited 
PTEN transcription and translation (Wang et al., 2011b). Diminished PTEN 
expression in PTENKO (OVX+T) uterus resulted in increased P-AKT 
expression in glandular and luminal epithelial cells supporting previous reports 
of negative correlation between PTEN and P-AKT in uterus (Stambolic et al., 
2000, Stambolic et al., 1998). Hence, further investigations are warranted to 
investigate AR and PTEN interaction in the origins of uterine cancers. 
Interestingly, we found that the expression of tumor suppressor p27 appeared 
to be reduced (p=0.082) in PTENARKO uterus when compared to PTENKO. 
This could be due to reduced p27 expression in glandular epithelial cells of 
PTENARKO uterus. This was unexpected as the p27 levels are usually 
negatively correlated with malignancy with the level of p27 being reduced in 
approximately 50% of human cancers (Slingerland and Pagano, 2000, 
Sgambato et al., 2000). However, our finding suggesting a positive correlation 
between p27 expression and uterine cancer was supported by a clinical studies 
where p27 expression was increased in patients with endometrioid 
adenocarcinomas (Watanabe et al., 2002) and advanced grading endometrial 
carcinoma (Nycum et al., 2001). However, contrary to our findings, other clinical 
studies reported a negative correlation between p27 expression and uterine 
cancers (An et al., 2002). Hence, our study suggests the positive correlation 
between p27 and uterine cancer which would require further investigations. The 
increase in p27 could be due to a compensatory mechanism, as a tumor 
suppressor gene combating uterine cancer rather than causing uterine cancer, 
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which warrants further investigations. Furthermore, we have shown increased 
p27 expression throughout PTENKO (OVX+T) uterus compared to PTENKO 
uterus suggesting testosterone alone, in absence of other steroid hormones, 
can upregulate p27 expression in the uterus. Yet, in prostate cancer and 
epithelial cells, a negative correlation was observed between androgens and 
p27 expression (Waltregny et al., 2001, Fang et al., 2012).  
The most widely accepted mechanism of increased risk for uterine cancer in 
PCOS patients is that of excessive unopposed estrogen exposure (Gambrell et 
al., 1983) as these women have persistent circulating E2 levels but, as they are 
frequently anovulatory, they lack the usual P4 opposition against excessive 
estrogen action (Lobo et al., 1981). While we were unable to measure serum E2 
concentrations as they were below sensitivity of our LC-MS/MS methodology 
(limit of quantitation 2.5pg /ml), ovarian E2 content was not significantly different 
between the genotypes suggesting the circulating E2 levels were probably 
similar for each genotype. Furthermore, serum T levels did not differ according 
to genotype. However, as testosterone could can be aromatized within the 
uterus (Huhtinen et al., 2012), uterine content of E2 should be analyzed in the 
future. In addition, while an exclusively direct role of androgens has not been 
confirmed, AR expression is increased in endometrium of women with PCOS, 
suggesting the direct AR mediated androgen actions in uterine carcinogenesis 
(Apparao et al., 2002). AR is also strongly expressed in various endometrial 
disorders including different types of endometrial cancers (Ito et al., 2002), 
further supporting a role of androgens acting via AR. Hence, these findings 
raise the hypothesis that antiandrogens may have an unrecognized role in 
prevention and the early stages of uterine carcinogenesis or in treatment.  
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Interestingly, the increased uterine estrogen sensitivity due to PTEN 
inactivation in PTENKO females corresponded to increasing expression of not 
only ERα but also a variety of estrogen sensitive target genes (lactoferrin, 
G6PDH and complement C3) in the PTENKO uterus. However, further analysis 
is warranted to determine if the increase in estrogen-regulated genes in 
PTENKO uterus is due to increased estrogen sensitivity or due to increased 
epithelial cell number as well as increased E2 levels and prolonged proestrus in 
PTENKO mice. This finding extends to an in vivo model and previous in vitro 
study where PTEN inactivation increased ERα expression (Lian et al., 2006). 
Similarly, the loss of Pten and subsequent AKT activation in uterus was shown 
to activate ERα dependent pathways in mouse endometrial cancer (Vilgelm et 
al., 2006). Furthermore, our findings suggest that the reduced uterine pathology 
following AR inactivation in PTENARKO females could be due to reduced ERα 
expression, consistent with the reduced ERα immunointensity in endometrial 
stroma and ERα mRNA expression. There could be number of possible 
mechanisms for how global AR inactivation reversed increased ERα induced by 
PTEN deletion. Firstly, AR directly modifies ERα expression in the uterus. 
Secondly, AR could interact with PTEN to indirectly modify ERα expression. 
Also, the loss of AR could indirectly affect uterine ERα level through systemic 
alterations. Supporting the first mechanism, testosterone was shown to 
suppress ERα expression in mammary tissue (Zhou et al., 2000). However, our 
study has shown that testosterone treatment in ovariectomised PTENKO 
female caused marked increase in ERα expression in PTENKO uterus in all 
cells. The second mechanism is supported by our findings whereby AR 
mediated actions modify PTEN (noting our model still has one functional PTEN 
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allele) and results in alterations in ERα expression (Vilgelm et al., 2006). Either 
or both of these mechanisms could represent the molecular pathway involved in 
the impact of AR mediated androgen action on PTEN inactivation induced 
uterine cancer. Clearly further mechanistic studies are warranted to further 
elucidate the role of AR mediated androgen action at various stages of uterine 
carcinogenesis.  
Our study is also informative about the role of P4 action in uterine 
carcinogenesis; however, further analysis is required. Whereas progestins are 
known to protect against uterine cancer (Martin et al., 1973a, Persson, 1996), 
we observed unexpectedly (given that P4 protects against uterine cancer) that 
serum P4 was significantly increased in PTENKO females compared to other 
genotypes. However, in our study PTENKO uterus did not seem to benefit from 
the increased serum P4 levels although PR was expressed in all cells of the 
uterus, consistent with a previous finding that heterozygous PTEN inactivation 
induced uterine cancer was unresponsive to progestin treatments (Fyles et al., 
2008). Nevertheless, our finding of increased serum P4 is consistent with a 
previous study showing increased CL numbers in ovaries of the granulosa cell 
specific PTEN inactivation in mice (Fan et al., 2008), a finding which might 
explain increased serum P4 as CLs characteristically secrete P4. Conversely, 
complete AR inactivation in female mice results in reduced CL numbers 
compared with WT (Walters et al., 2007). Therefore we analyzed CL numbers 
in our experimental females and observed that CL numbers were significantly 
increased in the ovaries of PTENKO females and this increase was also 
prevented by simultaneous AR inactivation in PTENARKO females. While there 
were no obvious differences in PR immunopositivity between PTENKO and 
159 
 
PTENARKO uterus, we showed that testosterone treatment in ovariectomised 
PTENKO females increased PR immunopositivity throughout PTENKO uterus. 
However, this could be due to the supraphysiological levels of testosterone 
produced by our testosterone implant which may not reflect normal 
physiological effects of testosterone in intact mouse. 
Among the many non-uterine abnormalities found in our PTEN inactivated mice, 
mammary tumors were the most common. A majority (54%) of PTENKO and 
PTENARKO females displayed abnormal mammary glands which contained 
mainly lymphoma and fibroadenomas (Stambolic et al., 2000) but also benign 
pathology of inappropriate mammary alveolarization and milk production in 
virgin mice (Conneely et al., 2003). In mammary pathology, however, there 
were no significant differences between PTENKO and PTENARKO females. 
Previously, the role of androgens in breast cancer has been controversial but a 
recent study have suggested inhibitory role of androgens in breast cancer 
(Simanainen et al., 2012). However, the present study did not show a protective 
role of androgen actions via AR on PTENKO induced breast cancer incidence 
compared to PTENARKO. This suggests a different mechanism such as 
involving the increased serum P4 level in PTENKO but not in PTENARKO 
females. It has been shown P4 may promote breast tissue proliferation and 
could thereby increase the risk of breast cancer in PTENKO to the same level 
as in PTENARKO (Russo et al., 2000). In addition, the different mechanisms of 
inducing experimental breast cancers (i.e. PTEN inactivation vs overactive 
ERBB2 signaling vs chemically induced) could explain the findings. Finally, 
while overactive ERBB2 and chemically induced cancers are mainly 
carcinomas, the PTEN knockout induced fibroadenomas. Mammary glands with 
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alveolarization could be due to the increase P4 levels, as P4 is known to cause 
alveolarization and milk production (Conneely et al., 2003). A previous study 
also observed increased mammary gland alveolarization in heterozygous 
PTENKO females, but P4 levels were not determined (Guigon et al., 2011). We 
also showed that less PTENARKO females appeared to have alveolarized 
mammary glands compared to PTENKO, further supporting the reduced P4 
levels in PTENARKO compared to PTENKO females.  
As we have used global PTEN and/or AR inactivation in our experimental mice, 
we found changes in organ weights other than uterus such as adrenal glands, 
breast, liver, lung, ovaries, pancreas and spleen. These findings were 
supported by previous studies using PTEN inactivated mouse models. PTEN 
inactivation causes hyperplastic adrenal glands, enlarged liver, epithelial 
hyperplasia in lung, altered ovarian physiology, and increased spleen weight 
(Knobbe et al., 2008). From our study, the role of androgens in these organs 
remain speculative, however, androgens may play an organ specific role of 
inducing or inhibiting pathogenesis which requires further investigations. 
In conclusion, our study has suggested that the global AR inactivation reduced 
PTEN inactivation induced uterine carcinogenesis by possibly decreasing 
stroma ERα expression and thereby estrogen sensitivity. However, further 
investigation is required to understand how PTEN and AR may modify ERα 
expression in the uterus. Most importantly, our study provides first in vivo 
evidence that androgen actions via AR play a significant role in the uterine 
cancer development and raises the hypothesis that antiandrogen therapy may 
have a role in prevention and early stages of uterine carcinogenesis and or its 
treatment. 
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Chapter 5: 
Glandular epithelial AR inactivation 
enhances PTEN inactivation-induced 
uterine pathology by cell specific 
modification of PR expression 
 
 
The content in this chapter is under revision in response to reviewers’ 
comments in Endocrine-Related Cancer journal as of February 2016. 
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5.1 Abstract  
Experimentally PTEN (phosphatase and tensin homolog) deletion induces 
uterine pathology while androgen actions via androgen receptor (AR) support 
uterine growth so thereby may modify uterine cancer risk. We hypothesized that 
the androgen actions mediated via uterine glandular epithelial AR could modify 
PTEN inactivation-induced uterine pathology. Hence, our aims of this 
experiment are to determine: 
i) The effect of glandular epithelial AR inactivation in PTEN inactivation 
induced uterine pathology as well as uterine morphology. 
ii) If glandular epithelial AR inactivation modified uterine P-AKT, ERα, PR 
and Cox-2 expression. 
To test our hypothesis, we developed uterine glandular epithelial specific PTEN, 
AR and the double knockout mouse models with uterine pathology compared 
between wild-type (WT), glandular epithelium specific AR inactivation 
(ugeARKO), PTEN deletion (ugePTENKO) and the combined PTEN and AR 
knockout (ugePTENARKO) female mice. The double knockout restricted to 
glandular epithelium showed that AR inactivation enhanced PTEN knockout-
induced uterine pathology with development of intraepithelial neoplasia in 
ugePTENARKO by 20 weeks of age. In ugePTENARKO females, 6/10 (60%) 
developed intraepithelial neoplasia while 30% developed glandular hyperplasia 
whereas only glandular hyperplasia (3/10, 30%) were observed in ugePTENKO 
females. No uterine pathology was observed in WT (n=8) and ugeARKO (n=7) 
uteri. Uterine weight was increased in ugePTENARKO [374±97mg (mean±SE)] 
compared with WT (97±6mg), ugeARKO (94±12mg) and ugePTENKO 
(205±33mg) (p=0.002). ERα and P-AKT immunopositivity was modified by 
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uterine pathology but did not differ between ugePTENKO and ugePTENARKO 
suggesting ERα and P-AKT expressions are not directly affected by genotype. 
However, PR expression was decreased throughout ugePTENARKO uterus 
compared to ugePTENKO suggesting PR expression could be regulated by 
glandular epithelial AR. In conclusion, glandular epithelial AR inactivation (with 
persistent stromal AR action) enhanced PTEN deletion-induced uterine 
pathology possibly by down-regulating PR expression in the uterus. 
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5.2 Introduction 
The role of androgens in uterine growth is supported by experimental findings. 
The non-aromatizable androgen dihydrotestosterone (DHT) promotes uterine 
growth and differentiation of the rodent uterus (Schmidt and Katzenellenbogen, 
1979), while global AR inactivation in female mice resulted in thinner uterus 
with reduced total uterine area compared to wild-type (WT) controls (Walters et 
al., 2009). In chapter 3 of this thesis, we demonstrated that the effect of 
androgens (testosterone or DHT) on uterine growth is mediated via AR. In 
contrast, an in vitro study suggested that androgens, acting via AR may inhibit 
uterine growth as androstenedione (an aromatizable pro-androgen) inhibited 
proliferation of human endometrial cells, effects which were reversed by 
administration of the steroidal antiandrogen and progestin, cyproterone acetate 
(Tuckerman et al., 2000). These finding suggest that androgens may have cell 
specific roles in the uterus, as demonstrated for prostate (Heinlein and Chang, 
2004, Simanainen et al., 2007). 
AR is also strongly expressed in various uterine cancer types, suggesting a role 
of AR mediated androgen action in the origins and progression of uterine 
cancer (Ito et al., 2002). This is supported by clinical studies showing that 
increased tissue androgen sensitivity due to the presence of polymorphic 
shorter CAG repeat lengths in exon 1 of the AR was associated with increased 
uterine cancer risk (McGrath et al., 2006). Similarly, our study using global 
PTEN (a phosphatase and tensin homolog) knockout-induced experimental 
uterine cancer was enhanced when combined with global AR inactivation 
further suggested that AR mediated androgen action enhances PTEN 
inactivation-induced uterine cancer (Chapter 4).  
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Pten is a tumor suppressor gene located on chromosome 10 (Dahia, 2000). 
Physiologically, PTEN functions as a phosphatase which inhibits growth factor 
signaling transduced through PI3K by inhibiting phosphorylation of AKT (Li et 
al., 1998). Pten is mutated or deleted in a wide range of human cancers 
including uterine cancers (Dahia, 2000). Pten mutations are observed in 30-80% 
of type 1 endometrial carcinomas (EMC) and in 20-70% of complex atypical 
hyperplasia, a premalignant stage of EMC (Tashiro et al., 1997, Levine et al., 
1998, Lee et al., 2012). As uterine cancers commonly arise from the uterine 
endometrial glands (Newbold et al., 1990), we therefore investigated the impact 
of AR mediated androgen action on PTEN deletion-induced uterine cancer in 
our novel uterine cancer mouse model where deletions are restricted to uterine 
glandular epithelium (Chapter 3). The goal of the study was to investigate the 
role and potential mechanisms of androgen action in the susceptibility of the 
murine uterus to experimental cancer.  
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5.3 Experimental design 
Experimental design for the current study is as follows: 
i) The effect of glandular epithelial AR inactivation in PTEN inactivation 
induced uterine pathology as well as uterine morphology was compared 
between ugePTENKO and ugePTENARKO females at 20 weeks of age.  
ii) To determine the molecular changes caused by glandular epithelial AR 
inactivation in PTEN inactivation induced uterine pathologies, AKT, P-
AKT, ERα, PR and Cox-2 uterine expressions were compared between 
WT, ugeARKO, ugePTENKO and ugePTENARKO females at 20 weeks 
of age. 
 
Uterine disorder classification  
All uteri from experimental mice were classified into three categories based on 
histological characteristics: normal glands (Figure 5.1A), hyperplastic glands 
(Figure 5.1B) and intraepithelial neoplasia (Figure 5.1C). Normal glands had 
widely separated tubular ductular glands embedded in a cellular stroma (Figure 
5.1A). Hyperplastic glands had marked increase in the number of irregularly 
disorganized glands lined by enlarged glandular epithelial cells (Figure 5.1B). 
Intraepithelial neoplasia was characterized by high-grade atypia which exhibited 
intraglandular epithelial cell proliferation that was papillary or cribriform in 
appearance as previously reported (Stambolic et al., 2000) (Figure 5.1C).   
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5.4 Results  
5.4.1 Glandular epithelial PTEN deletion induced uterine 
pathology that was enhanced by glandular AR inactivation 
Uteri were classified into three progressive histological categories of 
carcinogenesis using H&E staining: uteri with normal glands (Figure 1A), 
hyperplastic glands (Figure 1B) or intraepithelial neoplasia (Figure 1C). All uteri 
of WT and ugeARKO females were categorized as normal featuring a clear 
distinction between myometrium and endometrium layers as well as regularly 
shaped endometrial glands. As previously reported, glandular epithelial PTEN 
deletion caused formation of hyperplastic glands (Choi et al., 2015b). In the 
present study, abnormal uteri were found solely in ugePTENKO and 
ugePTENARKO females (Figure 1: Table) where glandular epithelial 
hyperplasia was present in 30% of both the ugePTENKO and ugePTENARKO 
uteri. In addition, intraepithelial neoplasia characterized by cellular atypia was 
present in 60% of ugePTENARKO but not in any ugePTENKO uteri   (Figure 1: 
Table). Intraepithelial neoplasia incidence was significantly increased by the AR 
inactivation (p=0.008; Fisher’s exact test). 
The uterine pathology in ugePTENKO and ugePTENARKO was also reflected 
in increased uterine weight (Figure 1D). The uterine weights were significantly 
(p=0.003; two-way ANOVA) increased by PTEN deletion but was not affected 
by AR inactivation (p=0.172) or any interaction between PTEN deletion and AR 
inactivation. As a result, weight of ugePTENARKO uteri were significantly 
increased compared to other genotypes whereas uterine weight did not differ 
between WT and ugeARKO uteri (Figure 1D). Macroscopic anatomy of 
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ugePTENKO uterus (Figure 1E) and ugePTENARKO (Figure 1F) are shown. 
Body weights (Figure 1G) and ovarian weights (Figure 1H) were not affected by 
genotype.  
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Figure 5.1. Histological categorization of uterine phenotype and uterine 
weight. A-C) Representative photos of H&E staining of three different uterine 
histological categories: A) Normal glands. B) Hyperplastic uterine glands. C) 
Intraepithelial neoplastic glands (scale bar=100µm). Table: Histological 
categorization of uterine abnormalities in WT, ugeARKO, ugePTENKO and 
ugePTENARKO females (a= significantly different to WT, ugeARKO and 
ugePTENARKO, p<0.05; Pearson Chi-Square). D) Uterus weights in WT, 
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ugeARKO, ugePTENKO and ugePTENARKO females at termination (a= 
significantly different to WT, ugeARKO and ugePTENARKO, p<0.05; one-way 
ANOVA, mean±SE; n≥9). E-F) Representative gross anatomy images of 
ugePTENKO (E) and ugePTENARKO (F) uterus. G-H) Body weight (G) and 
ovary weight (H) were compared among WT, ugeARKO, ugePTENKO and 
ugePTENARKO (mean±SE; n≥9). 
 
5.4.2 Simultaneous glandular epithelial AR inactivation and 
PTEN deletion increased endometrial area but did not affect 
myometrial area 
As uterine weight was increased in ugePTENARKO uterus, we investigated 
whether different layers of the uterus were affected (Figure 2A-D). The total 
uterine area was significantly (p=0.029; two-way ANOVA) increased by AR 
inactivation but was not affected by PTEN deletion (p=0.098). The endometrial 
area was significantly increased by both the AR inactivation (p=0.01) and PTEN 
deletion (p=0.015). There was a significant interaction between AR inactivation 
and PTEN deletion (p=0.025). As a result, the total uterine (Figure 2A) and 
endometrial (Figure 2B) cross-sectional areas were increased in 
ugePTENARKO compared to other genotypes. However, the myometrial areas 
were not significantly affected by either AR inactivation (p=0.085) or PTEN 
deletion (p=0.486) (Figure 2C). These changes resulted in increased 
endometrial to myometrial ratio in ugePTENARKO females (1.4±0.1) compared 
to WT (0.7±0.1), ARKO (0.8±0.2) and PTENKO (0.9±0.1) which indicates 
uterine abnormality (De Bosschere et al., 2002) in ugePTENARKO uterus 
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(Figure 2D). The endometrial to myometrial ratios were significantly increased 
by both the AR inactivation (p=0.036) and PTEN deletion (p=0.009); interaction 
of AR inactivation and PTEN deletion was not significant. 
 
 
Figure 5.2. Morphological analysis of the uterus. Total (A), endometrial (B) 
and myometrial (C) uterine areas (mm2) were measured in WT, ugeARKO, 
ugePTENKO and ugePTENARKO females. Endometrial to myometrial ratio 
(E/M) was calculated by dividing area of endometrium with area of myometrium 
(D) (a= significantly different to WT, ugeARKO and ugePTENKO, p<0.05; one-
way ANOVA, mean±SE; n≥5). 
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5.4.3 P-AKT expression was increased as uterine pathology 
progressed 
As PTEN regulates the AKT signaling pathway, to investigate if glandular 
epithelial AR inactivation influenced total AKT and P-AKT expression, we 
compared AKT immunopositivity in ugePTENKO and ugePTENARKO uteri. In 
all uteri, AKT was present throughout with similar expression in ugePTENKO 
and ugePTENARKO when compared within the same histopathological 
categories (normal and hyperplastic) (Figure 3A-E). However, AKT 
immunopositivity was stronger in the epithelia with intraepithelial neoplasia 
compared to normal or hyperplastic epithelium (Figure 3E). 
P-AKT is the active form of AKT which promotes cell growth. Similar to total-
AKT, P-AKT immunopositivity was stronger in intraepithelial neoplasia (Figure 
3J) compared to normal (Figure 3F and G) or hyperplastic (Figure 3H and I) 
glandular epithelial cells. P-AKT expression appeared similar between 
ugePTENKO and ugePTENARKO within normal (Figure 3F and G) and 
hyperplastic (Figure 3H and I) glands.  
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Figure 5.3. Representative AKT and P-AKT immunohistochemistry in 
ugePTENKO and ugePTENARKO. AKT expression (A-E) was compared 
between normal ugePTENKO (A) and ugePTENARKO (B), hyperplastic glands 
ugePTENKO (C) and ugePTENARKO (D) and intraepithelial neoplastic glands 
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(E). P-AKT expression (F-J) was compared between normal ugePTENKO (F) 
and ugePTENARKO (G), hyperplastic glands ugePTENKO (H) and 
ugePTENARKO (I) and intraepithelial neoplastic glands (J) (Scale bar=100µm 
for A-B, E-G and J & 200µm for C-D and H-I; n≥4). 
 
5.4.4 ERα expression was reduced in uterine stroma and 
myometrium with intraepithelial neoplastic glands when 
compared to the uteri with hyperplastic glands 
As uterine pathology is highly hormone dependent and promoted by E2 (Bender 
et al., 2011), we investigated ERα expression by immunohistochemistry. ERα 
expression was quantified according to percentage immunopositive (Figure 4A) 
while the intensity of staining (Figure 4B) was quantified using the H-Score 
method. Samples analysis was stratified according to their histopathology as 
different uterine pathology stage is expected to affect ERα expression (Choi et 
al., 2015a). 
ERα immunopositivity and immunointensity were not signficantly different 
between histologically normal WT (Figure 4C) and ugeARKO (Figure 4D) uteri 
noting that ERα was relatively weakly expressed in all cells types (epithelia 
stroma, and myometrium). On the other hand, glandular epithelial PTEN 
deletion significantly increased ERα immunopositivity (p≤0.028) and 
immunointensity (p≤0.028) throughout the uterus in histologically normal 
appearing ugePTENKO (Figure 4E). The histologically normal ugePTENARKO 
(Figure 4F) uterus had a similar ERα expression as ugePTENKO (normal), 
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however, immunopositivity and immunointensity could not be quantified as 
there was only one case of histologically normal ugePTENARKO.  
In the uterus containing hyperplastic glands (ugePTENKO and ugePTENARKO) 
(Figure 4G and H), ERα immunopositivity (p≤0.028) and immunointensity 
(p≤0.028) were signficantly  increased when compared to histologically normal 
WT and ugeARKO uterus (Figure 4C and D) regardless of cell type. However, 
when compared with histologically normal ugePTENKO and ugePTENARKO 
uterus (Figure 4E and F) there were no signficant changes. The ERα 
immunopositivity was similar in ugePTENKO (Figure 4G) and ugePTENARKO 
(Figure 4H) uterus with hyperplastic glands. 
The intraepithelial neoplastic glands were only detected in ugePTENARKO 
females (Figure 4I and J). In these samples, the ERα immunopositivity 
(p≤0.032) and immunointensity (p≤0.032) in glandular epithelial cells as well as 
immunointensity in stromal cells (p≤0.037) were signficantly  increased 
compared to histologically normal uterus in WT and ugeARKO females. 
However, in intraepithelial neoplastic glands detected in ugePTENARKO 
females, the ERα immunopositivity and immunointensity in stroma and 
myometrium were signficantly (p=0.037) decreased compared to ugePTENKO 
(normal), ugePTENKO (hyperplasia) and ugePTENARKO (hyperplasia). No 
signficant changes were observed in luminal epithelial ERα expression.  
Collectively, these results suggest that the ERα expression is dependent on the 
histopathological stage as the glandular epithelial ERα expression was 
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increased in uterus with intraepithelial neoplastic glands compared to 
histologically normal uterus whereas stromal and myometrium ERα expression 
was decreased compared to hyperplastic uterus. In addition, glandular epithelial 
PTEN deletion upregulated ERα expression whereas glandular epithelial AR 
inactivation may not significantly affect ERα expression in uterus.  
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Figure 5.4. ERα immunohistochemistry on uterus at 20 weeks old. A-B) 
Percentage of ERα positive cells (A) and intensity (B) in different compartments 
of the uterus [a= significantly different to WT and ugeARKO and b=significantly 
different to ugePTENKO (normal), ugePTENKO (hyperplasia) and 
ugePTENARKO (hyperplasia) (p≤0.037; non-parametric test, mean±SE; n≥3)]. 
C-J) Representative images of ERα immunohistochemistry in WT (C), 
ugeARKO (D), histologically normal ugePTENKO (E) and ugePTENARKO (F), 
ugePTENKO (G) and ugePTENARKO (H) with hyperplastic glands and 
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ugePTENARKO with intraepithelial neoplastic glands (I-J). (Scale bar=100µm 
for C-D, G-H and J & 200µm for E-F and I; n≥4).  
 
5.4.5 Glandular epithelial AR inactivation decreases glandular 
and luminal epithelial, stromal and myometrial PR expression 
As P4 action protects against uterine cancer (Bender et al., 2011), expression of 
PR was also investigated by immunohistochemistry. Similar to ERα, PR 
expression was also quantified into immunopositivity (Figure 5A) and 
immunointensity (Figure 5B) using H-Score method and further categorized 
based on histopathology. 
PR was abundantly expressed all cell types (epithelial, stromal and smooth 
muscle cells) of WT uterus (Figure 5C). PR immunopositivity (p≤0.021) and 
immunointensity (p≤0.021) in ugeARKO uterus (Figure 5D) were significantly 
reduced compared to WT in all cell types suggesting glandular epithelial AR 
inactivation down regulates PR expression in uterus. On the other hand, in 
histologically normal uterus of ugePTENKO females (Figure 5E), PR 
immunopositivity (p≤0.028) and immunointensity (p≤0.028) were significantly 
increased in stroma and myometrium compared to WT and ugeARKO (Figure 
5C, D). The PR expression in glandular epithelial and luminal epithelial cells 
was not affected by PTEN deletion. PR expression in ugePTENARKO (normal) 
uterus (Figure 5F) appeared to be similar to ugePTENKO (normal) but PR 
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expression was not quantified as there was only one case of histologically 
normal ugePTENARKO.  
In uterus with hyperplastic glands (both ugePTENKO and ugePTENARKO) 
(Figure 5G and H), PR was strongly expressed throughout the uterus and PR 
immunopositivity (p≤0.028) and immunointensity (p≤0.028) was significantly 
increased compared to WT and ugeARKO uterus. PR immunopositivity was 
similar between ugePTENKO (hyperplasia) and ugePTENARKO (hyperplasia). 
However, when the uterine pathology progressed to intraepithelial neoplasia 
(only in ugePTENARKO), PR expression was very weak throughout the uterus 
(Figure 5I-J). PR immunopositivity (p=0.037) and immunointensity (p=0.037) 
were significantly reduced in all cell types compared to hyperplastic uterus. 
Furthermore, stroma and myometrium PR expression were significantly (p≤0.05) 
reduced compared to WT and ugeARKO uterus as well. Hence, simultaneous 
glandular epithelial AR inactivation along with PTEN deletion significantly 
reduced PR expression in uterus. 
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Figure 5.5. PR immunohistochemistry on uterus at 20 weeks old. A-B) 
Percentage of PR positive cells (A) and intensity (B) in different compartments 
of the uterus [a= significantly different to WT, and b=significantly different to 
ugeARKO, c=significantly different to ugePTENKO (normal) and d=significantly 
different to ugePTENKO (hyperplasia) and ugePTENARKO (hyperplasia) 
(p≤0.05; non-parametric test, mean±SE; n≥3)]. Representative images of PR 
immunohistochemistry in WT (C), ugeARKO (D), histologically normal 
ugePTENKO (E) and ugePTENARKO (F), ugePTENKO (G) and 
181 
 
ugePTENARKO (H) with hyperplastic glands and ugePTENARKO with 
intraepithelial neoplastic glands (I-J). (Scale bar=100µm for C-D and J & 200µm 
for E-F, G-H and I; n≥4).  
 
5.4.6 ERα and PR and expression of their dependent genes 
were not significantly affected by genotype. 
Real-time RT-PCR was performed to determine the expression of ERα and PR 
and their dependent genes in uterus. No significant changes were observed in 
ERα gene expression as well as in expression of ERα dependent genes, 
G6PDH and Complement C3 (Figure 6A-C). Although PR and its dependent 
genes, Ihh and Il13ra2, appeared to be increased by PTEN deletion 
(ugePTENKO) which was reversed by simultaneous AR inactivation 
(ugePTENARKO), the changes were not statistically significant (Figure 6D-F).  
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Figure 5.6. mRNA expression of ERα and PR and its dependent genes.  
ERα (A) and ERα dependent genes (B-C) and PR (D) and PR dependent genes 
(E-F) were measured in the uterus at 20 weeks of age. Gene expressions were 
relative to 18s rRNA housekeeping gene. 
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5.4.7 Cox-2 gene expression was significantly increased in 
ugePTENARKO uterus  
As modification of COX signaling is reported in PTEN knockout-induced uterine 
cancers where Cox-2 expression was increased in early stages of endometrial 
cancers in mouse (Daikoku et al., 2008), we quantified the Cox-1 and Cox-2 
mRNA expression to determine if the expression was modified by PTEN and/or 
AR knockout. Cox-2 mRNA expression significantly increased by both the AR 
inactivation (p=0.006; two-way ANOVA) and PTEN deletion (p=0.013). As a 
result, Cox-2 mRNA expression was increased in ugePTENARKO compared to 
WT and ugePTENKO whereas Cox-2 expression was similar among WT, 
ugeARKO and ugePTENKO uterus (Figure 7A). Cox-1 mRNA expression was 
not affected by either AR inactivation (p=0.76) or PTEN deletion (p=0.241) 
(Figure 7B).  
 
 
Figure 5.7. Uterine cox-1 and cox-2 gene expression at 20 weeks. Cox-2 (A) 
and cox-1 (B) mRNA expression was compared among experimental groups 
and gene expression was standardized using rpl19 and cyclophillin (a= 
significantly different to WT and ugePTENKO; p<0.03; non-parametric test, 
mean±SE; n≥5).  
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5.5 Discussion 
We recently demonstrated that androgen action mediated via AR specifically 
exerted in the epithelial glands of the uterine endometrium can support uterine 
growth (Choi et al., 2015b). As androgens may also have roles in uterine 
pathology (Walters et al., 2010, Somboonporn and Davis, 2004) and AR is 
expressed in many uterine cancers notably of epithelial cells (Ito et al., 2002), 
we investigated the role of AR mediated androgen action confined to uterine 
glandular epithelium in experimental, PTEN deletion-induced uterine pathology. 
We demonstrate that AR mediated androgen action exerted in the same cells 
as having PTEN deletion-induced pathology, has a direct and significant role in 
the uterine carcinogenesis. This is also consistent with a previous study 
proposing that endometrial cancers arise from endometrial glands (Newbold et 
al., 1990). In our study, glandular epithelial AR inactivation significantly 
enhanced and accelerated progression of PTEN deletion-induced uterine 
pathology. We provide some evidence that this may be due to down-regulation 
of uterine PR expression, which normally protects against uterine cancer 
development. 
 
A clinical study suggested that increased androgen sensitivity (McGrath et al., 
2006) and increased androgen levels (Nagamani et al., 1986, Smyczek-Gargya 
and Geppert, 1992) in women were associated with a higher risk of uterine 
cancer, suggesting that androgen action may enhance or promote uterine 
cancer development. These clinical observations were supported by our recent 
study where androgens acting via AR promoted PTEN deletion (global) induced 
185 
 
experimental uterine cancer (Choi et al., 2015a). However, due to systemic 
effects of increased androgen sensitivity/levels or AR inactivation, the uterine 
specific role of AR mediated androgen actions could not be established. 
Therefore, we explored the specific role of AR mediated androgen actions 
occurring simultaneously with PTEN knockout to induce glandular cell 
proliferation. Unexpectedly, contrary to our hypothesis and the clinical studies 
as well as our global AR inactivation (Choi et al., 2015a), the present study 
suggests that androgens acting via glandular epithelial AR decelerated 
progression of experimental, PTEN deletion-induced uterine pathology. 
Alternatively, the this observation may be due to persistent stromal AR actions 
in the absence of the balancing act of glandular epithelial AR. Similar regulatory 
balance between the stromal and epithelial AR has been previously suggested 
for prostate (Simanainen et al., 2007, Wen et al., 2015). 
 
The major differences between our previous (Choi et al., 2015a) and current 
knockout mouse model is outlined in table 5.1. In our previous report, AR 
and/or PTEN were knocked-out in all cells of the mouse including all uterine 
cells (glandular epithelium, luminal epithelium, stroma and myometrium). In the 
current uterine gland-specific model, the AR and/or PTEN were knocked-out 
selectively in the uterine glandular epithelial cells (Choi et al. 2015b), whereas 
both the AR and PTEN are still functional in all other cells of the uterus (luminal 
epithelium, stroma and myometrium) and rest of the mouse. Furthermore, 
global knockout model has AR and/or PTEN knocked out in other hormone 
dependent organs such as ovaries and pituitary whereas uterine gland specific 
knockout model has functional AR and PTEN in these non-target organs (Choi 
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et al. 2015b). Furthermore, the heterozygous and homozygous loss of PTEN in 
inducing uterine pathology should be considered in future studies. 
 
Table 5.1. Comparison of glandular epithelial and global knockout mouse 
models.  
 
 
In previous studies, heterozygous PTEN deletion in uterus induced glandular 
hyperplasia (premalignant precursor to endometrial cancer) in the uterus 
(Daikoku et al., 2008). Previously, we demonstrated that PTEN deletion in 
uterine glands induced uterine hyperplasia (Choi et al., 2015b). In our current 
study, simultaneous glandular epithelial AR inactivation along with PTEN 
deletion significantly accelerated severity of uterine pathology from hyperplastic 
glands detected in both ugePTENKO and ugePTENARKO uterus to 
intraepithelial neoplastic glands with atypia only in ugePTENARKO uterus. The 
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increased uterine pathology in ugePTENARKO females was also reflected in 
increased uterine weights and in increased endometrial area of the uterus. 
These findings suggested that the AR mediated androgen actions in glandular 
epithelial cells decelerated progression of PTEN deletion-induced uterine 
pathology. In line with our findings, an in vitro study suggested growth 
preventing effect of androgens via AR in endometrial cells where 
androstenedione (an aromatizable pro-androgen) inhibited proliferation of 
human endometrial cells (Tuckerman et al., 2000). The effect was reversed by 
cyproterone acetate (antiandrogen) demonstrating AR mediated effects. 
Together with the results of the current study, it is proposed that cell specific 
effects of androgens acting via AR in the uterus warrants further investigation to 
more clearly define the mechanism of the cell specific role of AR including the 
relationship of AR activity in non-epithelial uterine cells, notably in the uterus, 
the stroma and other epithelial cells. 
 
Our study has supported previous reports of PTEN negatively regulating P-AKT 
expression (Stambolic et al., 2000, Stambolic et al., 1998). P-AKT was only 
present in glandular epithelial cells of the uterus following complete deletion of 
PTEN, whereas P-AKT was absent in luminal epithelial cells, stroma and 
myometrium as well as in WT glandular epithelial cells where PTEN was 
present. Very low P-AKT levels in uterine cells expressing PTEN is supported 
by previous study (Stambolic et al., 2000). In uterus, AR does not appear to 
affect AKT signaling pathway as it has been suggested in breast and prostate 
cancer cells (Wang et al., 2011b). In the present study, P-AKT expression 
between ugePTENKO and ugePTENARKO glandular epithelial cells within the 
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same histopathological categories appeared to be similar. However, P-AKT 
expression was increased in intraepithelial neoplastic glands which were only 
present in ugePTENARKO. This suggests that glandular epithelial AR does 
have a significant affect the progression of uterine pathology; however, further 
investigation is required to determine whether AR has a direct role in increasing 
P-AKT pathway or increased P-AKT could be solely due to increased severity 
of the uterine pathology.  
 
A previous study suggested that PTEN inactivation increased ERα expression 
in mouse uterus (Lian et al., 2006). Similarly, AR can also regulate ERα 
expression as shown by testosterone-induced suppression of ERα expression 
in mammary tissue (Zhou et al., 2000). Alternatively, AR could interact with 
PTEN to indirectly modify ERα expression in prostate and breast cancers 
(Wang et al., 2011b). Therefore, we explored the possibility whether glandular 
epithelial AR inactivation modified ERα expression in PTEN deleted uterus. 
Supporting the previous study, we observed increased ERα expression 
throughout the uterus upon PTEN deletion. However, in our study, glandular 
epithelial AR inactivation in uterus did not modify ERα expression, unlike in the 
prostate where inactivation of prostate epithelial AR cells causes marked up-
regulation of ERα expression (Simanainen et al., 2011b). As the PTEN deleted 
uterus developed hyperplastic glands, uterine ERα expression was stronger 
than histologically normal PTEN deleted uterus. Furthermore, when 
hyperplastic glands progressed to intraepithelial neoplastic glands which were 
only found in ugePTENARKO uterus, ERα expression in the glandular epithelial 
cells increased but ERα expression in luminal epithelial cells, stroma and 
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myometrium decreased. This could be due to the increased P-AKT expression 
in glandular epithelial cells as it has been reported that P-AKT and ERα is 
positively correlated (Vilgelm et al., 2006). Collectively, these data suggest that 
the increased uterine gland pathology following PTEN deletion in glandular 
epithelial cells could be due to increased P-AKT and ERα expression as 
supported by our immunohistochemistry results. However, accelerated uterine 
pathology in ugePTENARKO uterus compared to ugePTENKO may not be due 
to altered P-AKT and ERα expression. Therefore, we have further investigated 
PR expression. 
 
The protective effect of P4 on uterine cancer is known from using progestin 
(synthetic P4 analogs) (Mortel et al., 1990) where progestin actions mediated 
via PR (Mulac-Jericevic et al., 2000, Kurita et al., 1998) protect against uterine 
cancer (Martin et al., 1973a, Persson, 1996). Therefore we investigated PR 
expression in the uterus of our experimental female mice. In our study, WT 
uterus showed weak expression PR in glandular and luminal epithelial cells, 
stroma and myometrium. Glandular epithelial AR inactivation in the ugeARKO 
uterus further diminished PR expression throughout the ugeARKO uterus 
compared to WT, suggesting glandular epithelial AR action was maintains PR 
expression. Secondly, in glandular epithelial PTEN deleted uterus, we observed 
increased PR expression in luminal epithelial cells, stroma and myometrium but 
decreased PR expression in glandular epithelial cells of intraepithelial 
neoplastic ugePTENARKO uterus. The finding supports previous findings that 
PTEN down-regulation was correlated with PR down-regulation in breast 
cancers (Alen et al., 1999). Further, the present study demonstrates that a 
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uterus bearing intraepithelial neoplastic glands has further diminished PR 
expression in all cells when compared to a uterus with hyperplastic glands 
regardless of genotype. Whether this is due to the histopathological change or 
glandular AR inactivation is uncertain. However, as the pathology in 
ugePTENKO uterus did not progress to intraepithelial neoplastic glands, it is 
unlikely that progression to intraepithelial neoplasia is due to further diminished 
uterine PR expression alone, even if it is due to glandular AR inactivation. 
However, based on the findings in histologically normal uterus (reduced PR 
immunopositivity), the possibility of AR (specifically glandular epithelial AR) 
regulating PR expression in uterus should be further explored.  
 
In addition, cell specific interaction of AR should be explored in future. As 
previously suggested, the different effects of P4 via PR in endometrial cancer 
(inhibitory) and breast cancer (stimulatory) may be due to the key difference 
between these tissues such as in the paracrine interactions of PR-expressing 
stroma and epithelium (Kim et al., 2013). Hence, the AR interaction between 
epithelial and stromal cells could also determine the role of AR in uterine 
pathogenesis. Our global AR knockout study where both the epithelial and 
stromal AR in uterus are inactivated, promoted uterine pathogenesis (Choi et al., 
2015a). On the other hand, in current study, where only the glandular epithelial 
AR is inactivated (with persistent stromal AR activity), the AR activity appeared 
to inhibit uterine carcinogenic progression. Therefore, we suggest possible 
paracrine interaction of AR-expressing cells in the uterus (i.e. epithelial and 
stroma). 
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Furthermore, as the glandular epithelial PTEN deleted uterus developed 
hyperplastic glands, PR expression increased in glandular epithelial cells as 
well resulting in strong PR expression throughout the uterus. Increased PR 
expression in uterus with hyperplastic glands could be due to a compensatory 
mechanism to combat developing pathology in the glands as P4 is known to 
oppose uterine epithelial proliferation (Mortel et al., 1990, Fang et al., 2004). A 
previous study observed that 90% of hyperplastic uteri had moderate to strong 
PR expression (Arnett-Mansfield et al., 2001). However, when hyperplastic 
glands progressed to intraepithelial neoplasia as in ugePTENARKO alone, an 
adenocarcinoma precursor, uterine PR expression was very weak throughout 
the uterus including neoplastic glands. Furthermore, our finding was supported 
by the observations that PR expression decreased as uterine pathology 
advances to endometrial cancers (Kim et al., 2010, Arnett-Mansfield et al., 2001, 
Ehrlich et al., 1981). Therefore, accelerated uterine pathogenesis in 
ugePTENARKO compared to ugePTENKO could be due to the down-regulation 
of PR by glandular epithelial AR inactivation resulting in diminished protective 
role of P4 via PR. However, decreased PR expression in intraepithelial 
neoplastic glands could also be due to increased P-AKT expression in the 
glands as reported in breast cancers (Tokunaga et al., 2007). 
 
Despite the PR immunohistochemistry results, we did not observe any 
significant changes in PR gene expression or expression of PR-dependent 
genes, Ihh and Il13ra2, expressions. A probable explanation for this is that 
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gene expression was quantified using RNA extracted from whole uterus 
whereas the AR and PTEN deletions are only in glandular epithelial cells 
constituting only a very small fraction of all uterine cells. Hence significant 
changes could have been diluted and lost. Nevertheless, we did observed 
similar, though not statistically significant, pattern where PR, Ihh and Il13ra2 
gene expressions were increased by PTEN deletion (ugePTENKO) compared 
to WT and ugeARKO which was reversed by simultaneous AR inactivation 
(ugePTENARKO). This could also be due to the high variability due to variation 
in PTEN knockout induced pathology which varies in rate of progression 
between individuals, as shown in histopathology/immunostaining. Therefore, in 
the future, more specific cell retrieval and/or individual samples with 
comparable stage of histopathology should be analyzed.  
 
As uterus is highly hormone dependent organ, changes in hormone profile 
could regulate its pathogenesis. However, we did not observe any changes in 
steroid hormone levels in our mouse model in the more radical global knockout 
study (Choi et al., 2015a) in which both PTEN and/or AR were inactivated 
(including in ovaries as well). Hence, we do not expect any significant hormonal 
changes in current study where the PTEN and/or AR inactivation is restricted to 
only the glandular epithelial cells in the uterus (Choi et al. 2015b). However, it 
would be interesting to measure serum and especially intrauterine steroid 
hormone levels as we observed very unusual PR immunohistochemistry 
expression despite all the uteri were collected at diestrus. Previous study has 
reported varying progesterone and testosterone levels in endometrium and 
endometriosis lesions (Huhtinen et al., 2014). 
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Cox enzymes are associated with development of many cancers (Mazhar et al., 
2005) and its expression is regulated by androgens (Yazawa et al., 2013, 
Simanainen et al., 2015) and AKT (St-Germain et al., 2004, Leng et al., 2003). 
Therefore, we measured uterine Cox-1 and Cox-2 mRNA expressions. Cox-2 is 
important in progression of uterine hyperplasia to carcinoma, where Cox-2 
decreases apoptosis and increases angiogenesis with its levels associated with 
invasiveness (Boruban et al., 2008). We found that Cox-2 expression was not 
significantly affected by glandular epithelial AR or PTEN mutations alone but 
was significantly increased by simultaneous AR and PTEN mutation in 
ugePTENARKO uterus. Increased Cox-2 expression could be due to increased 
P-AKT expression in intraepithelial neoplastic glands found in ugePTENARKO 
uterus as previous studies in human endometrial cancer cells (St-Germain et al., 
2004) and hepatocellular carcinoma cells (Leng et al., 2003) reported positive 
correlation between P-AKT and Cox-2 expression. Furthermore, previous 
clinical studies have reported overexpression of uterine Cox-2 in patients with 
endometrial carcinoma (Erkanli et al., 2007, Nasir et al., 2007). On the other 
hand, Cox-1 which is involved in cell signaling and maintains tissue 
homeostasis was not affected by uterine specific PTEN or AR knockout in our 
study. Cox-1 has been shown to be expressed in most tissues and its 
expression is not altered by cytokines and growth factors (Erkanli et al., 2007). 
However, further analysis of Cox gene expression (i.e. immunohistochemistry) 
in uterus is required to localize its expressions in different uterine cell types to 
further clarify a possible role of Cox pathway in the present murine uterine 
carcinogenesis model. 
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In conclusion, our study has demonstrated that the glandular epithelial PTEN 
deletion is likely to cause uterine gland pathology by increasing P-AKT and ERα 
expression in glandular epithelial cells and resulting in increased uterine Cox-2 
expression. Furthermore, glandular epithelial AR inactivation enhanced PTEN 
inactivation-induced uterine gland pathology possibly by decreasing PR 
expression hence diminishing the protective role of P4 in uterine pathogenesis. 
This suggests a different mechanism as to our previous global knockout study 
(Choi et al., 2015a), where global AR inactivation reduced uterine pathology 
incidence by decreasing ERα compared to glandular epithelial AR inactivation 
increased uterine pathology by reducing PR (table 1). Overall, our study 
suggests more localized uterine cell-specific effect of AR in uterine 
carcinogenesis which warrants further investigations on the role of AR in 
different uterine cells as well as its paracrine-cell interaction. 
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Chapter 6:  
Conclusions and future directions 
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The biological effects of AR-mediated androgen actions in male physiology and 
pathology of hormone dependent organs such as prostate has been well 
established. However, the direct role of androgens in females has only recently 
been recognised (Walters et al., 2009) and has not yet been fully understood. 
This is exemplified in uterus which has been shown to express AR (Pelletier et 
al., 2004, Hirai et al., 1994, Kimura et al., 1993, Ito et al., 2002) and respond to 
androgens (Armstrong and Papkoff, 1976, Schmidt and Katzenellenbogen, 
1979, Nantermet et al., 2005, Walters et al., 2009), but there is only limited 
information on the specific role of androgens acting via AR during uterine 
development and pathology. Therefore, the aim of this thesis was to investigate 
the role of AR-mediated androgen actions in uterine development, function and 
pathogenesis using novel mouse models. 
 
The first aim was to generate and validate uterine glandular epithelial specific 
AR knockout (ugeARKO) mouse model using Cre/LoxP strategy. Thereby 
investigate the role of AR in uterine growth and function (Chapter 3). This study 
have successfully generated and characterized the first endometrial gland 
specific knockout mouse model. Using the model and along with global ARKO 
mouse model, we have demonstrated that androgens acting solely via AR can 
support full uterine growth in the absence of E2. Furthermore, we have shown 
endometrial glandular AR mediates uterine (including myometrial) growth via 
AR-mediated androgen actions. As AR is expressed throughout the uterus, our 
finding warrants further studies of the role of cell-specific AR and cross-talk 
involving AR expression in different types of uterine cells such as luminal, 
stromal and myometrial cells. This could be achieved in future by generating 
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uterine cell-specific knockout models. However, currently there are no known 
models other than our endometrial gland specific knockout model which is the 
first mouse model to selectively knock out glandular epithelial cells. This would 
be important as our results suggest that AR in different uterine cell types exhibit 
different androgens effects in uterus. Better understanding of the relationship 
between different uterine cell-specific AR could be implicated to uterine 
development disorders and uterine cancers as uterine cancers also express AR 
in all cells. 
 
Secondly, our aim was to investigate the role of global AR inactivation in PTEN 
deletion induced uterine cancer (Chapter 4). Importantly, our study is the first in 
vivo evidence that androgen actions via AR play a significant role in the uterine 
carcinogenesis where we have demonstrated that the global AR inactivation 
reduced its impact of PTEN inactivation-induced uterine carcinogenesis. This 
could be due to decreasing stromal ERa expression and thereby estrogen 
sensitivity.  However, as the PTEN can directly interact with ERα, the 
haploinsufficiency of PTEN and involvement of stromal ERα requires further 
investigation possibly using complete PTEN deletion in the uterus (i.e. PR-Cre 
mouse model). Therefore, our finding raises the hypothesis that antiandrogen 
therapy which are readily available for breast and prostate cancer patients may 
also benefit uterine cancer patients. However, this would require further studies 
on the cell specific effect of AR as androgens appears to promote or suppress 
uterine cancers depending on the cell-specific expression of AR. Furthermore, 
the future studies could be directed to better understand how PTEN and AR 
separately or via interaction with each other can modify ERα expression (as 
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suggested by the present study) or other signalling pathways in uterus. 
Understanding the mechanisms involved in PTEN induced uterine cancers as 
well as modification of cancer incidences by AR-mediated androgen actions is 
important and would benefit in providing better prevention and targeting 
pathways for uterine cancer treatment, as many uterine cancers are AR positive 
and have PTEN mutations. In addition, we must note that there could be other 
important pathways involved in modifying uterine cancer incidences in our study, 
which further displays a complex molecular pathways involved in uterine 
physiology and pathology. 
 
Lastly, our aim was to investigate the effect of glandular epithelial AR 
inactivation in PTEN inactivation induced uterine pathology (Chapter 5) using 
our novel endometrial gland specific knockout mouse model generated and 
characterized (Chapter 3). The study has demonstrated that the glandular 
epithelial PTEN deletion is likely to contribute uterine gland pathology by 
increasing P-AKT and ERα expression in glandular epithelial cells and resulting 
in increased uterine Cox-2 expression. Furthermore, glandular epithelial AR 
inactivation enhanced PTEN inactivation-induced uterine gland pathology 
possibly by decreasing PR expression hence diminishing the protective role of 
P4 in uterine pathogenesis. However, further investigations are required to 
understand the regulation of ERα and PR via AR in uterus. Nevertheless, in 
together with our global AR knockout study (Chapter 4); our findings suggest 
possible systemic or tissue-specific effects of androgens in uterus. Furthermore, 
supporting our uterine development study (Chapter 3), AR may also exhibit cell-
specific effects in uterine carcinogenesis. These possibilities warrant further 
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studies on the role of AR in uterine carcinogenesis where the study is very much 
insufficient.  
 
In conclusion, this thesis has provided multiple findings of novel in vivo evidence 
supporting the important role of androgens in uterine development and 
pathogenesis as well as providing mechanisms involved. Furthermore, we have 
generated the first endometrial gland specific knockout mouse model which 
could be used in other studies investigating the role of other important 
genes/protein in uterine research. However, as the study in this area is very 
much lacking, hence, the findings need to be validated in humans (i.e. cell 
culture studies). Nevertheless, our study provides wide platform and 
approaches to future uterine research which would lead to better prevention, 
biomarker and treatment of uterine disorders including endometrial cancers.  
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Appendix I: PCR procedures 
 
DNA extraction (Qiagen DNeasy Blood & Tissue Kit) 
1. Cut tissue (≤10 mg spleen or ≤25 mg other tissue) into small pieces, and 
place in a 1.5 ml microcentrifuge tube. Add 180 μl Buffer ATL. Add 20 μl 
proteinase K, mix by vortexing, and incubate at 56°C until completely 
lysed. Vortex occasionally during incubation. Vortex 15 s directly before 
proceeding to step 2. 
2. Add 200 μl Buffer AL. Mix thoroughly by vortexing. Incubate blood 
samples at 56°C for 10 min. 
3. Add 200 μl ethanol (96–100%). Mix thoroughly by vortexing. 
4. Pipet the mixture into a DNeasy Mini spin column placed in a 2 ml 
collection tube. Centrifuge at ≥ 6000 x g (8000 rpm) for 1 min. Discard 
the flow-through and collection tube. 
5. Place the spin column in a new 2 ml collection tube. Add 500 μl Buffer 
AW1. Centrifuge for 1 min at ≥6000 x g. Discard the flow-through and 
collection tube. 
6. Place the spin column in a new 2 ml collection tube, add 500 μl Buffer 
AW2, and centrifuge for 3 min at 20,000 x g (14,000 rpm). Discard the 
flow-through and collection tube. 
7. Transfer the spin column to a new 1.5 ml or 2 ml microcentrifuge tube. 
8. Elute the DNA by adding 200 μl Buffer AE to the center of the spin 
column membrane. Incubate for 1 min at room temperature (15–25°C). 
Centrifuge for 1 min at ≥6000 x g. 
9. Optional: Repeat step 8 for increased DNA yield. 
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Master Mix for genotyping PCR 
All the PCR reagents are purchased from Bioline (Alexandria, Australia) and 
prepared in sterile 0.5ml PCR tubes (ThermoFisher Scientific, Melbourne, 
Australia). 
Reaction 
mix 
Cre ARCUT ARFLOX PTEN ARCUT 
RT 
Conventional 
Autoclaved 
Milli-Q 
water 
12µl 11.5µl 12.875ul 10µl 12µl 12µl 
5x MyTaq 
Red 
reaction 
buffer 
4µl 4µl NA NA 4µl 4µl 
5x Mango 
Taq buffer 
NA NA 5ul 4µl NA NA 
MgCl2 
(50µM) 
NA NA 1ul 0.8µl NA NA 
dNTPs NA NA 2ul 2µl NA NA 
Forward 
primer-1 
(10µM) 
0.5µ
l 
0.5µl 0.5µl 0.5µl 0.5µl 0.5µl 
Forward 
primer-2 
(10µM) 
NA NA 0.5µl NA NA NA 
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Reverse 
primer-1 
(10µM) 
0.5µ
l 
1µl 1ul 0.25µl 0.5µl 0.5µl 
Reverse 
primer-2 
(10µM) 
NA NA NA 0.25µl NA NA 
MyTaq Red 
DNA 
polymerase 
1µl 1µl NA NA 1µl 1µl 
Mango Taq NA NA 0.125ul 0.2µl NA NA 
Template 2µl 2µl 2µl 2µl 2µl 2µl 
Total 
volume 
20µl 20µl 25ul 20µl 20µl 20µl 
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DNase treatment and cDNA conversion 
DNase I, amplification grade (Invitrogen, CA, USA) was used for DNase 
treatment and SuperScript® III First-Strand Synthesis SuperMix (Invitrogen, CA, 
USA) was used for cDNA conversion. 
1. DNase treatment 
RNA  2µg (calculate volume to be added using RNA concentration) 
DNase 10x buffer  1µL 
DNase I  1µL 
RNase free water  10µL-(RNA, DNase 10x buffer and DNase I) 
Total volume = 10µL 
i) Incubate for 15 mins at Room temperature (RT). 
ii) Add 1µL of EDTA (25mM) 
iii) Incubate for 10 mins at 65°C (use PCR machine) 
iv) Straight to ice for ~1 min. 
v) Spin down the tube and transfer liquid to new PCR tube. 
This is ready for cDNA conversion (reverse transcriptase treatment). 
2. cDNA conversion    
2x RT Reaction Mix  10µL 
RT Enzyme Mix  2µL 
RNA (upto 1µg)  XµL 
DEPC-treated water  to 20µL 
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i) Gently mix tube contents and incubate at 25ºC for 10 minutes. 
ii) Incubate tube at 50ºC for 30 minutes. 
iii) Terminate the reaction at 85ºC at 5 minutes, and then chill on ice. 
iv) Add 1µl of E.coli RNase H and incubate at 37ºC for 20 minutes. 
v) Dilute cDNA with RNase free water (1 to 5) and store at -20ºC until 
use. 
 
Master Mix for real-time PCR 
Reagent: SensiMix SYBR Hi-ROX Kit (Bioline, Alexandria, NSW, Australia) 
Reaction mix Real-time PCR 
RNase free water 2.5µl 
SensiMix (2x) 5µl 
Forward primer (10µM) 0.25µl 
Reverse primer (10µM) 0.25µl 
Template 2µl 
Total volume 10µl 
 
  
231 
 
Appendix II: Solutions 
Tris-borate-EDTA (TBE) buffer (1x) 
Dissolve 1 pack of TBE Buffer, 10x Ready-Pack (Amresco, Ohio, USA) in 1L of 
RO water. Dilute 100ml of 10x TEB buffer in 900ml of Reverse osmosis (RO) 
water (Millipore). Final concentration of 0.089M Tris base, 0.089M Borate, 
0.002M EDTA). 
 
0.9% Saline solution 
Dissolve 9g of sodium chloride (NaCl) (Bacto Laboratories PTY LTD, NSW, 
Australia) in 1L of milli-Q water (Millipore, Milli-Rx 45 with Milli-Q academic). 
 
0.5% toludine blue 
Dissolve 500mg of Toludine blue powder (Amresco, Ohio, USA) in 100ml of RO 
water. 
 
4% Paraformaldehyde (PFA)  
Dissolve 4g PFA (MERCK, Darmstadt, Germany) in 96ml of phosphate buffered 
saline (PBS with 1-2 drops of 10M NaOH. 4% PFA was stored in 4ºC for up to a 
week. 
 
 
232 
 
Phosphate buffered saline (PBS) 
Dissolve 8g NaCl, 0.2g KCl, 1.44g Na2HPO4 and 0.24g KH2PO4 in 800ml of RO 
water. Adjust pH to 7.4 and add RO water to bring final volume to 1L. Stored at 
room temperature with final concentration of 0.137M NaCl, 0.0027M KCl, 0.01M 
Na2HPO4 and 0.0018M KH2PO4. 
 
LacZ staining soutions 
Fixing solution: Mix 10µl of 100% NP40 (Sigma Aldrich, St Louis, USA), 0.5ml 
of 0.5M EDTA (pH=8) (Thermo-Fischer scientific, Waltham, USA), 0.4ml of 25% 
glutaraldehyde (4ºC) (Sigma Aldrich, St Louis, USA), 0.1ml of 1M MgCl2 (Sigma 
Aldrich, St Louis, USA) and add PBS to make the final volume of 50ml. 
Washing buffer: Mix 40µl of NP 40, 0.4ml of 1M MgCl2, 0.2ml of 10% Sodium 
Deoxycholate (Sigma Aldrich, St Louis, USA) and add PBS to make the final 
volume of 200ml. 
Staining solution: Mix and dissolve 1ml of 50mg/ml X-gal in 
dimethylformamide (-20ºC) (Astral Scientific, Caringbar, Australia), 0.106g of 
potassium ferrocyanide (Sigma Aldrich, St Louis, USA), 0.082g of potassium 
ferricyanide (Sigma Aldrich, St Louis, USA), 1ml of 1M Tris (pH=7.4) (Sigma 
Aldrich, St Louis, USA) and add washing buffer to make the final volume of 
50ml. 
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Appendix III: Histology and staining 
Paraffin embedding 
Tissues were processed at ANZAC Research Institute as the protocol below: 
Reagent Duration 
75% Ethanol 1 hour 
75% Ethanol 1 hour 
100% Ethanol 1 hour 
100% Ethanol 1 hour 
100% Ethanol 1 hour 
100% Ethanol 1 hour 
100% Ethanol 1 hour 
Xylene 1 hour 
Xylene 1 hour 
Xylene 1 hour 
Wax 1 hour 20 minutes 
Wax 1 hour 20 minutes 
Wax 1 hour 20 minutes 
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Haematoxylin and eosin (H&E) 
H&E staining was performed as the protocol below: 
Reagent Duration 
Xylene 5 minutes 
Xylene 5 minutes 
100% Ethanol 3 minutes 
100% Ethanol 3 minutes 
70% Ethanol 3 minutes 
Milli-Q water 3 minutes 
Harris Haematoxylin 5 minutes 
Tap water 5 minutes 
Acid alcohol* Dip 1-2 times 
Tap water 5 minutes 
Scott’s bluing solution 1 minute 
Tap water 5 minutes 
Eosin 30 seconds to 1 minute 
Tap water 5 minutes 
70% Ethanol 3 minutes 
100% Ethanol 3 minutes 
100% Ethanol 3 minutes 
Air Dry Overnight 
DPX coverslip 1-2 days 
*Acid alcohol: 175ml of 100% ethanol + 75ml of RO water + 2.5ml of 36% HCl 
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Immunohistochemistry 
Immunohistochemistry was performed as the protocol below: 
1. Dewax paraffin sections through xylene and rehydrate through series of 
100% ethanol to 70% ethanol and to Milli-Q water. 
2. Perform antigen retrieval with 10mM citric acid (pH 6) in microwave for 
10 minutes. 
3. Block endogenous peroxidase with H202 for 10 minutes at room 
temperature (in hood) to reduce non-specific background staining. 
4. Wash PBS for 3 minutes. 
5. Block unspecific binding sites with Pierce superblock (containing 0.5% 
Bovine serum albumin) for 1 hour at room temperature. 
6. Without rinsing the slides, add primary antibody or PBS (negative control) 
and incubate for 1 hour at 37ºC. 
7. Wash PBS for 3 minutes twice. 
8. Add secondary biotinylated antibody and incubate for 30 minutes at 
room temperature. (Make up ABC reagent using Vectastain Kit and allow 
standing for formation of ABC complex). 
9. Wash PBS for 3 minutes twice. 
10. Add ABC reagent and incubate for 30 minutes at room temperature. 
11. Wash PBS for 3 minutes twice. (Make up 3,3'-Diaminobenzidine (DAB) 
staining solution). 
12. Apply DAB and observe colour (brown) development. Expose all 
sections to DAB for the same amount of time (15 seconds to 10 minutes). 
13. Rinse DAB in Milli-Q water for 5 minutes 
14. Counterstain slides in Harris haematoxylin for 15-30 seconds. 
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15. Rinse Harris haematoxylin by rinsing in running water for 5 minutes. 
16.  Dehydrate through a series of 70% ethanol to 100% ethanol. 
17. Allow to air dry for overnight. 
18. Coverslip using DPX and allow it to dry (1-2 days). 
 
Immunohistochemistry negative controls (scale bar=200µm): 
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Appendix IV: Primer sequences for real-time PCR 
Target gene Annealing 
temperature 
(ºC) 
Primer sequences 
18s rRNA 59 Forward: 5-’AACTTTCGATGGTAGTCGCCG-3’ 
Reverse: 5’-AAACGGCTACCACATCCAAGG-3’ 
Rpl 19 57 Forward: 5’-GATCATCCGCAAGCCTGTGACTG-3’ 
Reverse: 5’-GTGCTTCCTTGGTCTTAGAC-3’ 
Β-actin 58 Forward: 5-’AGCCATGTACGTAGCCATCC-3’ 
Reverse: 5’-GGAACCGCTCGTTGCCAATA-3’ 
Hmbs 64 Forward: 5-’GGCAATGCGGCTGCAA-3’ 
Reverse: 5-’GGGTACCCACGCGAATCAC-3’ 
ERα 67 Forward: 5’-ATGAAAGGCGGCATACGGAAAG-3’ 
Reverse: 5’-CACCCATTTCATTTCGGCCTTC-3’ 
Cyclophillin 65 Forward: 5’-ATCACGGCCGATGACGAGCC-3’ 
Reverse: 5’-TCTCTCCGTAGATGGACCTGC-3 
Lactoferrin 59 Forward: 5’-CTAACCAGACCAGATCCTGCA-3’ 
Reverse: 5’-CCTTCTCAGCCAGACACCTT-3’ 
C3 57 Forward: 5’-AACTGCTGGCCTCTGGAGTA-3’ 
Reverse: 5’-GCATGATTCCTCGAGGTTGT-3’ 
G6PDH 61 Forward: 5’-GCCTGGCATGTTCTTTAACC-3’ 
Reverse: 5’-CAATCTTGTGCAGCAGTGGT-3’ 
Probasin 65 Forward: 5'-GGAGGAGATGACGGAGTTCA-3' 
Reverse: 5'-ACAGTTGTCCGTGTCCATGA-3' 
 
Cox-1 60 Forward: 5’-ACCTACGTCTACGCCAAAGG-3’ 
Reverse: 5’-GTGGTTTCCAACCAAGATCA-3’ 
Cox-2 60 Forward: 5’-CCGTGCTGCTCTGTCTTAAC-3’ 
Reverse: 5’-TTGGGAACCCTTCTTTGTTC-3’ 
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Appendix V: Additional PTEN western blots 
 
